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Systematic review of interventions for treating or
preventing antipsychotic-induced tardive dyskinesia
Hanna Bergman,1 Dawn-Marie Walker,2 Adriani Nikolakopoulou,3
Karla Soares-Weiser4 and Clive E Adams5*
1Cochrane Response, Cochrane, London, UK
2Faculty of Health Sciences, University of Southampton, Southampton, UK
3Institute of Social and Preventative Medicine, University of Bern, Bern, Switzerland
4Cochrane Editorial Unit and Cochrane Innovations, Cochrane, London, UK
5Institute of Mental Health, University of Nottingham, Nottingham, UK
*Corresponding author clive.adams@nottingham.ac.uk
Background: Antipsychotic medication can cause tardive dyskinesia (TD) – late-onset, involuntary,
repetitive movements, often involving the face and tongue. TD occurs in > 20% of adults taking
antipsychotic medication (first-generation antipsychotics for > 3 months), with this proportion increasing by
5% per year among those who continue to use these drugs. The incidence of TD among those taking
newer antipsychotics is not different from the rate in people who have used older-generation drugs in
moderate doses. Studies of TD have previously been found to be limited, with no treatment approach
shown to be effective.
Objectives: To summarise the clinical effectiveness and safety of treatments for TD by updating past
Cochrane reviews with new evidence and improved methods; to undertake public consultation to gauge
the importance of the topic for people living with TD/the risk of TD; and to make available all data from
relevant trials.
Data sources: All relevant randomised controlled trials (RCTs) and observational studies.
Review methods: Cochrane review methods, network meta-analysis (NMA).
Design: Systematic reviews, patient and public involvement consultation and NMA.
Setting: Any setting, inpatient or outpatient.
Participants: For systematic reviews, adults with TD who have been taking a stable antipsychotic drug
dose for > 3 months.
Interventions: Any, with emphasis on those relevant to UK NHS practice.
Main outcome measures: Any measure of TD, global assessments and adverse effects/events.
Results: We included 112 studies (nine Cochrane reviews). Overall, risk of bias showed little sign of
improvement over two decades. Taking the outcome of ‘TD symptoms improved to a clinically important
extent’, we identified two trials investigating reduction of antipsychotic dose [n = 17, risk ratio (RR) 0.42,
95% confidence interval (CI) 0.17 to 1.04; very low quality]. Switching was investigated twice in trials that
could not be combined (switching to risperidone vs. antipsychotic withdrawal: one RCT, n = 42, RR 0.45,
95% CI 0.23 to 0.89; low quality; switching to quetiapine vs. haloperidol: one RCT, n = 45, RR 0.80,
95% CI 0.52 to 1.22; low quality). In addition to RCTs, six observational studies compared antipsychotic
discontinuation with decreased or increased dosage, and there was no clear evidence that any of these
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strategies had a beneficial effect on TD symptoms (very low-quality evidence). We evaluated the addition to
standard antipsychotic care of several treatments, but not anticholinergic treatments, for which we identified
no trials. We found no clear effect of the addition of either benzodiazepines (two RCTs, n = 32, RR 1.12,
95% CI 0.6 to 2.09; very low quality) or vitamin E (six RCTs, n = 264, RR 0.95, 95% CI 0.89 to 1.01; low
quality). Buspirone as an adjunctive treatment did have some effect in one small study (n= 42, RR 0.53, 95% CI
0.33 to 0.84; low quality), as did hypnosis and relaxation (one RCT, n = 15, RR 0.45, 95% CI 0.21 to 0.94;
very low quality). We identified no studies focusing on TD in people with dementia. The NMA model found
indirect estimates to be imprecise and failed to produce useful summaries on relative effects of interventions
or interpretable results for decision-making. Consultation with people with/at risk of TD highlighted that
management of TD remains a concern, and found that people are deeply disappointed at the length of time
it has taken researchers to address the issue.
Limitations: Most studies remain small and poorly reported.
Conclusions: Clinicians, policy-makers and people with/at risk of TD are little better informed than they
were decades ago. Underpowered trials of limited quality repeatedly fail to provide answers.
Future work: TD reviews have data from current trials extracted, tabulated and traceable to source. The
NMA highlights one context in which support for this technique is ill advised. All relevant trials, even if not
primarily addressing the issue of TD, should report appropriate binary outcomes on groups of people with
this problem. Randomised trials of treatments for people with established TD are indicated. These should
be large (> 800 participants), necessitating accrual through accurate local/national registers, including an
intervention with acceptable treatments and recording outcomes used in clinical practice.
Study registration: This study is registered as PROSPERO CRD4201502045.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Antipsychotic medication can cause involuntary, repetitive body movements, frequently involving theface and tongue. This condition is known as tardive (because it is a side effect that usually does not
appear until after you have been taking medication for a while) dyskinesia (meaning abnormal or unusual
movements), or TD.
It has been estimated that TD occurs in about one-fifth of people using antipsychotics. Other studies
have found that closer to 1% find it sufficiently severe or persistent to change antipsychotics as a result.
Management varies and is particularly problematic where discontinuation or change of treatment is not
desired or easily achieved. This work updates past reviews with new evidence and methods. There is
frequently an advantage in revisiting old work to see if information that was previously impossible to use
can now be employed in building a more complete picture. In recent years, newer methods of presenting
and analysing the information in reviews has helped make reviews more accessible and useful.
Although there are many new relevant studies, it appears that little has been learnt from past work.
The conduct, analysis and reporting of trials of these treatments continue to be of such poor quality that
it is impossible to really trust the results.
This work found that:
l researchers continue to do trials, but take little heed of calls for increased quality and relevance to
everyday care
l some new methods used within sophisticated reviews of care really do not work if the building blocks
of the reviews (the trials) are of very limited quality
l people with TD feel disappointed and angry at the length of time it has taken for researchers to
address the issue of how to treat TD
l we still do not know how to treat people with/at risk of TD effectively.
All information from the reports of past trials, reliably and painstakingly extracted, is fully, freely accessible
to anyone online.
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Scientific summary
Background
Since the 1950s, antipsychotic medication has been used extensively to control psychotic symptoms and
to reduce the harm caused by the symptoms of chronic mental illness, including schizophrenia, bipolar
disorder and dementia. Antipsychotic drugs are associated with a wide range of adverse effects, including
tardive dyskinesia (TD), the late onset of involuntary, repetitive body movements, often involving the
face and tongue. Critical problems associated with severe TD include difficulty swallowing, locomotion
difficulties, involvement of respiratory muscles, and speech being rendered unintelligible. TD can be
extremely disfiguring, compounds stigma and is associated with poor compliance with treatment.
Tardive dyskinesia occurs in > 20% of people who use first-generation antipsychotic drugs continually for
> 3 months, and every year about 5% of those who continually use these drugs begin to show signs of
TD. When second-generation antipsychotic (SGA) drugs were introduced in the 1990s, many hoped that
they would not cause TD. Risks of developing TD with SGA drugs seem to be reduced but not eliminated.
There is, however, some evidence to indicate that rates of TD do not differ at all between first- and
second-generation antipsychotic drugs. Increasingly the distinction between first and second generation
has become redundant.
The need for prevention or treatment is clear. Unfortunately, there has been sparse evidence to guide
clinicians and, although many treatments have been tested, no one intervention has been shown to be
clearly effective. Although antipsychotic reduction and/or cessation would seem to be a logical first step in
the management of TD, this is not always possible because of the over-riding need to manage current
psychotic symptoms and/or reduce the risk of relapse. Many other approaches have been proposed,
including changing medication, anticholinergic drugs, use of benzodiazepines, vitamin E (tocopherol),
buspirone and non-pharmacological treatments such as relaxation techniques and hypnosis.
High-quality Cochrane reviews assessing treatments for TD were first published in 1995–6, and an
overview was published in 1999. They found no compelling evidence for the effect of any approach. This
project has been funded to update relevant reviews fully with new evidence, using more sophisticated
techniques of synthesis while also undertaking a public consultation process and making all data from
reports fully accessible to future reviewers.
Objectives (list of research questions)
1. To identify all relevant evaluative studies.
2. To produce an overview of evaluative research in this area and prioritise the top 10 candidate
treatments for head-to-head comparisons.
3. To extract and make accessible all relevant useful data from reports of evaluations of treatments and to
ensure that the source of these data is entirely transparent.
4. To update existing relevant Cochrane reviews on antipsychotic-induced TD in people with schizophrenia
and, if possible, to create comparisons relevant to people with dementia while ranking identified
interventions according to their relevance for the NHS, and performing a network meta-analysis (NMA).
5. To consult people with/at risk of TD on the degree to which they believe these research questions to
be important.
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Methods
Data sources
1. We sought to consult with the public in order to access voices of people with personal experience of
TD. The consultation process was held at the McPin Foundation offices in London. All discussions were
audio-recorded for transcription while the attendees were asked to write down their ideas throughout
the day on paper tablecloths and Post-it® (3M, Bracknell, UK) notes to help keep an accurate record of
discussion, and to encourage everyone to participate.
2. For the reviews, we attempted to identify all relevant studies regardless of language or publication
status (published, unpublished, in press and in progress).
We searched Cochrane Schizophrenia Group’s Study-Based Register of Trials (on 16 July 2015) as well
as Cochrane Dementia and Cognitive Improvement Group’s Register of Trials via the Cochrane Register
of Studies Online (CRSO; www.crso.cochrane.org) (on 21 July 2015). We also searched electronic
databases for observational studies (on 9 January 2017).
We inspected references of all identified studies for further relevant studies.
Study selection (inclusion criteria)
Methods
Randomised controlled trials (RCTs).
Participants
Adults who had used antipsychotic drugs for ≥ 3 months and in whom the antipsychotic doses had been
stable for at least 1 month.
Interventions
Any intervention, but with a particular focus on those relevant to the NHS.
Outcomes
Any clinical outcomes, however measured – but with a particular focus on those chosen in the public
consultation process as being of particular importance:
l TD
¢ improved to a clinically important extent
¢ deteriorated
l adverse effect
¢ any adverse event
¢ adverse effects: no clinically significant extrapyramidal adverse effects
l acceptability of treatment
¢ leaving the study early
l social confidence, social inclusion, social networks or personalised quality-of-life measures
¢ no important change in social confidence, social inclusion, social networks or personalised
quality-of-life measures for either recipients of care or caregivers.
SCIENTIFIC SUMMARY
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We excluded data from studies that were over 10 years old and reported no useable data, but which
otherwise qualified for inclusion. In those cases, we contacted study authors to request data and excluded
studies for which we received no reply, no new information or for which we were unable to contact
study authors.
Data extraction (and assessment of validity)
Search results were uploaded into a web-based system and two reviewers independently screened all
citations and abstracts. Two reviewers inspected all studies from the nine Cochrane reviews on TD. We
obtained full reports for potentially eligible studies and these were independently screened by two review
authors. One reviewer extracted data from all included studies, which were then cross-checked by another
researcher. We attempted to contact authors in order to obtain missing information or for clarification
whenever necessary.
Two reviewers worked independently and rated studies as having a low, unclear or high risk of bias based on
domain-specific assessments of risk of bias, done using Cochrane’s existing risk-of-bias tools for randomised
and non-randomised studies. When inadequate details of randomisation and other characteristics of trials
were provided, authors of studies were contacted for clarification. These judgements were incorporated into
the process of assessing limitations in study design for outcomes in the summary-of-findings tables.
Data, quantitative and qualitative, were extracted into tabular format, but each original document was
fully ‘marked up’ to allow tracing back from extracted data to origin. All data extracted in this way are
fully available.
Data synthesis
Study level
For each study, for binary outcomes the risk ratio (RR) and 95% confidence interval (CI) were derived for
people receiving the intervention compared with those in the control group. For continuous data, we
included data from valid rating scales and calculated the mean difference (MD) between groups and
95% CIs.
Meta-analyses
Where studies were considered substantively similar enough for meta-analysis to be appropriate, fixed-effect
analyses were carried out using RevMan software version 5.3.5 (The Cochrane Collaboration, The Nordic
Cochrane Centre, Copenhagen, Denmark).
Visual inspection of the forest plots was used to evaluate the potential statistical heterogeneity (differences
between the true intervention effects in the different studies). Heterogeneity was quantified by estimating
the between-study variance χ2 and the I2-statistics, which measure the percentage of observed variation
that can be attributed to true differences between the studies.
Quality assessment
We used the Grading of Recommendations, Assessment Development and Evaluation (GRADE) approach
to assess the quality of the evidence for the various interventions. We have presented a ‘summary of
findings’ table based on GRADE results for all NHS-prioritised interventions and outcomes.
Network meta-analysis
Odds ratios were employed for dichotomous outcomes. When continuous outcomes were measured, we
analysed them using the MD if all studies used the same measure to assess the same outcome. Standardised
mean difference Hedges’ adjusted g was used when a different measure was used across studies to assess a
common continuous outcome. We estimated P-scores, which are frequent analogues of surface under the
cumulative ranking curve, to obtain a hierarchy of the competing interventions. We assessed the presence of
clinical and methodological heterogeneity within each pairwise comparison by comparing trial and study
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population characteristics across all eligible trials. We were unable to compare the distribution of effect
modifiers across comparisons as a result of limited data, but we compared particular study characteristics
qualitatively. Moreover, we assessed whether or not the indication of the included interventions varied
according to the alternative it is compared against. Initially, standard pairwise meta-analyses were performed
for all pairwise comparisons with at least two studies using the random-effects inverse variance model
in Stata® 2015 (StataCorp LP, College Station, TX, USA). We intended to perform the NMA using the
methodology of multivariate meta-analysis, in which different treatment comparisons are handled as different
outcomes using the ‘network’ package (which includes the ‘mvmeta’ command) in Stata. As a result of the
substantial number of treatment nodes, we used the ‘netmeta’ package in R 3.2.3 (The R Foundation for
Statistical Computing, Vienna, Austria). We used available Stata routines to present the evidence base and
illustrate the results. We produced a plot to present jointly the relative ranking of treatments for ‘no clinical
improvement’ and ‘total discontinuation rates’, and we used a hierarchical cluster analysis to group
interventions in meaningful subsets.
In pairwise meta-analysis we assumed different heterogeneity variances for each comparison. In NMA, we
assumed a common heterogeneity variance across all treatment comparisons in the network. Between-study
variance τ2 was estimated in both pairwise meta-analysis and NMA using the DerSimonian and Laird
estimator. We assessed statistical heterogeneity based on the magnitude of the estimated parameter.
We also compared the magnitude of τ2 with empirical distributions.
Results
We included 112 randomised trials (nine Cochrane reviews) and eight prospective cohort studies. Overall,
risk of individual study biases was rated as being high and this showed little sign of improvement across
decades of research. Cochrane reviews were indeed outdated, both in content and in methods; however,
their findings have not substantively changed by the inclusion of new data and novel methods.
Studies reported thousands of outcomes measured in many ways over different periods of time. The public
consultation process of this project, however, helped focus the reviewing process on targeted outcomes of
importance to people with/at risk of TD (see Outcomes). The key outcome was binary – TD symptoms
improved to a clinically important extent.
Seventy-nine separate interventions were the focus of the trials, whereas prospective cohort studies
focused on comparing different strategies for antipsychotics. We categorised these and then invested most
effort into those thought to be of practical importance within the NHS. These were grouped into three
broad categories:
1. reducing antipsychotic dose
2. switching antipsychotic drug
3. adjunctive treatments in addition to antipsychotic drugs.
No intervention outside those thought to be relevant to NHS practice shows convincing promise.
Reducing antipsychotic dose
For this important and practical intervention we identified only two trials (n = 17). The combined result of
these extremely small trials found no clear effect for the outcome of TD symptoms improved to a clinically
important extent (RR 0.42, 95% CI 0.17 to 1.04). These data were judged to be of very low quality.
In addition, six observational studies (n = 160) found that psychiatric patients with TD whose antipsychotic
medication was reduced or discontinued showed greater improvement in TD symptoms after 1–10 years of
follow-up. These data were unreliable, varied from 19% to 75% improvement and were judged to be of
very low quality.
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Switching antipsychotic drug
There are many possibilities for how, when and what to switch to, but we identified only two relevant
trials reporting on ‘TD symptoms improved to a clinically important extent’. The first switched people off
their antipsychotic drug altogether or to risperidone (n = 42; RR 0.45, 95% CI 0.23 to 0.89), and the
second (n = 45) switched from older drugs to either quetiapine or haloperidol (RR 0.80, 95% CI 0.52 to 1.22).
Both studies were judged to report data of low quality.
Adjunctive treatments in addition to antipsychotic drugs
We found no trials reporting relevant outcomes of anticholinergic continuation versus withdrawal.
Two small trials (n = 32) reported on the effects of adding benzodiazepine drugs compared with placebo
(TD symptoms improved to a clinically important extent; RR 1.12, 95% CI 0.60 to 2.09; very low-quality
evidence). For the same outcome, vitamin E was found to have no clear effect when compared with
placebo (six RCTs, n = 264; RR 0.95, 95% CI 0.89 to 1.01; low-quality evidence). Adding buspirone in
the one trial that compared this with placebo caused a clear effect favouring the experimental treatment
(n = 42, TD symptoms improved to a clinically important extent RR 0.53, 95% CI 0.33 to 0.84), but these
data were felt to be of low quality. Finally, adding hypnosis and relaxation to treatment as usual did help
(TD symptoms improved to a clinically important extent; RR 0.45, 95% CI 0.21 to 0.94) in one very small
study (n = 15). Data were judged to be of very low quality.
The NMA model found that, for data such as those reported in TD trials, indirect estimates were imprecise
and failed to produce useful summaries on relative effects of interventions or interpretable results for
decision-making.
Consultation with people with/at risk of TD highlighted that management of TD remains a concern and
found that people are deeply disappointed by the amount of time researchers have taken to investigate
the issue. They supported the outcomes used in the TD Cochrane reviews, but would recommend the field
is broadened to address issues such as social stigma, as public reactions to people living with TD can be as
hard to cope with as the symptoms of underlying mental health problems themselves, like schizophrenia.
Conclusions
Implications for health care
Clinicians, policy-makers and people with/at risk of TD are little better informed than they were decades
ago. Underpowered trials of limited quality repeatedly fail to provide answers.
Although it seems prudent to use the lowest effective dosage of antipsychotic drug possible (within the
licensed range) for individual patients, there is no evidence that antipsychotic discontinuation will improve
TD symptoms.
Current treatments for TD are prescribed in the hope that they will have an impact on TD, but do not have
a strong evidence base. It could be argued that these treatments are only ethical within well-designed
pragmatic trials aimed at informing clinical practice with people with this disfiguring problem.
Recommendations for research (in order of priority)
Tardive dyskinesia reviews have data from current trials extracted, tabulated and traceable to source.
TD reviews, whether or not those within Cochrane, should use this resource to save time and money.
The NMA highlights one context in which support for this technique is ill advised. When studies are short,
small, have similar results and are of poor quality, NMA is not indicated.
All relevant trials, even if not primarily addressing the issue of TD, should report appropriate binary
outcomes on groups of people with this problem.
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Randomised trials of treatments for people with established TD are indicated, with the most obvious
intervention being dose reduction. These trials should be large (> 800), necessitating accrual through
accurate local/national registers, intervention with acceptable treatments, and recording outcomes used in
clinical practice.
Public consultation findings may be best summarised by a quotation from a person concerned with this
problem. This person wrote ‘It’s about time TD was addressed. It [has] only been 30 years coming!!!’.
This review summarises > 30 years of pioneering work, but also of systemic failure to properly address the
ongoing issue of TD. Public consultation has provided a list of simple, universally relevant and practical
outcomes for the large trials that should happen before another three decades or more lapses.
Study registration
This study is registered as PROSPERO CRD4201502045.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
S ince the 1950s, antipsychotic medication has been used extensively to control psychotic symptoms andto reduce the harm caused by the symptoms of chronic mental illness, including schizophrenia, bipolar
disorder and dementia. Other illnesses that necessitate long-term antipsychotic treatment include autism,
Tourette syndrome and other behavioural disturbances. Antipsychotic drugs are associated with a wide
range of adverse effects, including tardive dyskinesia (TD), the late onset of involuntary, repetitive body
movements, often involving the face and tongue. Critical problems associated with severe TD include
difficulty swallowing, locomotion difficulties, involvement of respiratory muscles and speech being
rendered unintelligible. TD can be extremely disfiguring, compounds stigma and is associated with poor
compliance to treatment.1
Tardive dyskinesia occurs in > 20% of people who use first-generation antipsychotic (FGA) drugs continually
for > 3 months,1 and every year 4–5% of those who continually use these drugs begin to show signs of TD.1
When second-generation antipsychotic (SGA) drugs were introduced in the 1990s, many hoped that they
would not cause TD.2,3 Although the risks of developing TD with SGA drugs do seem to be reduced, they
have not been eliminated.1,3 There is some evidence to indicate that rates of TD do not differ at all between
first- and second-generation antipsychotic drugs, making the distinction between the two ‘generations’ of
drugs increasingly redundant.2 Recent assessments of the incidence and prevalence of TD range from 5% to
60% of patients taking antipsychotic medication for long periods.4 For example, one recent, well-conducted
survey from the Netherlands found that, of 209 people with chronic severe mental illness receiving antipsychotic
medication, 28% had TD (yearly incidence rate of TD 19.6%).5,6 Furthermore, the study reconfirmed that
TD was positively associated with age [hazard ratio per year exposure 1.04, 95% confidence interval (CI)
1.02 to 1.06].5,6
The large, definitive US randomised trial of antipsychotic treatments for schizophrenia [Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE)], with a 4-year period of follow-up, obtained an
incidence rate of TD of around 17% and found no significant difference in rates between first- and
second-generation (olanzapine, quetiapine, risperidone, ziprasidone) antipsychotics.7 A prospective cohort
study of 352 psychiatric outpatients confirmed this,8 but a meta-analysis of nine other studies carried out
by the same study authors showed that the yearly TD incidence rate for FGAs was significantly higher than
for SGAs; however, many of these studies were not predesigned to detect TD.8 Another, later, prospective
cohort study found no significant difference in TD incidence rates between risperidone and olanzapine in
207 elderly psychiatric in- and outpatients.9
As a result of widespread use of SGA drugs, increased off-label use and an ageing population, the
frequency of TD is likely to be higher than thought,10,11 and increasing. The problem will be considerably
greater for people in countries in which the use of newer drugs is less prevalent.12,13
Given this high incidence and prevalence, the need for prevention or treatment is clear; unfortunately,
there has been sparse evidence to guide clinicians.14,15 Although many treatments have been tested, no
one intervention has been shown clearly to be effective.
Although antipsychotic reduction and/or cessation would seem to be a logical first step in the management
of antipsychotic-induced TD, this is not always possible in the clinical setting because of the over-riding need
to manage current psychotic symptoms and/or reduce the risk of relapse. Changes in several antipsychotic
medications have been produced in the last few decades that claim to cause less or no TD.16 These claims
may or may not be true, and certainly evidence does point to the fact that thoughtful use of older-generation
drugs is not associated with more TD than with newer treatments.17 In the search for ways to manage
antipsychotic-induced TD, certain antipsychotic medications have themselves been proposed as specific
treatments for the condition.18 The usual rationale for such trials relates to variations in the receptor-blocking
profile that distinguishes the compound of interest from antipsychotics in general. As for TD, treatment
DOI: 10.3310/hta21430 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 43
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bergman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
options for other movement disorders also include antipsychotic dose reduction or the switch to a newer
antipsychotic.19–21 Tetrabenazine is the only Food and Drug Administration-approved drug to specifically treat
a movement disorder, Huntington’s chorea;20,22 consequently, and because of the lack of viable treatment
options for TD, tetrabenazine has been suggested as a treatment for TD as well.23
Drugs that reduce the activity of the cholinergic cells (anticholinergic drugs) are widely used to help treat
other antipsychotic-induced movement disorders, such as Parkinsonism and dystonia. It is hypothesised that
alterations in striatal cholinergic neurons could serve as pathophysiological basis for TD24 and, therefore,
patients would benefit from cholinergic drugs. Benzodiazepines, the most widely used gamma-aminobutyric
acid (GABA) agonists, have also been suggested as potential interventions for TD. Chronic blockade of
dopamine receptors in TD leads to inactivity in another set of cells that employ GABA.25 Also, there is
evidence from animal experiments suggesting that GABA dysfunction may be associated with movement
disorders.26 Benzodiazepines have been included as a candidate treatment for TD in several practice
guidelines27–29 and are also used to treat other movement disorders.19,21,30
Vitamin E (tocopherol) is a lipid-soluble antioxidant that acts as a free radical scavenger and has also
been proposed as a treatment for antipsychotic-induced TD.31 There has been some suggestion that the
chronic use of antipsychotics may cause abnormal production of highly active atoms and chemical groups
(cytotoxic free radicals), which may damage specific cells in the brain. This, in turn, could be responsible
for the appearance of TD.32 Vitamin E may assist in minimising damage caused by cytotoxic free radical
overproduction, and may prevent or decrease the severity of TD, particularly among those in whom onset
occurred in the preceding 5 years.33,34
Another agent under investigation for treatment of TD is buspirone, an anxiolytic drug acting as a partial
agonist for the serotonin 5-HT1A (5-hydroxytryptamine subtype 1A) receptors, with additional low affinity as
an antagonist for the dopamine D2 autoreceptors. A number of studies on TD animal models have found
that buspirone ameliorated symptoms.35,36
Other, non-pharmacological, treatments should also be examined in the context of TD. ‘Mind–body’
interventions, including both relaxation techniques and hypnosis, are reported to benefit patients with a
number of neurological disorders.37 The use of different relaxation techniques38,39 and hypnosis40 has also
been examined in tic disorders and in Parkinson’s disease, with some positive preliminary findings; however,
their effectiveness in movement disorders and TD specifically has yet to be systematically investigated.
We are aware that TD is not exclusive to people with schizophrenia, but, to illustrate the point regarding the
disparate nature of evidence, a comprehensive database with more than 500 controlled trials comparing
101 different interventions used to improve or prevent deterioration of symptoms of antipsychotic-induced
TD in schizophrenia was published in 1996.41,42 The studies in this database were, largely, very small and
poorly reported.41,42 After categorisation according to treatment groups, nine Cochrane reviews were
performed (first published in 1995–6 and periodically updated since).18,23,43–49 An overview of all published
Cochrane reviews was published in 1999.50 These reviews reported a lack of information on the efficacy of
most interventions, in particular the logical – but often impractical – step of stopping antipsychotic
treatment.18 Many with TD are faced with a lifetime of suffering from this disfiguring adverse effect.
This is a good time to revisit this difficult area for several reasons:
1. The research community has recognised that TD is not a problem of the past and may be an increasing
problem of the future.
2. Widening the inclusion criteria to well beyond people with schizophrenia may lead to a broader
appreciation of the research landscape, with opportunities for cross-fertilisation of ideas for
prevention/treatment.
3. New approaches have been tested.51
BACKGROUND
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4. Methods in systematic reviewing have become considerably more sophisticated, with new techniques to
employ evidence from, for example, network meta-analysis (NMA).52
5. Dissemination of information is warranted, and methods for dissemination are much wider than has
previously been the case, potentially generating further impact for this neglected area of research.
There may not be definitive answers available for the best way to prevent or treat TD, but this work will
use all the best available evidence, highlight if there is good evidence for a specific treatment path, and
provide high-quality evidence for choice of treatments and techniques for future testing.
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Chapter 2 Hypotheses tested in the review
(research questions)
To summarise evidence from clinical trials and observational studies of interventions used for treating orpreventing deterioration of symptoms of antipsychotic-induced TD by performing an overview of
systematic reviews, including updating Cochrane reviews, and NMA.
Specific objectives
1. To identify all relevant evaluative studies.
2. To produce a broad-brush overview of the evaluative research in this area and prioritise the top 10
candidate treatments for head-to-head comparisons.
3. To extract all relevant useful quantitative data on evaluations of the treatments, and to ensure that the
source of these data is entirely transparent and made available for future researchers.
4. To produce reviews by:
i. updating nine existing relevant Cochrane reviews for different groups of interventions comparing TD
with placebo
ii. adding head-to-head comparisons reporting for the treatment and prevention of deterioration of
symptoms of antipsychotic-induced TD to all Cochrane reviews in:
– adults with schizophrenia
– adults with dementia
iii. ranking identified interventions according to relevance for the NHS and selecting the potentially
relevant ones for NMA
iv. performing a NMA.
5. To work collaboratively to tailor this evidence to clinical, research and public needs using dissemination
techniques appropriate for all three.
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Chapter 3 Methods
Part A: methods for patient and public involvement
This project brought together expertise from a range of fields to plan and deliver the review. The main part
was review work. In order to assess if current research met the needs of people with experience of TD, a
small consultation was planned, taking results from the reviews and exploring whether or not the assessed
outcomes matched service user priorities for managing TD. The consultation was advertised by e-mail via
the McPin Foundation’s large circulation list of people who are interested in being involved. It was also
advertised on their website. Interested people were asked to contact the McPin Foundation to book a
place to attend. Reimbursement for time and out-of-pocket expenses was offered.
A lay overview of the previously published version of a Cochrane review evaluating the effects of vitamin E
in TD47 gave the foundation for the discussions. All of the researchers involved in the consultation were
extremely experienced in involving patients and the public. The session was planned to provide time to
reflect on current research on TD and to consider gaps in knowledge.
The discussion was audio-taped and the service users were invited to write comments on Post-it® (3M,
Bracknell, UK) notes and paper tablecloths, which were then collected and reviewed. The researchers
listened to the recordings after the session and noted any points relevant to the above-mentioned
questions that would have an impact on the funded systematic review. Full transcription and formal
analyses were not appropriate in this case, as the consultation was not a piece of empirical qualitative
work. Furthermore, two of the consultation facilitators had extensive experience in involving patients and
the public in research and expert knowledge in this paradigm, including hosting focus groups (or, in this
case, a consultation).
Informed by the results of the consultation, we updated outcomes for the summary-of-findings table for
the systematic reviews. See Appendix 1 for the full report.
Part B: methods for systematic review
Please see Appendix 2 for differences between the project protocol and the review.
Interventions being assessed
We aimed to evaluate any intervention used for treating or preventing deterioration of symptoms of
antipsychotic-induced TD. There is a vast array of strategies to deal with TD – one review identified over
100.50 Based on our experience with Cochrane reviews in this research area, we grouped the interventions
as follows:
1. vitamins
2. GABA agonists
3. benzodiazepines
4. anticholinergics
5. cholinergics
6. calcium channel blockers
7. non-antipsychotic dopaminergics and noradrenergics
8. specific antipsychotic drugs
9. antipsychotic reduction or cessation including intermittent therapy
10. other interventions, including botulin toxin, insulin or lithium, among others.
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We compared interventions with other interventions used to treat or prevent deterioration of symptoms of
antipsychotic-induced TD of relevance to people in the NHS, placebo or no intervention.
Prioritisation of interventions for the NHS
From the included studies we listed all interventions, regardless of the primary condition, in order to map
research activity. From this mapping, we chose to target, for this report, the top 10 interventions that seem
to have demonstrated some efficacy and that are relevant for clinical practice and the NHS.
Measurement of outcomes
The following outcomes were included in the overview:
l clinical improvement of TD symptoms
l deterioration of TD symptoms
l adverse events – extrapyramidal symptoms
l adverse events – all
l mental state
l acceptability of the treatment – leaving the study early
l social confidence, social inclusion, social networks, or personalised quality-of-life measures [this
outcome was designated as important to patients, informed by the results of the patient and public
involvement (PPI) consultation].
The Cochrane reviews included several more outcomes.
Design and theoretical/conceptual framework
We included randomised or quasi-randomised controlled trials containing data related to antipsychotic-
induced TD, irrespective of language or place of publication. We also considered observational studies for
inclusion with the following designs: (1) non-randomised controlled trials, (2) prospective cohort studies
with a control group and (3) case–control studies. The systematic reviews and the overview of reviews
follow Cochrane design and methodology.53
Target population
We included studies of adults with a diagnosis of antipsychotic-induced TD (according to any criteria),
regardless of the primary condition.
Inclusion/exclusion criteria
We excluded studies in which participants had used antipsychotic drugs for < 3 months or in which the
antipsychotic doses had not been stable for at least 1 month4 (except in analyses of antipsychotic switch,
withdrawal or reduction). In addition, we excluded studies evaluating children and adolescents, or studies
evaluating interventions that are not relevant to the NHS.
We also excluded studies that were > 10 years old that otherwise qualified for inclusion, but reported no
useable data and in which:
l we contacted study authors requesting data, but received no reply
l we were unable to contact any of the study authors.
Setting/context
Participants may be receiving treatment in any setting, any country or any health-care system.
Search strategy
We attempted to identify all relevant studies regardless of language or publication status (published,
unpublished, in press and in progress).
METHODS
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We searched Cochrane Schizophrenia Group’s Study-Based Register of Trials on 16 July 2015 using the
following string:
*Tardive Dyskinesia* in Healthcare Condition Field of Study.
In such a study-based register, searching the major concept retrieves all the synonym keywords and
relevant studies because all the studies have already been organised based on their interventions and
linked to the relevant topics. The Cochrane Schizophrenia Group’s Register of Trials is compiled by
systematic searches of major resources [including Allied and Complementary Medicine Database (AMED),
Bioscience Information Service, Cumulative Index to Nursing and Allied Health Literature (CINAHL),
EMBASE, MEDLINE, PsycINFO and PubMed, and registries of clinical trials including CT.Gov, International
Standard Randomised Controlled Trial Number (ISRCTN) and the World Health Organization’s International
Clinical Trials Registry Platform registries] and their monthly updates, hand-searches, grey literature and
conference proceedings (see Group’s Module: http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/
SCHIZ/frame.html). There are no language, date, document type or publication status limitations for
inclusion of records into the register.
We also searched the Cochrane Dementia and Cognitive Improvement Group’s Register of Trials via the
Cochrane Register of Studies Online (CRSO; http://crso.cochrane.org/) on 21 July 2015 using the
following string:
DEMENTIA:CC AND (*Tardive* OR *Dyskinesia*):TI,AB,KY.
For more information about this register, see the register’s page (www.medicine.ox.ac.uk/alois/content/
about-alois).
Finally, we searched EMBASE, MEDLINE, and PsycINFO for observational studies on 9 January 2017, and
details of the search strategy can be found in Appendix 3.
We inspected references of all identified studies for further relevant studies.
As some of the Cochrane reviews have not been updated during the past decade, and systematic reviews
methods have changed considerably during this period of time, we also cross-checked all included,
awaiting assessment, ongoing and excluded studies in the suite of nine Cochrane reviews on
antipsychotic-induced TD.
Selection of studies
We uploaded search results into a web-based system (DistillerSR®, Evidence Partners, Ottawa, ON, Canada;
www.systematic-review.ca). At least two reviewers (out of Antonio Grande, Rosie Asher, Hanna Bergman
and Karla Soares-Weiser) independently screened all citations and abstracts identified by the search. Two
reviewers (Hanna Bergman and Karla Soares-Weiser) inspected all studies from the nine Cochrane reviews
on TD. We obtained full reports for potentially eligible studies and these were independently screened by
two review authors (Antonio Grande and Rosie Asher). Disagreements were resolved through discussion
with reviewers (Hanna Bergman and Karla Soares-Weiser). We documented justifications for excluding
studies from the review.
Data extraction and management
Reviewer Rosie Asher extracted data from all included studies. These were cross-checked by Antonio Grande,
and further validated by Hanna Bergman. Any disagreements about data extraction were documented and
resolved by consensus. Any potential differences or data entry problems were discussed and decisions
documented.
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If more than one publication was identified reporting data from the same participants, the main
publication was considered as the one with more information or with longer-term outcomes; all others
were considered companion publications and data were only collected from these if they had not been
provided in the main publication.
We attempted to contact authors in order to obtain missing information or for clarification
whenever necessary.
We extracted data into tabular format, with an ‘address’ to each point in the document from which each
data element had been taken. This allows future researchers to verify extraction and avoid duplication of
effort. All data extracted in this way are fully available to researchers.54
We extracted data from graphs in GetData Graph Digitizer software version 2.26 (GetData Graph Digitizer,
S Federov, Moscow, Russia).
Some specific outcomes
No clinically important improvement in tardive dyskinesia
‘No clinically important improvement’ was defined as < 50% improvement on any scale measuring TD, or
as defined by triallists of the individual studies. For this outcome we assumed that participants with missing
data did not improve.
We have shown details of the scales that provided usable data below.
Brief Psychiatric Rating Scale
The Brief Psychiatric Rating Scale (BPRS) is an 18-item scale measuring positive symptoms, general
psychopathology and affective symptoms.55 The original scale has 16 items, although a revised 18-item
scale is commonly used. Total scores can range from 0 to 126. Each item is rated on a seven-point scale,
with high scores indicating more severe symptoms.
Extrapyramidal Symptom Rating Scale
The Extrapyramidal Symptom Rating Scale (ESRS) was developed to assess four types of drug-induced
movement disorders: Parkinsonism, akathisia, dystonia and TD.56 The score for TD, ranging from 0 to 42,
is based on the sum of all seven items in the TD objective examination.
Simpson–Angus Scale
The Simpson–Angus Scale (SAS)57 is a 10-item scale, with a scoring system of 0–4 for each item,
measuring drug-induced Parkinsonism, a short-term drug-induced movement disorder. A low score
indicates low levels of Parkinsonism.
Udvalg for Kliniske Undersøgelser Side-Effect Rating Scale
The Udvalg for Kliniske Undersøgelser (UKU) was developed to provide a comprehensive side-effect rating
scale with well-defined and operationalised items to assess the side effects of psychopharmacological
medications.58 The scoring sheet includes 48 items, with higher scores indicating more side effects.
Assessment of risk of bias of the included studies
Rosie Asher classified and Hanna Bergman cross-checked studies as being at low, unclear or high risk of
bias, based on domain-specific assessments of risk of bias done using the Cochrane Collaboration’s
existing risk-of-bias tool.53 If the raters disagreed, we made the final rating by consensus, with the
involvement of another member of the review group. Where inadequate details of randomisation and
other characteristics of trials were provided, we contacted authors of the studies in order to obtain
further information.
METHODS
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We incorporated these judgements in assessing limitations in study design for outcomes in the summary-
of-findings table (see Table 2).
Risk-of-bias assessment for observational studies was performed by a senior systematic reviewer (Artemisia
Kakourou) using a tool that is currently being tested by Cochrane.59 The following domains were assessed:
(1) confounding and selection bias (including confounders measured and addressed, use of matching and
methods of adjustment), (2) performance bias (including any considerations of co-intervention), (3) missing
data, (4) detection (for cohort studies) or recall bias (for case–control studies) and (5) selective reporting bias.
Data analysis
Analyses of single studies
Dichotomous data
For each study, the risk ratio (RR) and 95% CI were derived for people receiving the intervention compared
with the control.
Continuous data
We included continuous data from rating scales only if:
l the psychometric properties of the measuring instrument had been described in a peer-reviewed journal60
l the measuring instrument was not written or modified by only one of the authors of the particular
study from which the data were taken, but had also received independent validation.
For each study, the mean difference (MD) between groups and 95% CIs were estimated.
We also produced descriptive tables summarising information about study design, risk of bias and results
of all included studies. Data were presented by each specific intervention according to the main diagnosis
(schizophrenia or dementia).
Crossover trials
A major concern of crossover trials is the carry-over effect. This occurs if an effect (e.g. pharmacological,
physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a
consequence, on entry to the second phase the participants can differ systematically from their initial state,
despite a washout phase. For the same reason, crossover trials are not appropriate if the condition of
interest is unstable.61 As both effects are very likely in severe mental illness, we used only data of the first
phase of crossover studies.
Meta-analyses
Where studies were considered substantively similar enough for meta-analysis to be appropriate, we
carried out fixed-effects analyses using the RevMan software version 5.3.5 (The Cochrane Collaboration,
The Nordic Cochrane Centre, Copenhagen, Denmark).
We understand that there is no closed argument for preference for use of fixed- or random-effects models.
The random-effects method incorporates an assumption that the different studies are estimating different,
yet related, intervention effects. This often seems to be true to us and the random-effects model takes into
account differences between studies, even if there is no statistically significant heterogeneity. There is,
however, a disadvantage to the random-effects model. It puts added weight onto small studies, which
often are the most biased ones. Depending on the direction of effect, these studies can either inflate or
deflate the effect size. We chose the fixed-effects model for all analyses.
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Observational studies
We provided an overview of evidence from observational studies. Study characteristics, results and
conclusions were tabulated and summarised.
Variation in efficacy according to characteristics of individuals and studies
Visual inspection of the forest plots was used to evaluate the potential statistical heterogeneity (differences
between the true intervention effects in the different studies). Heterogeneity was quantified by estimating
the between-study variance τ2- and the I2-statistics,62,63 which measures the percentage of observed variation
that can be attributed to true differences between the studies.62 In forest plots and meta-analyses, τ2 was
estimated using the restricted maximum likelihood estimator,64 whereas its 95% CIs were estimated by the
Q-profile method.65
Summarising and interpreting results
We used the Grading of Recommendations, Assessment Development and Evaluation (GRADE)
approach66–68 to assess the evidence of the various interventions. For all NHS-prioritised interventions and
outcomes, we have presented a summary-of-findings table (see Table 2) based on the GRADE results.
Investigation of heterogeneity
We considered a degree of heterogeneity inevitable, and hence we planned to explore only important
heterogeneity (I2 ≥ 75%) using metaregression or subgroup analyses for the effect modifiers: (1) risk of
bias in the different study designs; (2) length of antipsychotic use; (3) underlying disease (dementia or
schizophrenia); (4) sex/age; (4) type of treatment use, specifically first- or second-generation antipsychotics;
and (5) whether or not other concomitant drug interventions were used. Analyses were homogeneous
with no important heterogeneity (I2 ≥ 75%).
Sensitivity analyses
To ensure that our imputations did not bias our results, we planned to restrict the analyses to studies
considered to be at low, and low or unclear risk of selection and detection bias. However, all studies were
at unclear risk of selection and detection bias, and we did not carry out this restricted analysis.
Planning of future studies
To judge the sufficiency of the evidence for the comparison of switching to any FGAs versus any SGAs,
we calculated the conditional power of an updated meta-analysis for the particular comparison as
described in Sutton et al.69 We further investigated whether or not hypothetical future studies are likely
to alter the meta-analysis results using extended funnel plots.70 Given the small number of studies
available, a fixed-effect inverse-variance meta-analysis model was assumed for this analysis.
Power of an updated meta-analysis based on simulations of new studies
We estimated the power of an updated meta-analysis through the simulation of (sufficiently similar)
hypothetical ‘new’ studies and calculating the proportion of times that the meta-analysis result would be
statistically significant.69 The event rate was assumed to be equal to that observed, and the number of
simulations on which we estimated power was 1000.
Extended funnel plots
We further assessed whether or not future studies are likely to alter the meta-analysis result via extended
funnel plots.70 A colour code appended in conventional funnel plots illustrates where the result of an
updated meta-analysis would lie, depending on the effect estimate and the standard error of a
hypothetical new study to be added to the evidence base.
METHODS
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Part C: methods for network meta-analysis
In order to facilitate clinical decision-making and a plan of future research, we planned to conduct a NMA
as we expected that few studies reported trials with head-to-head comparisons of different interventions.
We carried out an exploratory NMA, and the results are presented in Appendix 4. The main reasons for the
decision of only presenting the results in the appendix are (1) there were few data, (2) there was a median of
one study per comparison, ranging up to 11 for cholinergic drugs and 13 for vitamin E, (3) there were no
differences between pairwise meta-analyses and NMA and (4) there were no sufficiently connected networks.
DOI: 10.3310/hta21430 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 43
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bergman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
13

Chapter 4 Part A: results of patient and
public involvement
Dawn-Marie Walker worked with the McPin Foundation to organise an event to which a group ofservice users (n = 6) were invited and at which there was the opportunity to discuss the review’s
results. All of the service users had TD or were at risk of developing it. All attendees recognised TD as a
serious condition: ‘TD can be as debilitating as the psychosis itself’. They recognised that TD could increase
stigma, as one could not hide it, which in turn would have a negative impact on one’s self-esteem. Indeed,
there were suggestions for a therapeutic intervention to help people with TD learn coping mechanisms.
The attendees argued that prevention was better than cure, and wondered how much psychiatrists knew
about TD and, in turn, how much patients knew prior to taking a medication. With regard to the outcomes
of the trial, they thought that the review placed too much emphasis on pharmaceutical interventions and
were concerned that an adverse effect of medication was being treated by other medications. Owing to the
lack of definite findings about a treatment for TD, one commented: ‘I’m appalled by the poverty of this
evidence base given how debilitating TD is’ (Figure 1).
One of the questions participants posed was whether or not research could be done to try to identify
those who are at risk of TD. There was also some debate about the similarities in presentation between
Tourette syndrome and TD, with a number of public awareness campaigns helping reduce the stigma of
Tourette syndrome, and some participants asked if a similar approach would work for TD. When the
outcome measures cited in the review were discussed, the attendees thought all of them were important;
however, they felt that some relating to empowerment and autonomy, such as knowledge of TD (health-care
practitioner, patient and public) or a social integration scale (see Appendix 1), were missing.
FIGURE 1 Message from one of the participants of the PPI consultation of service user perspectives on TD research.
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Chapter 5 Part B: results of systematic reviews
Search and screening
The update search retrieved 704 references from the Cochrane Schizophrenia Group’s Register and
29 references from the Cochrane Dementia and Cognitive Improvement Group’s Register. Four duplicate
reports included in both these registers were removed. In addition, as we aimed to code all studies, we
independently re-extracted the data of all included and excluded studies in the published TD Cochrane
reviews and cross-checked all references; 222 additional records were found in the reference lists of
previously published Cochrane reviews. In total, we screened 947 records. After excluding irrelevant
references when screening the titles and abstracts, we identified 565 potentially relevant full-text articles
that were assessed for eligibility. We excluded 398 full-text articles (grouped into 329 studies) with
documented reasons for exclusion (see Appendix 5). We included 112 studies (167 references) in the nine
Cochrane reviews (see Appendix 6), including two studies awaiting classification and 11 ongoing studies.
We did not identify any included studies for people with dementia and antipsychotic-induced TD.
See Figure 2 for the screening and study selection process.
Records after duplicates removed
(n = 947)
Records screened
(n = 947)
Full-text articles
assessed for eligibility
(n = 565)
Records identified through
database searching
(n = 729)
Additional records identified
through searching published
Cochrane reviews on TD
(n = 222)
Records
excluded
(n = 382)
Full-text
articles 
(329 studies)
excluded,
with reasons
(n = 398)
Studies (167 references) included in the Cochrane reviews
(n = 112)
Studies (54 references) (n = 30)
Ongoing studies (n = 3)
Studies awaiting classification of
interventions prioritised in this
systematic review as the most
relevant for the NHS (n = 2)
Studies (99 references) (n = 69) 
Ongoing studies (9 references)
included only in the Cochrane
reviews as they report on
interventions that were not
prioritised for the NHS (n = 8)
FIGURE 2 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
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Studies were assessed in Chinese, Danish, French, German, Japanese, Korean, Persian, Portuguese, Spanish
and English. There were 10 included studies in Chinese,71–80 three in German,81–83 three in Japanese,84–86
and one each in Persian87 and in Portuguese.88
The observational studies search retrieved 3312 references. After de-duplication, 2702 references were
screened. A total of 2261 titles and abstracts were excluded, and 41 full texts were retrieved and screened.
Thirty studies (31 references) were excluded and eight studies (10 references) were included [see Figure 11
in Appendix 3 for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
flow diagram].
Prioritisation of interventions
In consultation with a NHS consultant psychiatrist (Clive E Adams), we identified the 10 interventions that
are mostly relevant for the NHS, and these interventions (30 unique studies) were included in the current
report. The 10 were chosen for ‘local’ accessibility, breadth of approach and practicality. We realise that
opinions could differ on which choice should have been made, but it was directed by having available trials
and also being accessible in the UK’s NHS. The 10 interventions prioritised as the most relevant for the NHS
were anticholinergics, antipsychotics, antipsychotic reduction, antipsychotic withdrawal, benzodiazepines,
buspirone, hypnosis and relaxation, placebo, treatment as usual (TAU) and vitamin E. These 10 interventions
are included in the pairwise comparisons of this report and in the NMA.
Box 1 lists all interventions from eligible randomised trials included in the Cochrane reviews, and the
interventions prioritised and reported in this overview are highlighted in bold. The full Cochrane reviews
should be the point of reference for details of every study and outcome (see Appendix 6). This report
represents a summary.
Accessible data
Because of copyright it is not possible to share the full text of original papers, but all data have been
extracted and tabulated, and the exact location of every piece of data is recorded in these tables. Pairing
these tables with the original report allows tracking of data back to full text. These extracted data are
freely available on Cochrane Schizophrenia Group’s website via ResearchGate (ResearchGate GmBH,
Berlin, Germany).54 Also, the extracted data beside the linked full-text reports are available to be used for
research purposes in Cochrane Schizophrenia Group’s Study-Based Register of Trials.
Description of studies
Studies included in overview
Randomised controlled trials
We included 30 unique clinical trials (54 articles published between 1973 and 201175,78,89–139) reporting
results for the effects of the prioritised interventions on clinical improvement and deterioration of TD
symptoms, mental state, adverse events and acceptability of treatment. None of the included studies
reported on quality of life. All studies were described as being randomised controlled. Seven of the
30 studies used a crossover design with two periods89–95 and, as planned, we used only data from before
the first crossover (see Appendix 2, Unit of analysis issues). Studies were conducted in North America
(15 studies89,92,93,96,97,101,104,117,120,121,123,128,129,137,139), Asia (10 studies75,78,90,91,94,108,112,115,127,138), Europe (four
studies95,98,119,130) and Africa (one study110), with a total of 1255 participants included. Studies included both
men and women of mostly wide age ranges, but participants were mainly men in their fifties, with mean
ages ranging from 32 to 68 years.
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BOX 1 Prioritised interventions for treatment of TD from eligible randomised trials (those in bold are prioritised
interventions)
l Anticholinergic: procyclidinea.
l Anticholinergic continuation: biperiden.
l Anticholinergic withdrawal: biperiden.
l Antipsychotic continuation.
l Antipsychotic reduction.
l Antipsychotic withdrawal (with placebo).
l Benzodiazepine: clonazepam.
l Benzodiazepine: diazepam.
l Calcium channel blocker: diltiazem hydrochloride.
l Calcium channel blocker: diltiazem hydrochloride.
l Calcium channel blocker: nifedipine.
l Cholinergic medication: deanol.
l Cholinergic medication high dose: deanol, 2 g.
l Cholinergic medication low dose: deanol, 1 g.
l Cholinergic medication: galantamine.
l Cholinergic medication: lecithin.
l Cholinergic medication: meclofenoxate hydrochloride.
l Cholinergic medication: rivastigmine.
l GABA agonist: baclofen.
l GABA agonist: GABA.
l GABA agonist: progabide.
l GABA agonist: sodium valproate.
l GABA agonist: THIP.
l Miscellaneous: L-stepholidine.
l Miscellaneous: branched-chain amino acids.
l Miscellaneous: buspirone.
l Miscellaneous: ceruletide.
l Miscellaneous: cyproheptadine.
l Miscellaneous: dihydrogenated ergot alkaloids/co-dergocrine mesylate.
l Miscellaneous: oestrogen.
l Miscellaneous: gamma-linolenic acid supplementation (oil of evening primrose).
l Miscellaneous: Ginkgo biloba standardised extract (EGb-761).
l Miscellaneous: hypnosis or relaxation.
l Miscellaneous: insulin.
l Miscellaneous: levetiracetam.
l Miscellaneous: lithium.
l Miscellaneous: MAO inhibitors (isocarboxazid, selegiline).
l Miscellaneous: melatonin.
l Miscellaneous: omega-3 fatty acid (ethyl-eicosapentaenoic acid).
l Miscellaneous: papaverine.
l Miscellaneous: pemoline.
l Miscellaneous: phenylalanine.
l Miscellaneous: piracetam.
l Miscellaneous: promethazine.
l Miscellaneous: ritanserin.
l Miscellaneous: VMAT2 inhibitor (NBI-98854).
l Non-neuroleptic catecholaminergic: amantadine.
l Non-neuroleptic catecholaminergic: bromocriptine.
l Non-neuroleptic catecholaminergic: carbidodopa/levodopa.
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An overview of characteristics of the included studies contributing data for this report are presented in
Table 1 and full details of study characteristics are available in Appendix 7.
In addition to the included studies:
1. We have requested details on participants from study authors to determine the eligibility for one study
comparing dexetimide and benzhexol.140
2. One study described as a double-blind, randomised study on vitamin E could not be identified after
exploring numerous sources.141
3. The full text of a randomised controlled trial (RCT), published in 1992, comparing buspirone and
placebo could not be identified.142
4. The full text of a RCT described in a trial registry comparing quetiapine with risperidone could not
be identified143
5. One study comparing cannabidiol extract with vitamin E is ongoing.144
Full details of characteristics for ongoing trials and studies awaiting classification are available in Appendix 8.
l Non-neuroleptic catecholaminergic: L-DOPA.
l Non-neuroleptic catecholaminergic: oxypertine.
l Non-neuroleptic catecholaminergic: reserpine.
l Non-neuroleptic catecholaminergic: tiapride.
l Non-neuroleptic catecholaminergic: tetrabenazine.
l Non-neuroleptic catecholaminergic: celiprolol.
l Non-neuroleptic catecholaminergic: methyldopa.
l Phenobarbital (as active placebo).
l Placebo.
l Switch to a different FGA.
l Switch to a different FGA (not specified).
l Switch to a different FGA (haloperidol).
l Switch to a different FGA [molindone (Moban®; Endo Pharmaceuticals Inc., Malvern, PA, USA)]b.
l Switch to a different FGA (thiopropazate)b.
l Switch to a different FGA (zuclopentixol)b.
l Switch to SGA.
l Switch to SGA (amisulpride).
l Switch to SGA (clozapine).
l Switch to SGA (olanzapine).
l Switch to SGA (quetiapine).
l Switch to SGA (risperidone).
l Switch to SGA (ziprasidone).
l TAU.
l Vitamin B6 (pyridoxal 5′-phosphate).
l Vitamin E.
L-DOPA, L-3,4-dihydroxyphenylalanine; MAO, monoamine oxidase; THIP, 4,5,6,7-tetrahydroisoxazolo[5,4-c]
pyridin-3-ol; VMAT2, vesicular monoamine transporter 2.
a Not used (in a head-to-head comparison with isocarboxazid).
b Not used (in a head-to-head comparison with another FGA).
BOX 1 Prioritised interventions for treatment of TD from eligible randomised trials (those in bold are prioritised
interventions) (continued)
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Observational studies
We included eight unique observational studies (10 articles published between 1983 and 2016145–154)
reporting results for the effects of the prioritised interventions on clinical improvement and deterioration
of TD symptoms and mental state. None of the included studies reported on quality of life, adverse events
or acceptability of the intervention. Two studies (three references) were described as non-randomised
controlled145–147 and six (seven references) were described as prospective cohorts.148–154 Studies were conducted
in North America (four studies145,149,151,153), Asia (two studies150,152) and Europe (two studies146,148). A total of
200 participants were included. Studies included adults, both men and women of mostly wide age ranges,
with mean ages ranging from 26 to 84 years.
An overview of characteristics of the included observational studies contributing data to this report is
presented in Appendix 3 (see Table 4).
Studies excluded from this review
Randomised controlled trials
Sixty-nine studies (99 articles) did not investigate prioritised comparisons and were not included in this
report. These studies investigated calcium channel blockers (three studies), cholinergic medication
(14 studies), GABA antagonists (11 studies), non-antipsychotic dopaminergic or noradrenergic medication
(nine studies), FGAs versus other FGAs (three studies), anticholinergic versus monoamine oxidase (MAO)
inhibitors (one study) and various miscellaneous, experimental treatments, such as lithium, melatonin and
insulin (28 studies). Full details of these studies and results of comparisons are available in the Cochrane
reviews and an overview is available in Appendix 9.
Observational studies
Please see Appendix 3 (see Table 5) for details of references excluded at full-text screening. In addition,
one of the included observational studies was not prioritised for this report because it investigated
deep-brain stimulation, not one of the NHS-relevant interventions.146,147
Risk-of-bias assessments
Randomised controlled trials
Detailed risk-of-bias assessments of all included studies are in Appendix 7.
Overall risk of bias for the included studies was rated as being high to unclear. It is astonishing to note
that only one of the studies was rated as being free from risk of selection bias.137 The remaining trials
reported inadequately on randomisation and allocation concealment. Furthermore, seven studies were
rated as being at high risk of performance bias and 13 were rated as being of unclear risk. This was mainly
a result of trials being open label, or poor reporting of blinding. One study was rated as being at high risk
of detection bias and 18 were rated as being of unclear risk; this is mainly because of poor reporting.
Ten studies were rated as being at high risk of attrition bias (because of high or imbalanced dropout rates)
and two at unclear risk. Thirteen studies were rated as being at high risk of reporting bias as a result of
selective reporting of outcome measures, and 12 were rated at an unclear risk. We sought information
from study authors where risk of bias was rated as being unclear.
As a post hoc comparison, we evaluated risk of bias in studies published within the past 20 years
(1997–2011) compared with older studies published until 1996 (Figure 3). We found that methodological
quality had improved only marginally over time on most risk-of-bias categories (selection, performance,
attrition and reporting biases). There was no change for detection bias, and other bias had improved
over time.
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TABLE 1 Overview of included RCTs characteristics
Included
studies
(first author
and year of
publication)
Study characteristic
Methods Participants Interventions
Randomised
Double
blind Design
Duration
(weeks) Diagnosis n
Age
(years) Sex
Group 1
intervention Dose
Antipsychotic drugs
Kazamatsuri
et al., 197396
✗ ✗ Parallel 24 Chronic SCZ
and TD
13 Mean
55.8
F and M Haloperidol
(after 4-week
washout)
4mg b.i.d. (weeks
15–24 16mg/day)
Kane et al.,
198397
✗ ✗ Parallel 48 SCZ/
schizoaffective
and TD
8 17–60 Unknown Fluphenazine Low dose
(1.25–5mg every
2 weeks)
Cookson,
198798
✗ ✗ Parallel 44 SCZ 18 Mean
44.5
F and M Flupentixol
decanoate
50% reduction
from original dose
Chouinard and
Arnott,
1992,99,100
1993;102
Chouinard
et al., 1993;103
Chouinard,
1995101
✗ ✗ Parallel 8 SCZ 135 Mean 39 F and M Risperidone 2mg per day
(n= 8), 6mg per
day (n= 6), 10mg
per day (n= 6),
16mg per day
(n= 11)
Tamminga
et al., 1994104
✗ ✗ Parallel 52 SCZ and TD 32 Mean
35.57
F and M Clozapine
and placebo
293.8mg per day
Bai et al.,
2002,105
2003,108
2005;106 Pai
et al., 2002,107
2001109
✗ ✗ Parallel 12 SCZ and TD 42 Mean
50.2
F and M Risperidone
(after 2-week
washout)
2mg per day
increased to 6mg
per day (6 weeks)
and maintenance
(12 weeks)
Emsley et al.,
2004110,111
✗ Parallel 50 SCZ and TD 45 Mean
49.2
F and M Quetiapine
(after 2-week
washout)
100mg per day
increased to
400mg per day
Bai et al.,
2005112–114
✗ Parallel 24 SCZ and TD 80 Mean
50.2
F and M Olanzapine Unknown
Chan et al.,
2010115,116
✗ Parallel 24 SCZ/
schizoaffective
and TD
60 Mean
45.3
F and M Risperidone
(after
3–7 days
washout)
1.9mg per day
increased to
4.1mg per day
Caroff et al.,
2011;117 Miller
et al., 2005118
✗ ✗ Parallel 78 SCZ and TD 200 Mean
47.2
F and M Olanzapine 7.5mg q.d./b.i.d./
t.i.d./q.i.d.
Anticholinergic drugs
Greil et al.,
1984119
✗ ✗ Parallel 7 SCZ and TD 10 Mean
56.6
F and M Biperiden Dose stopped
after 4 weeks
and placebo was
then given for
3 weeks
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Outcomes
Group 2
intervention Dose Other groups
Other
medications
allowed
TD
symptoms
Study
discontinued
QoL
measures
Mental
state
Adverse
events
Tetrabenazine
(after 4-week
washout)
50mg b.i.d.
(weeks 15–24
200mg/day)
Antidiabetics
and
anticonvulsants
✗ ✗
Fluphenazine
maintenance
Standard
dose 12.5–
50 mg/2 weeks)
Procyclidine/
flurazepam/
diazepam
✗ ✗
Flupentixol
maintenance
Standard dose Procyclidine/
haloperidol/
zuclopentixol
decanoate/
amitriptyline
✗ ✗
Haloperidol 20mg per day Placebo Benzodiazepines/
biperiden or
procyclidine
✗
Haloperidol
and
benztropine
28.5mg/day N/A ✗
Placebo 2mg per day
increased to
6mg per day
(6 weeks) and
maintenance
(12 weeks)
Benzodiazepines/
antiparkinson
medications
✗ ✗ ✗
Haloperidol
(after 2-week
washout)
5mg per day
increased to
10mg per day
Benzodiazepines/
anticholinergic
agents
✗ ✗ ✗
Amisulpride Unknown FGA (unknown
dose)
N/A ✗ ✗ ✗ ✗
Olanzapine 8.1mg per day
increased to
12.6mg per
day
N/A ✗ ✗ ✗
Quetiapine 200mg/q.d./
b.i.d./t.i.d./q.i.d.
Risperidone
1.5mg/q.d./
b.i.d./t.i.d./q.i.d.
or ziprasidone
40mg/q.d./
b.i.d./t.i.d./q.i.d.
N/A ✗
Biperiden Dose stopped
after 1 week
and placebo
given for
6 weeks
Antipsychotic
medications
✗
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TABLE 1 Overview of included RCTs characteristics (continued )
Included
studies
(first author
and year of
publication)
Study characteristic
Methods Participants Interventions
Randomised
Double
blind Design
Duration
(weeks) Diagnosis n
Age
(years) Sex
Group 1
intervention Dose
Benzodiazepines
Bobruff et al.,
1981120
✗ ✗ Parallel 2 Psychiatry
patients and
TD
21 Mean
51.6
F and M Clonazepam 3.9mg per day
Weber et al.,
198389
✗ Cross
over
24 SCZ/brain
syndrome/
unknown and
TD
15 Mean
57.4
F and M Standard
care and
diazepam
6–25mg per day
Csernansky
et al.,
1988121,122
✗ ✗ Parallel 5–6 SCZ and TD 17 Unknown Unknown Diazepam 7.2mg per day
Xiang and
Zhen, 199775
✗ ✗ Parallel 8 SCZ and TD 24 Mean
39.4
F and M Standard
care and
clonazepam
4–6mg per day
Vitamin E
Elkashef et al.,
199093
✗ ✗ Cross
over
10 SCZ/
schizoaffective
and TD
10 Mean
56.6
F and M Vitamin E 400 IU per day
(1 week), 400 IU
b.i.d. (1 week),
400 IU t.i.d.
(2 weeks)
Schmidt et al.,
199195
✗ ✗ Cross
over
4 SCZ/
schizoaffective/
depression and
TD
23 Mean 45 F and M Vitamin E 1200 IU per day
Egan et al.,
199292
✗ ✗ Cross
over
12 SCZ/
schizoaffective/
depression/BD
and TD
21 Mean
43.9
F and M Vitamin E Week 1: 400 IU per
day; week 2:
800 IU per day;
week 3: 1200 IU
per day; weeks
4–6: 1600 IU per
day
Adler et al.,
1992,124
1993,125,126
1998123
✗ ✗ Parallel 36 SCZ/
depression and
TD
40 Mean 58 F and M Vitamin E Dose increasing to
1600 IU per day
Akhtar et al.,
1993127
✗ ✗ Parallel 4 Psychiatry
patients and
TD
32 Mean 53 F and M Vitamin E 600mg per day
increased to
1200mg per day
Dabiri et al.,
1994128
✗ ✗ Parallel 12 Psychiatry
patients and
TD
12 Mean 51 F and M Vitamin E Week 1: 400 IU per
day; week 2:
800 IU per day;
weeks 3–12:
1200 IU per day
Lam et al.,
199494
✗ ✗ Cross
over
16 SCZ and TD 16 Mean
61.8
F and M Vitamin E Week 1: 400 IU per
day; week 2:
400 IU b.i.d.;
weeks 3–6: 400 IU
t.i.d.
Lohr and
Calgiuri,
1996129
✗ ✗ Parallel 8 SCZ/
depression/BD
and TD
55 Mean
48.9
F and M Vitamin E 1600 IU per day
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Outcomes
Group 2
intervention Dose Other groups
Other
medications
allowed
TD
symptoms
Study
discontinued
QoL
measures
Mental
state
Adverse
events
Phenobarbital
(as active
placebo)
88.6mg per
day
Antipsychotics ✗ ✗ ✗
Standard care Unknown Antipsychotic
and
anticholinergic
medications
✗ ✗ ✗
Placebo 48.3mg per
day
Alprazolam Anticholinergics ✗ ✗
Standard care
and placebo
Unknown Antipsychotic
and
anticholinergic
medications
✗ ✗
Placebo Unknown Antipsychotics ✗ ✗ ✗
Placebo Unknown Antipsychotics ✗ ✗ ✗
Placebo Unknown Antipsychotics ✗ ✗ ✗
Placebo Unknown Antipsychotics ✗ ✗
Placebo Unknown Antipsychotics ✗ ✗ ✗ ✗
Placebo Unknown Antipsychotics ✗ ✗ ✗
Placebo Unknown Antipsychotics ✗ ✗
Placebo Unknown Antipsychotics ✗ ✗ ✗
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TABLE 1 Overview of included RCTs characteristics (continued )
Included
studies
(first author
and year of
publication)
Study characteristic
Methods Participants Interventions
Randomised
Double
blind Design
Duration
(weeks) Diagnosis n
Age
(years) Sex
Group 1
intervention Dose
Dorevitch
et al., 199791
✗ ✗ Cross
over
20 SCZ and TD 10 Mean
63.1
F and M Vitamin E Dose increasing to
1600 IU per day
Dorevitch
et al., 199790
✗ ✗ Cross
over
20 SCZ/
schizoaffective
and TD
40 Mean
64.4
F and M Vitamin E Week 1: 400 IU per
day; week 2:
800 IU per day;
week 3: 1200 IU
per day; weeks
4–8: 1600 IU
Sajjad, 1998130 ✗ ✗ Parallel 28 TD 20 Mean 68 F and M Vitamin E 400mg per day
increased to
1600mg per day
Tracy et al.,
1997;131 Lohr
and Lavori,
1998;132 Edson
et al., 1997;133
Caligiuri
et al., 1997;134
Adler et al.,
1994,135
1999;137
Brindler,
2001136
✗ ✗ Parallel 52 SCZ/
schizoaffective
and TD
158 Mean 50 F and M Vitamin E 1600 IU per day
Zhang et al.,
2004138
✗ ✗ Parallel 12 SCZ and TD 41 Mean
54.5
F and M Vitamin E Week 1: 800 IU per
day; weeks 2–12:
1200 IU per day
Buspirone
Zeng, 199578 ✗ ✗ Parallel 6 TD 42 Mean
32.5
F and M Buspirone Dose management
(1–12 capsules per
day)
Hypnosis and relaxation
Glover,
1980139
✗ Parallel 8 sessions SCZ and TD 15 Mean
34.9
F and M Hypnosis or
relaxation
8 sessions
BD, bipolar disorder; b.i.d., twice per day; F, female; M, male; N/A, not applicable; q.d., one per day; q.i.d., four times
per day; QoL, quality of life; RCT, randomised controlled trial; SCZ, schizophrenia; t.i.d., three times per day.
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Outcomes
Group 2
intervention Dose Other groups
Other
medications
allowed
TD
symptoms
Study
discontinued
QoL
measures
Mental
state
Adverse
events
Placebo Unknown Chlorpromazine ✗ ✗
Placebo Unknown Antipsychotics ✗ ✗ ✗
Placebo Unknown Antipsychotics ✗ ✗ ✗
Placebo Unknown Antipsychotics ✗ ✗ ✗ ✗
Placebo Unknown Antipsychotics ✗ ✗
Placebo Dose
management
(1–12 capsules
per day)
Antipsychotic
and
anticholinergic
medications
✗ ✗
TAU 8 sessions Psychotropics ✗
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Observational studies
Detailed risk-of-bias assessments of all included studies are in Appendix 3 (see Table 4).
Overall risk of bias for the included observational studies was rated as being high to unclear. None of the
observational studies was free from risk of selection bias, one study reported controlling for baseline
confounding, and three studies reported a reliable outcome assessment. For the domains of incomplete
outcome data and selective outcome reporting, none of the studies reported mechanisms to avoid bias
(Figure 4).
Proportion with low
risk of bias
New
(> 1997)
Old
(< 1996)
New
(> 1997)
Old
(< 1996)
New
(> 1997)
Old
(< 1996)
New
(> 1997)
Old
(< 1996)
New
(> 1997)
Old
(< 1996)
New
(> 1997)
Old
(< 1996)
New
(> 1997)
Old
(< 1996)
New: 3/11 (27%)
Old: 2/19 (11%)
New: 1/11 (9%)
Old: 1/19 (5%)
New: 4/11 (36%)
Old: 6/19 (32%)
New: 4/11 (36%)
Old: 7/19 (37%)
New: 7/11 (64%)
Old: 11/19 (58%)
New: 3/11 (27%)
Old: 2/19 (11%)
New: 6/11 (55%)
Old: 1/19 (5%)
0 50 10025 75
Selection bias (sequence generation)
Selection bias (allocation concealment)
Performance bias
Detection bias
Attrition bias
Reporting bias
Other bias
Percentage
Low
High
Medium
Risk of bias
FIGURE 3 Old (1973–96) vs. new (1997–2011) studies risk of bias.
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Effects of interventions
Table 2 summarises the results from RCTs for all comparisons. Forest plots for all analyses from RCTs are in
Appendix 10. An overview of results from observational studies is in Appendix 3 (see Table 4).
Comparison 1: reduced dose of antipsychotics versus continuing antipsychotics
Two very small randomised trials97,98 conducted with schizophrenia or schizoaffective disorder inpatients and
outpatients in the UK and USA reported on reduced doses compared with standard doses of flupentixol and
fluphenazine. Evidence was of very low quality (see Table 2); therefore, we are uncertain of the results:
l TD symptoms improved to a clinically important extent for significantly more people allocated to
antipsychotic reduction than antipsychotic continuation after 44–48 weeks (very low-quality evidence,
two RCTs,97,98 17 people; RR 0.42, 95% CI 0.17 to 1.04; I2 = 0%).
l There was no significant difference in deterioration of TD symptoms at 44–48 weeks (very low-quality
evidence, two RCTs,97,98 17 people; RR 0.61, 95% CI 0.11 to 3.31; I2 = 33%).
l The number relapsing was not significantly different in the antipsychotic reduction group (1/4) and the
antipsychotic maintenance group (0/4) at 44–48 weeks (one RCT,97 eight people; RR 3.00, 95% CI
0.16 to 57.36).
l The number of people leaving the study early was not significantly different in the antipsychotic
reduction group (1/4) and the antipsychotic maintenance group (3/4) (very low-quality evidence, one
RCT,97 eight people; RR 0.33, 95% CI 0.06 to 1.99).
For this comparison there were no studies that reported on adverse events or social confidence, social
inclusion, social networks or personalised quality of life.
Observational studies
First-generation antipsychotics: dose discontinuation versus decrease versus increase
Three small observational studies reported on discontinuing antipsychotics compared with a decrease or
increase of the antipsychotic doses.145,150,153,154 The studies were conducted in patients with a serious
mental illness, mainly schizophrenia, in Canada, Japan and the USA. Evidence was rated as being of low to
very low quality; therefore, we are uncertain of the results:
l Casey and Toenniessen,145 a small prospective cohort study (n = 27), found that psychiatric patients
with TD whose antipsychotic medication was reduced or discontinued showed greater improvement in
TD symptoms after 5 years of follow-up than patients whose dosage of antipsychotic medication was
increased (55–65% vs. 35%). Other outcomes were not reported.
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FIGURE 4 Overview of included observational studies risk of bias.
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l Koshino et al.,150 a small prospective cohort study (n = 28), found that the severity of TD was
unchanged in 39.3% of the patients, improved in 17.9%, fluctuated in 21.4% and worsened in
21.4% at 11 years’ follow-up. The outcome was not associated with discontinuation, increase or
decrease in the dosage of antipsychotics.
l Yassa et al.,153,154 also a small prospective cohort study (n = 44), reported that 50% of patients had no
change in their TD severity, 20% had an improvement and 30% had a worsening of their TD. Little
difference was noted in those patients whose medication was decreased (33% had no change in TD
severity, 42% had increased TD severity and 25% had decreased TD severity) and those whose
medication remained unchanged (56% had no change in TD severity, 25% had increased TD severity
and 19% had decreased TD severity) at 10 years’ follow-up.
Comparison 2: switch to a different antipsychotic versus antipsychotic withdrawal
(with placebo)
Two small randomised trials101,108 conducted with schizophrenic inpatients in Canada and Taiwan reported
on switching to risperidone or haloperidol compared with placebo and withdrawing antipsychotics. Evidence
was rated as being of low to very low quality (see Table 2); therefore, we are uncertain of the results:
l TD symptoms improved to a clinically important extent for significantly more people allocated to
antipsychotic switch to risperidone than those allocated to placebo at 12 weeks (low-quality evidence,
one RCT,105–109 42 people; RR 0.45, CI 0.23 to 0.89).
l There was no significant difference in the use of antiparkinsonism drugs between switching to
risperidone or haloperidol compared with placebo at 8–12 weeks (two comparisons from one RCT,99–103
48 people; RR 2.08, CI 0.74 to 5.86; I2 = 0%).
l General mental state was measured using the continuous BPRS scale (see Some specific outcomes).
There was no significant difference between switching to risperidone compared with placebo on the
average end-point score of the BPRS at 12 weeks (one RCT,105–109 42 people; MD –4.30, CI –10.48
to 1.88).
l Using antipsychotics did not significantly increase the chances of a person leaving the study early at
12 weeks (very low-quality evidence, one RCT,105–109 50 people; RR 0.60, CI 0.16 to 2.25).
For this comparison there were no studies that reported on deterioration of TD symptoms or social
confidence, social inclusion, social networks or personalised quality of life.
Observational studies
First-generation antipsychotics: dose discontinuation versus maintenance
Three small observational studies reported on discontinuing antipsychotics compared with maintenance of
the standard doses.149,151,152 The studies were conducted in patients with a serious mental illness, mainly
schizophrenia, in the USA and Japan. Evidence was rated as being of low to very low quality; therefore,
we are uncertain of the results:
l Huang,149 a very small prospective cohort study (n = 10), found that psychiatric patients with TD whose
antipsychotic medication was reduced or discontinued showed a greater improvement in TD symptoms
after 4 years of follow-up than patients whose dosage of antipsychotic medication remained
unchanged (60% vs. 21%). Other outcomes were not reported.
l Peselow et al.,151 a small prospective cohort study (n = 31), reported a statistically significant decrease in
abnormal movements at 1 year of follow-up; this improvement was offset by the fact that 15 of the 21
(71.4%) patients discontinued from antipsychotic treatment relapsed.
l Yagi and Itoh,152 also a small prospective cohort study (n = 20), reported that, at 10 years’ follow-up,
64% (9/14) of patients in whom antipsychotics were discontinued or decreased after the occurrence of
TD presented a clinically important improvement in symptoms; this also occurred in 75% (3/4) of those
for whom the antipsychotic dose had been maintained. The authors suggested that the outcome of TD
was determined by the patient’s age at onset rather than by the course of antipsychotic treatment.
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Comparison 3a: switch to one antipsychotic versus switch to a different antipsychotic
Six small randomised trials101,104,110,112,115,117 of inpatients and outpatients with schizophrenia and
schizoaffective disorder conducted in in Canada, South Africa, Taiwan and the USA reported on switching
to a SGA (amisulpride, clozapine, olanzapine, risperidone, quetiapine, ziprasidone) compared with switching
to a different antipsychotic, either a FGA (haloperidol, unspecified FGA) or another SGA. Evidence was rated
as being of low to very low quality (see Table 2); therefore, we are uncertain of the results:
l There were no significant differences on clinically important improvement in TD symptoms at 6 months
between quetiapine and haloperidol (low-quality evidence, one RCT,110,111 45 people; RR 0.80, 95% CI
0.52 to 1.22) or between olanzapine and risperidone (very low-quality evidence, one RCT,115,116
60 people; RR 1.25, 95% CI 0.82 to 1.90).
l The number of people in need of antiparkinsonism drugs was significantly lower in the group allocated
to quetiapine than in the group allocated to haloperidol (one RCT,110,111 45 people; RR 0.45, 95% CI
0.21 to 0.96), but there was no significant difference between the groups allocated to risperidone or
haloperidol (one RCT,99–103 37 people; RR 0.68, 95% CI 0.34 to 1.35).
l Extrapyramidal symptoms at 6 months, as measured by the ESRS, were lower among participants on
olanzapine than in those on risperidone (one RCT,115,116 60 people; MD –0.70, 95% CI –1.33 to –0.07),
but there was no significant difference in extrapyramidal symptoms at 6 months, as measured by on
SAS, at 6 months between participants on olanzapine and those receiving amisulpride (one RCT,112–114
54 people; MD –0.35, 95% CI –2.44 to 1.74).
l There were no significant differences in general adverse events at 6 months, as measured on the UKU
scale, between patients on olanzapine (one RCT,112–114 53 people; MD 0.08, 95% CI –1.85 to 2.01)
or amisulpride (one RCT,112–114 53 people; MD –0.55, 95% CI –2.33 to 1.23) and thos receiving an
unspecified FGA, or between those on olanzapine and those on amisulpride (one RCT,112–114 54 people;
MD 0.63, 95% CI –0.93 to 2.19).
l There were no significant differences in deterioration of mental state at 1 year between patients on
quetiapine and those on haloperidol (one RCT,110,111 45 people; RR 1.83, 95% CI 0.62 to 5.39), or at
6 months between patients on olanzapine and those on risperidone (one RCT,115,116 60 people; RR
1.00, 95% CI 0.15 to 6.64) or at 6 months, measured on the BPRS, between patients on olanzapine
and those on amisulpride (one RCT,112–114 54 people; MD 1.32, 95% CI –1.94 to 4.58).
l People allocated to olanzapine were less likely to leave the study early, that is after 6–18 months, than
those allocated to risperidone (two RCTs,115–118 170 people; RR 0.73, 95% CI 0.57 to 0.95; I2 = 0%)
or quetiapine (one RCT,117,118 116 people; RR 0.70, 95% CI 0.54 to 0.90).
l There were no significant differences at 6 months to 1 year in acceptability of treatment, defined as
not leaving the study early, between patients receiving olanzapine or amisulpride and those receiving
an unspecified FGA,112–114 or between those receiving clozapine or quetiapine and those receiving
haloperidol,104,110,111 or between patients receiving olanzapine and those receiving amisulpride112–114
or ziprasidone,117,118 or between those on quetiapine and those on risperidone or ziprasidone,117,118
or between patients on ziprasidone and those on risperidone.117,118
For this comparison there were no studies that reported on deterioration of TD symptoms or social
confidence, social inclusion, social networks or personalised quality of life.
Observational studies
First-generation antipsychotics and gabapentin versus second-generation antipsychotics
and gabapentin
One small observational study compared first-generation antipsychotics with gabapentin to second-
generation antipsychotics with gabapentin in patients with serious mental illness (schizoaffective, bipolar I
disorder and schizophrenic patients) and TD, in Italy.148 This prospective cohort study (n = 30) reported that
gabapentin treatment reduced TD symptoms with a mean percentage improvement on the Abnormal
Involuntary Movement Scale (AIMS) of 47.5% (standard deviation ±18.2%) among all treated patients
regardless of the antipsychotic used. Those on SGAs (mean 11.2 patients, standard deviation 4.8 patients;
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n = 18) reported that symptoms improved slightly more than those on FGAs (mean 18.2 patients, standard
deviation 5.5 patients; n = 4).
Comparison 3b: specific antipsychotic versus other drug – haloperidol versus tetrabenazine
A very small randomised trial96 conducted with psychiatric inpatients in the USA compared haloperidol with
tetrabenazine. The evidence was rated as being of very low quality (see Table 2); therefore, we are
uncertain of the results:
l There was no significant difference in clinically important improvement in TD symptoms at 18 weeks
between patients receiving haloperidol and those receiving tetrabenazine (very low-quality evidence,
one RCT,96 13 people; RR 1.07, 95% CI 0.51 to 2.23).
l There was no significant difference in deterioration of TD symptoms at 18 weeks between patients
receiving haloperidol and those receiving tetrabenazine (very low-quality evidence, one RCT,96
13 people; RR 0.86, 95% CI 0.07 to 10.96).
l At 18 weeks there was no significant difference in the proportion of participants who had left the
study early between the haloperidol (2/7 participants) and tetrabenazine groups (0/6 participants)
(very low-quality evidence, one RCT,96 13 people; RR 4.38, 95% CI 0.25 to 76.54).
For this comparison there were no studies that reported on adverse events, mental state or on social
confidence, social inclusion, social networks or personalised quality of life.
Comparison 4: withdrawal of anticholinergics versus continuation of anticholinergics
A very small randomised trial119 conducted in schizophrenia patients in Germany compared stopping
biperiden after 1 week or after 4 weeks. The evidence was rated as being of very low quality (see Table 2);
therefore, we are uncertain of the results:
l There was no significant difference at 7 weeks in the proportion of people leaving the study early
between those withdrawn from anticholinergic therapy (1/6 participants) and those who continues
(0/4 participants) (very low-quality evidence, one RCT,119 10 people; RR 2.14, 95% CI 0.11 to 42.52).
For this comparison there were no studies with useable data on clinically important improvement or
deterioration of TD symptoms, adverse events, mental state or on social confidence, social inclusion, social
networks or personalised quality of life.
Comparison 5: benzodiazepines versus placebo, treatment as usual or active placebo
(with antipsychotic management)
Four small randomised trials75,89,120,122 conducted with psychiatric inpatients and outpatients in China and
the USA compared diazepam or clonazepam and antipsychotic continuation with placebo, TAU or
phenobarbital as active placebo and antipsychotic continuation. The evidence was rated as being of very
low quality (see Table 2); therefore, we are uncertain of the results:
l There was no significant difference in ‘no clinically important improvement of TD symptoms’ at 5–10 weeks
between patients on benzodiazepines and those receiving placebo or no treatment (very low-quality
evidence, two RCTs,89,121,122 32 people; RR 1.12, 95% CI 0.60 to 2.09; I2 = 14%). One trial found that
clonazepam was more beneficial than phenobarbital (as active placebo) at 2 weeks (very low-quality
evidence, one RCT,120 21 people; RR 0.44, 95% CI 0.20 to 0.96).
l There was no significant difference in deterioration of TD symptoms at 5–10 weeks (very low-quality
evidence, two RCTs,89,121,122 30 people; RR 1.48, 95% CI 0.22 to 9.82; I2 = 19%).
l One study reported on mental state average end-point scores using the BPRS scale and noted no
difference between the diazepam and TAU groups at 10 weeks (one RCT,89 11 people; MD –0.50,
95% CI –13.83 to 12.83).
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l One trial found no significant difference in the number of participants experiencing adverse events
after 2 weeks’ treatment with clonazepam or phenobarbital (as active placebo) (very low-quality
evidence, one RCT,120 21 people; RR 1.53, 95% CI 0.97 to 2.41). All participants allocated to clozapine
(10) and 7 out of 11 participants allocated to phenobarbital experienced an adverse event.
l Three studies reported that no participants left the study early.75,120–122 One study reported that 2 out of
33 participants allocated to diazepam, but none (out of 23) allocated to TAU, left the study early and,
subsequently, found no significant difference between the two groups at 10 weeks (very low-quality
evidence, one RCT,89 56 people; RR 2.73, 95% CI 0.15 to 48.04).
For this comparison there were no studies that reported on social confidence, social inclusion, social
networks or personalised quality of life.
Comparison 6: vitamin E versus placebo (with antipsychotic management)
Thirteen randomised trials90–95,123,127–130,137,138 in psychiatric inpatients and outpatients in China (one study138),
Hong Kong (one study94), Israel (two studies90,91), India (one study127), Switzerland (one study95), the UK
(one study130) and the USA (six studies92,93,123–126,128,129,131–137) reported on vitamin E (gamma-tocopherol) and
antipsychotic continuation compared with placebo and antipsychotic continuation. The evidence was rated as
being of low to very low quality (see Table 2); therefore, we are uncertain of the results. After up to 1 year:
l There was no significant difference between the vitamin E and placebo groups in the numbers of
patients experiencing no clinically important improvement in TD symptoms (low-quality evidence,
six RCTs,93–95,123–126,130–137 264 people; RR 0.95, 95% CI 0.89 to 1.01; I2 = 0%).
l The number of participants who showed deterioration of TD symptoms was significantly lower in the
vitamin E group than in the placebo group (low-quality evidence, five RCTs,93–95,123–126,130 85 people;
RR 0.23, 95% CI 0.07 to 0.76; I2 = 0%)
l One study131–137 measured adverse events (extrapyramidal symptoms) using the SAS and found no
significant difference between the vitamin E and placebo groups (very low-quality evidence, 104
people; MD 1.10, 95% CI –1.02 to 3.22).
l There was no significant difference in the incidence of any adverse event (very low-quality evidence,
nine RCTs,90–93,95,123–128,130 205 people; RR 1.21, 95% CI 0.35 to 4.15; I2 = 0%).
l There was no significant difference in mental state, as measured by the BPRS, between vitamin E and
placebo groups (three RCTs,127,129,131–137 165 people; MD –0.20, 95% CI –3.21 to 2.82; I2 = 38%).
l There was no significant difference in acceptability of treatment (leaving the study early) [very low-quality
evidence, medium term (overall ≈20% loss to follow-up), eight RCTs,90–92,94,123–126,128,129,138 232 people;
RR 1.07, 95% CI 0.64 to 1.80; I2 = 0%].
For this comparison there were no studies that reported on social inclusion, social networks or personalised
quality of life.
Comparison 7: buspirone versus placebo (with antipsychotic management)
One small randomised trial,78 conducted with psychiatric inpatients in China, reported on buspirone and
antipsychotic continuation compared with placebo and antipsychotic continuation. Evidence was rated as
being of low quality (see Table 2); therefore, we are uncertain of the results:
l The number of participants reporting clinically important improvement in TD symptoms after 6 weeks
was signficicantly higher in the buspirone group than in the placebo group (low-quality evidence, one
RCT,78 42 people; RR 0.53, 95% CI 0.33 to 0.84).
l Acceptability of treatment, measured by the number of participants leaving the study early, could not
be estimated, as the included study did not report any events.
For this comparison there were no studies that reported on deterioration of TD symptoms, adverse events,
mental state or on social confidence, social inclusion, social networks or personalised quality of life.
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Comparison 8: hypnosis and relaxation versus treatment as usual (with antipsychotic
management)
One very small randomised trial,139 conducted with psychiatric inpatients in the USA, reported on hypnosis
or relaxation and antipsychotic continuation compared with TAU and antipsychotic continuation. The
evidence was rated as being of very low quality (see Table 2); therefore, we are uncertain of the results:
l Clinically important improvement in TD symptoms after eight sessions was reported by significantly
more participants in the hypnosis or relaxation group than in the TAU group (very low-quality evidence,
one RCT,139 15 people; RR 0.45, 95% CI 0.21 to 0.94).
l There was no significant difference in deterioration of TD symptoms after eight sessions between the
hypnosis or relaxation group and the TAU group (very low-quality evidence, one RCT,139 15 people;
RR 0.18, 95% CI 0.01 to 3.81).
l Acceptability of treatment (leaving the study early) could not be estimated, as the included study
reported no events.
For this comparison there were no studies that reported on adverse events, mental state or on social
confidence, social inclusion, social networks or personalised quality of life.
Analysis of the robustness of the results (sensitivity analyses)
Risk of bias
We planned to restrict the analyses to studies considered to be at low, and low or unclear, risk of selection
and detection bias. None of the included studies was rated as being at a low risk of both selection and
detection bias. Studies were rated as being either at an unclear risk of bias or at a low and unclear risk
(see Appendix 7, Table 13), except Glover,139 which was the only study rated as being at high risk of
selection bias. Glover139 was the only study that investigated hypnosis and relaxation.
Imputed values
We would have undertaken a sensitivity analysis to assess the effects of including data from cluster
randomised trials in which we used imputed values for the intracluster correlation coefficient in calculating
the design effect. However, we identified no cluster randomised trials for inclusion.
Planning future studies
No clinical improvement of tardive dyskinesia symptoms
Only one study110 comparing ‘switch to FGA’ with ‘switch to SGA’ reported the outcome ‘no clinical
improvement’. The odds ratio (OR) comparing these two treatments was 1.96 (95% CI 0.56 to 6.92),
indicating an insignificant advantage of ‘switch to SGA’ compared with ‘switch to FGA’. The wide CI
surrounding the effect estimate suggests that the existing evidence might not be adequate to conclude
which of the two interventions is more effective. The power curve in Figure 5 shows the power of an
updated meta-analysis considering that a new study with sample size indicated in the horizontal axis is
added to the evidence base. The power of a meta-analysis including a new study with a small sample size
would remain low (e.g. we would achieve a power of < 40% randomising 100 more patients). To achieve
a power of 80% for the meta-analysis, a new study with a total sample size of 800 patients would need to
be designed and included in the meta-analysis model. The extended funnel plot could not be drawn given
the availability of a single study.
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Total discontinuation rates
Three studies comparing ‘switch to FGA’ to ‘switch to SGA’ and reporting ‘total discontinuation rates’
were available. The resulting OR was 0.54 (95% CI 0.21 to 1.42) in favour of a ‘switch to FGA’ using the
fixed-effect inverse-variance meta-analysis model. For a new study to make an important contribution to
the existing evidence by rendering the power of the meta-analysis 80%, it would have to have a total
sample size of ≥ 1000 patients (Figure 6). The implications of including a hypothetical new study in the
meta-analysis are illustrated in the extended funnel plot of Figure 7. The inclusion of an additional study
lying in the left-hand light-green region of Figure 7 would result in the updated meta-analysis showing a
significant result in favour of a ‘switch to FGA’. As none of the existing studies lies in this region, it is
considered unlikely that a new trial will change meta-analysis conclusions. The possibility that a meta-
analysis would change the inference in favour of a ‘switch to SGA’ is even smaller, as it would require the
inclusion of a study with a very small standard error (smaller than 0.1) demonstrating a favoured outcome
for the particular treatment. Thus, despite the fact that meta-analysis is inconclusive, it is not likely that a
new study would change its conclusions given that its sample size is not substantially large.
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FIGURE 5 Power curves with 95% CIs for the outcome ‘no clinical improvement of TD symptoms’ for the
comparison ‘switch to FGA’ vs. ‘switch to SGA’.
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FIGURE 6 Power curves with 95% CIs for the outcome ‘total discontinuation rates’ for the comparison ‘switch to
FGA’ vs. ‘switch to SGA’.
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FIGURE 7 Extended funnel plot for the outcome ‘total discontinuation rates’ for the comparison ‘switch to FGA’ vs.
‘switch to SGA’: contours for impact of a new study.
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Chapter 6 Part C: results of the network
meta-analysis
We intended to synthesise available evidence from treatment options of interest using a NMAmodel.155–157 However, the sparseness of the existing evidence imposed important barriers in
the analysis rendering the presentation of NMA results as our main analysis impractical. In particular,
comparisons were typically informed by very few studies, and many studies had few or even zero events.
Analysing and interpreting few data can be particularly challenging, and simulation studies have shown
that many of the most commonly used meta-analytic methods produce biased estimates and misleading
conclusions when events are rare.158,159 Challenges in the analysis of few data include the difficulty of
justifying the use of distributional approximations to statistics of interest and the potential risk of small
studies including unrepresentative populations.159,160
Use of NMA can benefit the evidence synthesis of few data by borrowing strength across treatment
comparisons and gaining information through the contribution of indirect evidence. Moreover, sharing
parameters across the entire network can provide information on their inference; here, we assumed a
common heterogeneity parameter across all treatment comparisons. Although the assumption of a common
heterogeneity is expected to hold in this setting, formal investigation of between-study variations is limited
by the sparseness of the data. Despite efforts to strengthen the evidence body and sharing parameters
across networks, analysing and interpreting NMA results under sparseness was challenging; results of NMA
for the outcomes ‘no clinical improvement of TD symptoms’ and ‘total discontinuation rates’ are presented
in Appendix 4. Network effects were almost identical to their pairwise meta-analysis counterparts when
direct evidence existed; any differences are attributed to the estimation of heterogeneity. When direct
evidence was absent, indirect estimates were highly imprecise, failing to produce useful summaries on the
relative effectiveness of the interventions of interest and consequently to provide interpretable results to be
used for decision-making. Moreover, no closed loops of evidence were formed in the network for the
primary outcome and only one existed for total discontinuation rates, making it impossible to evaluate the
validity of the consistency assumption. The interventions of interest that were set to be on the priority list did
not form a connected network that could be analysed at once; this further limited the value of performing
NMA and precluded us from presenting it as our main analysis.
Despite the barriers that lack of sufficient research data may impose, decisions often need to rely on few
data. Thus, exploration of possible ways in which inferences could be made based on a limited evidence
base would be useful. Use of external evidence, both eliciting expert opinions and using observational
data, has been considered elsewhere.160 The presence of few data, along with the associated highly
imprecise NMA effects, highlights the uncertainty surrounding the relative effectiveness between
alternative treatment options for TD and underlines the need for further research to be conducted. Future
studies should be planned (see Chapter 8, Recommendations for research) to enrich the existing evidence
base and, by making the synthesis of data in a NMA model sensible, to enlighten the relative effectiveness
between available treatment options.
Several methods, tailored to outcomes with very low frequency, have been developed.161–163 Rücker et al.161
proposed the arcsine difference as an alternative effect size measure that enables such studies to be
included in a meta-analysis. Despite its advantages, the arcsine method provides an effect size that is
difficult to interpret and is poorly understood by clinicians.
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Chapter 7 Discussion
Summary of main results
The search
This area of research does not seem to be active. We have identified additional data, but most trials
pre-date the year 2000, with only six studies (of prioritised interventions) published between 2000
and 2011. Possible explanations for this include lack of concern with TD in the research community,
discouragement regarding the possibility of identifying effective treatments, or, more positively,
decreased emergence of the problem in research-active communities because of more thoughtful use
of antipsychotic drugs.
In addition to RCTs, we identified eight small prospective cohort studies that reported on efficacy of
interventions (mostly antipsychotics) for the treatment of TD.
Few data
The great majority of studies testing treatments for people with TD are short and very small. This whole
review of many comparisons shows that only hundreds, not thousands, of people have been randomised,
and no one with dementia and TD. Any effect of treatment is likely to be subtle and so substantial sample
sizes are needed to show differences with acceptable confidence. This also applies to observational studies,
in which eight prospective studies reported on 200 patients with TD.
Many outcomes were not measured at all by included studies. We may have been overambitious in hoping
for some of these outcomes in TD trials, but simple reporting of social impact and quality of life does not
seem unreasonable, and is of particular interest to patients and carers.
Outcomes
Tardive dyskinesia symptoms
We found low-quality evidence of clinically important improvement in TD symptoms after 12 weeks for
switching antipsychotic to risperidone compared with withdrawing antipsychotics (with placebo) (one
study, 42 people; RR 0.45, 95% CI 0.23 to 0.89), and after 6 weeks for buspirone compared with placebo
while continuing antipsychotics as usual (one study, 42 people; RR 0.53, 95% CI 0.33 to 0.84). We also
found low-quality evidence that use of vitamin E could prevent deterioration of TD symptoms compared
with placebo while continuing antipsychotics as usual after 1 year (five studies, 85 people; RR 0.23, 95% CI
0.07 to 0.76). Because the quality of evidence is low, we have limited confidence in the effect estimates and
CIs; the true effects may be substantially different.
Furthermore, we found very low-quality evidence of clinically important improvement in TD symptoms after
1 year for antipsychotic reduction compared with antipsychotic continuation (two studies, 17 people; RR
0.42, 95% CI 0.17 to 1.04), after 2 weeks for clonazepam compared with phenobarbital as active placebo
while continuing antipsychotics as usual (one study, 21 people; RR 0.44, 95% CI 0.20 to 0.96) or for
hypnosis or relaxation compared with placebo while continuing antipsychotics as usual for eight sessions
(one study, 15 people; RR 0.45, 95% CI 0.21 to 0.94). Because the quality of evidence is very low, we have
very little confidence in the effect estimates and CIs; the true effects are likely to be substantially different.
There was very low-quality evidence from observational studies of an improvement in TD symptoms
when antipsychotics were discontinued or decreased; on average, these studies were very small, had an
unbalanced number of participants in each group and selective outcome reporting bias.
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For the remaining comparisons we found low- to very low-quality evidence of little or no difference
between groups, but, again, our confidence in these results is limited.
Adverse effects
There was low-quality evidence that fewer people taking SGAs than taking FGAs needed antiparkinsonism
medication because of extrapyramidal side effects after 1 year (two studies, 82 people; RR 0.52, 95% CI
0.31 to 0.89). There was also low-quality evidence that after 6 months extrapyramidal symptoms, as
measured on the ESRS, were less common in the olanzapine group than in the risperidone group (one
study, 60 people; MD –0.70, 95% CI –1.33 to –0.07). Finally, there was very low-quality evidence that
after 2 weeks fewer people on phenobarbital as an active placebo than on clonazepam had experienced
any adverse events (one study, 21 people; RR 1.53, 95% CI 0.97 to 2.41).
None of the observational studies reported on adverse events for the interventions.
As a result of the low to very low quality of this evidence, our confidence in these results is limited.
For the remaining comparisons, we found low- to very low-quality evidence of little or no difference
between groups, but, again, our confidence in these results is limited.
Mental state
We found low- to very low-quality evidence of little or no difference between groups of all comparisons,
but, again, our confidence in these results is limited.
Acceptability of treatment: leaving the study early
It is always unclear what leaving a study early means for the participant. It could be related to the participant
rejecting treatment for a series of reasons, or attributable to participants finding the trial intolerable. It also
could be a function of a trial design in which participants, although willing to continue, are asked to leave
because of some degree of protocol violation. In any event, for most of the interventions the numbers of
participants leaving the study early were not different for those allocated to either group. Fewer participants
allocated to olanzapine than to risperidone (two studies, 170 people; RR 0.73, 95% CI 0.57 to 0.95) or to
quetiapine (one study, 116 people; RR 0.70, 95% CI 0.54 to 0.90) left the study early after 6–18 months.
Evidence was of very low quality for both comparisons; therefore, we have very little confidence in the effect
estimates and CIs; the true effects are likely to be substantially different.
Social confidence, social inclusion, social networks or personalised quality of life
This group of outcomes was selected as being of importance to patients for the 2016 review update
following a service user consultation. No studies were identified that reported on any of these outcomes.
Overall completeness and applicability of evidence
Completeness
We excluded 22 studies of prioritised interventions published between 1971 and 2004 because they did
not report data that could be used in the review. We contacted the study authors wherever possible,
but no further information was available.
As part of this work, the service user consultation participants highlighted their preferred outcomes (Box 2).
These largely correlated with the perspectives of the clinicians and reviewers – listing clear, clinically
meaningful effects on TD, adverse effects or leaving the study early – as being of importance. The consultation
added the outcome of some measure of social confidence/inclusion/networks and/or quality of life. There
were no data for the measure of social confidence/inclusion/networks and/or quality of life, but in reality all
others were incomplete – perhaps with the exception of vitamin E. The large trials – or enough small trials on
the same topic – have just not been undertaken. The difficulty of carrying out randomised studies in this area
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should not be underestimated. However, time and time again pioneering triallists have proved that it
is possible.
Another problem is that there seems to be little evidence of collaboration; no two trials are the same.
With collaborative effort we could have enough people randomised across time to have answers to some
practical issues. Currently, we cannot even be confident that dose reduction really helps. Of course,
researchers will always be attracted to try the next compound, but this overview illustrates that there are
enough ‘loose ends’ in the past work regarding entirely practical interventions to encourage some large
collaborative efforts in randomisation.
This overview – and the clear incompleteness of the data on this old, well-recognised condition – also,
we think, serves to encourage some consideration about trial design. Past work does not serve people with
TD particularly well. In the 30 years of, largely, pilot studies, trial methodology within mental health has
evolved, with larger pragmatic trials becoming more prevalent. The service user consultation has provided
outcomes fitting with a pragmatic randomised trial design (see Box 2). This trial, which need not be that
expensive, could be undertaken wherever TD is a concern and need not be constrained to the somewhat
fragmented services often seen in ‘Western’ medicine.
Applicability
Most trials in this review were hospital based, but nevertheless featured the type of patients likely to be
encountered in everyday care. Many of the interventions are readily accessible. The outcomes pose a
greater problem of applicability. Scale-derived findings may be applicable, but even the original measures
do not really describe how findings are relevant to day-to-day care. Whenever possible, we have extracted
outcomes such as ‘improved/not improved to a clinically important extent’. For the degree of importance
BOX 2 Outcomes suggested by PPI consultation and implemented within summary-of-findings tables
1. Tardive dyskinesia
1.1 Improved to a clinically important extent.
1.2 Deteriorated.
2. Mental state
3. Adverse effects
3.1 Any adverse event.
3.2 Adverse effects: no clinically significant extrapyramidal adverse effects.
4. Acceptability of treatment
4.1 Leaving the study early.
5. Social confidence, social inclusion, social networks or personalised quality-of-
life measures
5.1 No significant change in social confidence, social inclusion, social networks or personalised quality-of-life
measures for either recipients of care or caregiver.
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of the change, we have to trust the judgement of triallists from a wide variety of backgrounds and
care cultures.
Quality of the evidence
Overall, the quality of the evidence is low to very low. This means that we have limited to very little
confidence in the effect estimates, and the true effect may be, or is likely to be, substantially different from
the estimate of the effect. The main reasons for our low confidence in the evidence were:
1. poor study methodology and reporting of methods, resulting in downgrading evidence for risk of bias
2. very small sample sizes, resulting in downgrading evidence for imprecision
3. wide CIs (often attributable to low event rates) that included appreciable benefit or harm for the
intervention as well as no effect, resulting in downgrading evidence for imprecision.
Please see Table 2 for full details.
Potential biases in the review process
Missing studies
We have made every effort to identify relevant trials. However, these studies are all small and it is likely
that we have failed to identify other studies of limited power. It is likely that such studies would also not
be in favour of the intervention investigated; if they had been so, it is more likely that they would have
been published in accessible literature. We do not, however, think it likely that we have failed to identify
large relevant studies.
Introducing bias
We have tried to be balanced in our appraisal of the evidence, but could have inadvertently introduced
bias. We have tried to intentionally add bias towards treatments useful within the NHS, but have found no
other innovations that really hold promise. We welcome comments or criticisms. We tried to ensure that
searches for trials were wide-ranging, covering as many data sources as possible, but we still could easily
have missed studies. We think it unlikely, however, that we would have missed large trials with
important outcomes.
It is an unavoidable fact that many of the authors were familiar with this literature for many years before
undertaking this full overview. However, the PPI exercise was undertaken, largely, blind to the results of
the Cochrane reviews and in time to pre-date (and therefore direct) the construction of the summary-of-
findings tables.
Agreements and disagreements with other studies or reviews
The only other relevant quantitative review on this topic we know of is the previous Cochrane review.50
This update expands and improves this review, but does not substantially change the findings or
the conclusions.
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Chapter 8 Conclusions
Implications for health care
Clinicians, policy-makers and people with/at risk of TD are little better informed on this issue than they
were decades ago. Underpowered randomised trials and observational studies of limited quality have
repeatedly failed to provide answers.
Although it seems prudent to use the lowest effective dosage of antipsychotic drug possible (within the
licensed range) for individual patients, there is no evidence that antipsychotic discontinuation will improve
TD symptoms.
Current treatments for TD are prescribed in hopes that they will have an impact on TD, but none have a
strong base in evidence. It could be argued that these treatments are only ethical within well-designed
pragmatic trials aimed at informing clinical practice in people with this debilitating problem.
Recommendations for research
Tardive dyskinesia reviews have data from current trials extracted, tabulated and traceable to source.54 TD
reviews, whether or not those within Cochrane, could use this resource to save time and money. These are
reliably extracted data for sharing.
The NMA highlights one context in which support for this technique is ill advised. Where studies are short,
small, have similar results and are of poor quality, NMA is not indicated.
All relevant trials, even if not primarily addressing the issue of TD, should report appropriate binary
outcomes on groups of people with this problem.
Our public consultation recognised the importance of TD, and participants reacted to the poor quality of
research evidence and lack of progress in addressing TD over time. People attending felt that the current
outcomes could be enhanced by addressing core concerns of service users such as social networks, quality
of life and employment. Ideas for further research included prevalence studies, addressing social stigma,
understanding causal mechanisms, developing psychological therapies to address TD specifically and
looking at the role of peer support in managing TD. The full details are reported in Appendix 1.
The recommendations of the public consultation for focusing on specific key outcomes in our work were
implemented directly into the summary-of-findings tables presented in this work and in the Cochrane
reviews. In turn, these form the basis of the outcome list.
This review summarises more than three decades of pioneering work, but also highlights a systemic failure
to properly address the ongoing issue of TD for clinicians or patients.
More thoughtful use of antipsychotic medication may reduce its prevalence, but TD nevertheless remains a
problem.5 Most people needing antipsychotic medication live in low- and middle-income countries, where
the highest potency antipsychotic drugs may be the only ones available. TD is with us from treatments of
the past, and continues to emerge from treatment practices of the present.
We realise that we are applying pragmatic clinical demands on studies that may never have been designed
to provide them. Largely, the studies we have identified for inclusion were of short duration and grossly
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underpowered. The studies used proxy outcomes, often out of necessity, as sensitive scales may show
effects even if they are not pragmatic clinical outcomes. However, even in the syntheses we have been
able to do, combining the power of similar studies on any outcome seems unlikely to provide sufficient
power to illustrate real effects. We feel that the overview, Cochrane reviews and NMA reported here
illustrate the need for not only more well-designed, -conducted and -reported pilot studies, but also much
larger pragmatic studies reporting outcomes familiar to clinicians and patients.
Pioneering researchers will probably continue to undertake pilot randomised studies. All such studies
should make all data available, including those on outcomes suggested by the public consultation, even if
underpowered, to highlight clear differences. Randomised trials of treatments for people with established
TD are indicated, with the most obvious recommended outcome for a large study being dose reduction.
Such trials should be large (> 800 participants), perhaps with accrual supported through accurate local/
national registers. The studies should be of adequate duration (1 year minimum), with test interventions
that are acceptable and record outcomes relevant to everyone. Such trials could open opportunities for
research in places that may be less well funded but carry the burden of care.
Public consultation in the UK has provided a list of simple, and, we think, universally relevant, practical
outcomes for the large trials. These, along with any other routinely collected data, include outcomes that
can be used for risk–benefit analyses and economic considerations.
These large trials should take place before another three decades pass.
There are many small, short trials investigating interventions for people with schizophrenia and TD but
none for those with dementia and TD. Public consultation highlighted the need for updated prevalence
studies of TD in groups of people with schizophrenia, those exposed to antipsychotic medication and,
finally, patients with dementia.
Use of crossover design
Triallists find it difficult to identify people with both TD and schizophrenia to participate in trials.95
Randomised crossover designs are used in the hope of improving the power of the study to find outcomes
of interest. In this design, participants are initially randomised to one of the experimental interventions and
then, at a prespecified time, cross over to the treatment that they did not receive at first. Conditions with a
more stable time course than TD are better suited for crossover studies.164
The carry-over effect introduces additional difficulties. Many substances used to treat TD may well persist in
the body for long periods after discontinuation; unless crossover studies include a mid-study washout period
(which ensure that the participant is free from the inital treatment before starting the next arm of the study),
any effect of treatment may continue into the second, placebo, arm of the trial – the ‘carry-over effect’. In
addition, carry-over may involve the regrowth or retreat of neuroreceptors. This slow rebalancing, if started,
could continue long after all traces of intervention drugs are gone, so the physiological half-life of the
experimental treatment may not be the only variable to consider when thinking through the issues of
carry-over. TD is also an unstable condition, and people with TD may not remain compliant with medication.
All these factors make the arguments for not using crossover methodology strong, despite the initial
attraction.164–166
Planning of future studies
The relative effectiveness and safety of a ‘switch to FGA’ compared with a ‘switch to SGA’ is considered to
be of great importance in terms of deterioration of symptoms of antipsychotic-induced TD. However, only
a handful of studies examined that particular comparison – one and three studies for the outcomes ‘no
clinical improvement of TD symptoms’ and ‘total discontinuation rates’ were available, respectively. NMA
did not offer any additional advantage or further insight on the ‘switch to FGA versus switch to SGA’
comparison; no indirect evidence feeding this comparison existed and, thus, the network estimates were
identical to their pairwise meta-analysis counterparts (see Appendix 4).
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Figures 6 and 7 imply that, although the meta-analysis can be considered reasonably robust to the addition
of new studies with a small sample size, conclusions might change if large studies are added. If further
studies are to be designed and conducted, a total sample size of 1000 patients would give a good
prospect of reaching a conclusive result for both outcomes. Decisions on whether or not new studies are
to be conducted should take into account the feasibility of such a sample size. In any case, informed and
evidence-based decisions would require the systematic assessment of existing evidence before embarking
into new research.167,168
DOI: 10.3310/hta21430 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 43
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bergman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53

Acknowledgements
People
Rosie Asher (Clinical Research Associate) screened references and full texts, extracted and source-coded
data, and assessed and data-extracted studies in Hebrew for Cochrane reviews. Antonio Jose Grande
(Research Associate) screened references and full texts, cross-checked data, helped organise references
and analyses, and assessed and data-extracted studies in Spanish and Portuguese for Cochrane reviews.
Farhad Shokraneh (Information Specialist) conducted the search, made the traceable data available, and
assessed and data-extracted studies in Persian for Cochrane reviews. Ben Grey (Senior Peer Researcher,
the McPin Foundation) advised on PPI and wrote plain language summaries for Cochrane reviews.
Vanessa Pinfold (Research Director, McPin Foundation) advised on PPI. Ruth Sayers (Peer Researcher,
McPin Foundation) and Megan Rees (Public Involvement in Research Co-ordinator, McPin Foundation)
conducted the PPI consultation together with author Dawn-Marie Walker. Artemisia Kakourou (Medical
Doctor, Systematic Reviewer) assessed and data-extracted observational studies and studies in French for
Cochrane reviews. Loukia Spineli (Research Associate, Statistician) helped with data extraction, data
cross-checking and organising references for Cochrane reviews. Nicholas Henschke (Systematic reviewer)
helped with report writing for Cochrane reviews. Nancy Owens (Senior Communications Manager) assisted
with proofreading. Molly Grimes (Clinical Psychologist) assisted with copy-editing. Linda Levi (Psychiatry
Research Co-ordinator) helped with creating tables for the National Institute for Health Research (NIHR)
report and updating background sections for Cochrane reviews. Daphna Fenchel (Psychiatry Research
Associate) helped with background for the NIHR report. Sai Zhao assessed and data-extracted studies in
Chinese for Cochrane reviews. Stefan Leucht and Johannes Schneider-Thoma assessed and data-extracted
studies in German for Cochrane reviews. Yusuke Ogawa assessed and data-extracted studies in Japanese
for Cochrane reviews. Lisa Korsbek assessed studies in Danish for Cochrane reviews. Suyoung Kim
assessed studies in Korean for Cochrane reviews
Funding
This report was funded by the UK’s NIHR Health Technology Assessment programme (NIHR HTA 14/27/02)
and without this our work for this report would have been impossible. The funding has built on the
volunteer input, which will continue after the end of the funding period. The funders have had no
influence on the content of the reviews or final report.
Contributions of authors
Hanna Bergman (Systematic Reviewer, systematic review methods) co-ordinated updates of the nine
Cochrane reviews on which this report is based, co-ordinated traceable data coding, selected studies,
extracted, analysed and interpreted data, created summary-of-findings tables and wrote the final report.
Dawn-Marie Walker (Associate Professor, PPI) was one of the researchers who was awarded the grant
with Karla Soares-Weiser and Clive E Adams, helped to design the project, oversaw the patient involvement
and discussed the findings from the review with them, helped write the PPI section and reviewed the
document through iterative drafts.
Adriani Nikolakopoulou (Doctor of Philosophy Student in Biostatistics, evidence synthesis methods)
planned and conducted the NMA, and wrote the NMA sections of the report.
DOI: 10.3310/hta21430 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 43
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bergman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
Karla Soares-Weiser (Deputy Editor in Chief for Cochrane, until September 2015 was the Managing
Director of Enhance Reviews, psychiatry, evidence synthesis) was actively involved in the preparation of the
original reviews, helped write the proposal, helped supervise the search and selection, co-ordinated the
overall process and wrote the final report.
Clive E Adams (Chairperson of Mental Health Services Research, systematic reviewing, schizophrenia)
helped do original reviews, helped supervise the search and selection, co-ordinated the overall process,
and helped assimilate and write the final report.
Publications
Currently, only this report is published, but nine Cochrane reviews (see Appendix 6) are updated and are
going through to full publication.
Soares-Weiser K, Mobsy C, Holliday E. Anticholinergic medication for neuroleptic-induced tardive
dyskinesia. Cochrane Database Syst Rev 1997;2:CD000204.
Tammenmaa IA, McGrath JJ, Sailas E, Soares-Weiser K. Cholinergic medication for neuroleptic-induced
tardive dyskinesia. Cochrane Database Syst Rev 2002;3:CD000207.
Soares-Weiser K, Irving Claire B, Rathbone J. Miscellaneous treatments for neuroleptic-induced tardive
dyskinesia. Cochrane Database Syst Rev 2003;2:CD000208.
Bhoopathi PS, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane
Database Syst Rev 2006;3:CD000205. http://dx.doi.org/10.1002/14651858.CD000205.pub2
El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Weiser K. Non-neuroleptic catecholaminergic drugs for
neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2006;1:CD000458.
Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific
treatments for tardive dyskinesia. Cochrane Database Syst Rev 2006;1:CD000459.
Alabed S, Latifeh Y, Mohammad HA, Rifai A. Gamma-aminobutyric acid agonists for neuroleptic-induced
tardive dyskinesia. Cochrane Database Syst Rev 2011;4:CD000203. http://dx.doi.org/10.1002/14651858.
CD000203.pub3
Essali A, Deirawan H, Soares-Weiser K, Adams CE. Calcium channel blockers for neuroleptic-induced
tardive dyskinesia. Cochrane Database Syst Rev 2011;11:CD000206. http://dx.doi.org/10.1002/14651858.
CD000206.pub3
Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane
Database Syst Rev 2011;2:CD000209. http://dx.doi.org/10.1002/14651858.CD000209.pub2
Data sharing statement
Extracted data are freely available on Cochrane Schizophrenia Group’s website via ResearchGate
(http://dx.doi.org/10.13140/RG.2.2.28907.95529).
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
References
1. Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of
modern antipsychotic drugs. Handb Clin Neurol 2011;100:601–16. http://dx.doi.org/10.1016/
B978-0-444-52014-2.00043-4
2. Rosenheck RA. Evaluating the cost-effectiveness of reduced tardive dyskinesia with
second-generation antipsychotics. Br J Psychiatry 2007;191:238–45. https://doi.org/10.1192/
bjp.bp.106.035063
3. Miller DD, Eudicone JM, Pikalov A, Kim E. Comparative assessment of the incidence and severity
of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of
schizophrenia: a post hoc analysis. J Clin Psychiatry 2007;68:1901–6. https://doi.org/10.4088/
JCP.v68n1210
4. Kane JM. Tardive dyskinesia: epidemiological and clinical presentation. In Bloom FE, Kupfer DJ,
eds. Psychopharmacology: 4th Generation of Progress. New York, NY: Raven Press; 1995.
URL: www.acnp.org/g4/GN401000143/Default.htm (accessed 20 July 2017).
5. Bakker PR, de Groot IW, van Os J, van Harten PN. Predicting the incidence of antipsychotic-
induced movement disorders in long-stay patients: a prospective study. Epidemiol Psychiatr Sci
2013;22:375–9. http://dx.doi.org/10.1017/S204579601300019X
6. Bakker PR, de Groot IW, van Os J, van Harten PN. Antipsychotic-induced movement disorders in
long-stay psychiatric patients: a prospective study. Schizophr Res 2014;153(Suppl. 1):88–9.
https://doi.org/10.1016/S0920-9964(14)70282-8
7. Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al. Extrapyramidal side-
effects of antipsychotics in a randomised trial. Br J Psychiatry 2008;193:279–88. http://dx.doi.org/
10.1192/bjp.bp.108.050088
8. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, et al. Incidence of
tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective
cohort study. J Clin Psychiatry 2010;71:463–74. https://doi.org/10.4088/JCP.07m03890yel
9. Woerner MG, Correll CU, Alvir JM, Greenwald B, Delman H, Kane JM. Incidence of tardive
dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in
antipsychotic-naïve patients. Neuropsychopharmacology 2011;36:1738–46. http://dx.doi.org/
10.1038/npp.2011.55
10. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common
disorder. Neurotherapeutics 2014;11:166–76. https://doi.org/10.1007/s13311-013-0222-5
11. Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of
atypical antipsychotics. J Manag Care Pharm 2012;18(Suppl. 5):1–20. https://doi.org/10.18553/
jmcp.2012.18.s5-b.1
12. Ballesteros J, Gonzalez-Pinto A, Bulbena A. Tardive dyskinesia associated with higher mortality in
psychiatric patients: results of a meta-analysis of seven independent studies. J Clin Psychopharmacol
2000;20:188–94. https://doi.org/10.1097/00004714-200004000-00011
13. Martins ES, Rosso A, Coutinho E, Adams C, Huf G. Prevalence of tardive dyskinesia and all-cause
mortality amongst patients in a large psychiatric institute in Rio de Janeiro. Rev Psiquiatr Clin
2011;38:44.
DOI: 10.3310/hta21430 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 43
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bergman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
14. National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults:
Treatment and Management. NICE Clinical Guideline 178. 2014. URL: www.nice.org.uk/guidance/
cg178 (accessed 20 January 2017).
15. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines. 10th edn. London: Informa
Healthcare; 2009. https://doi.org/10.3109/9780203092835
16. Lieberman JA, Fleishhacker W. Introduction. Br J Psychiatry 1996;168(Suppl. 29):7–8. https://doi.org/
10.1142/9789812819796_0001
17. Chouinard G, Chouinard V-A. Atypical antipsychotics: CATIE study, drug-induced movement
disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and
withdrawal discontinuation syndromes. Psychother Psychosom 2008;77:69–77. https://doi.org/
10.1159/000112883
18. Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific
treatments for tardive dyskinesia. Cochrane Database Syst Rev 2006;1:CD000459. http://dx.doi.org/
10.1002/14651858.CD000459.pub2
19. Bratti IM, Kane JM, Marder SR. Chronic restlessness with antipsychotics. Am J Psychiatry
2007;164:1648–54. https://doi.org/10.1176/appi.ajp.2007.07071150
20. Killoran A, Biglan KM. Current therapeutic options for Huntington’s disease: good clinical practice
versus evidence-based approaches? Mov Disord 2014;29:1404–13. http://dx.doi.org/10.1002/
mds.26014
21. van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ 1999;319:623–6.
https://doi.org/10.1136/bmj.319.7210.623
22. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic
treatment in Huntington’s disease. Cochrane Database Syst Rev 2009;3:CD006456. https://doi.org/
10.1002/14651858.cd006456.pub2
23. El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Weiser K. Non-neuroleptic catecholaminergic
drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2006;1:CD000458.
https://doi.org/10.1002/14651858.cd000458.pub2
24. Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-
induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia.
Bio Psychiatry 1993;34:713–38. https://doi.org/10.1016/0006-3223(93)90044-E
25. Barnes TRE, Edwards JG. The side-effects of antipsychotic drugs. I. CNS and neuromuscular
effects. In Barnes TRE, ed. Antipsychotic Drugs and their Side-Effects. London: Academic
Press/Harcourt Brace & Company; 1993. pp. 231–48. https://doi.org/10.1016/B978-0-12-079035-
7.50021-X
26. Gunne LM, Häggström JE, Sjöquist B. Association with persistent neuroleptic-induced dyskinesia
of regional changes in brain GABA synthesis. Nature 1984;309:347–9. https://doi.org/10.1038/
309347a0
27. Gardos G, Cole JO. The treatment of tardive dyskinesia. In Bloom FE, DJ K, eds. Psychopharmacology
The Fourth Generation of Progress. New York, NY: Raven Press; 1994. URL: www.acnp.org/g4/
GN401000145/Default.htm (accessed 20 July 2017).
28. American Psychiatric Association Task Force on Tardive Dyskinesia. Tardive Dyskinesia: A Task
Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric
Association; 1992.
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
58
29. Jeste DV, Lohr JB, Clark K, Wyatt RJ. Pharmacological treatments of tardive dyskinesia in the
1980s. J Clin Psychopharmacol 1988;8(Suppl. 4):38–48. https://doi.org/10.1097/00004714-
198808001-00008
30. Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR. Benzodiazepines for neuroleptic-induced
acute akathisia. Cochrane Database Syst Rev 2002;1:CD001950.
31. Rotrosen J, Adler L, Lohr J, Edson R, Lavori P. Antioxidant treatment of tardive dyskinesia.
Prostaglandins Leukot Essent Fatty Acids 1996;55:77–81. https://doi.org/10.1016/S0952-3278(96)
90149-0
32. Cadet JL, Lohr JB. Possible involvement of free radicals in neuroleptic-induced movement
disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann N Y Acad Sci
1989;570:176–85. https://doi.org/10.1111/j.1749-6632.1989.tb14918.x
33. Feltner DE, Hertzman M. Progress in the treatment of tardive dyskinesia: theory and practice.
Hosp Community Psychiatry 1993;44:25–34.
34. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull 1993;19:303–15. https://doi.org/
10.1093/schbul/19.2.303
35. Queiroz CM, Frussa-Filho R. Effects of buspirone on an animal model of tardive dyskinesia. Prog
Neuropsychopharmacol Biol Psychiatry 1999;23:1405–18. https://doi.org/10.1016/S0278-5846
(99)00074-3
36. Haleem DJ, Samad N, Haleem MA. Reversal of haloperidol-induced tardive vacuous chewing
movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
Pharmacol Biochem Behav 2007;87:115–21. https://doi.org/10.1016/j.pbb.2007.04.007
37. Wahbeh H, Elsas SM, Oken BS. Mind-body interventions: applications in neurology. Neurology
2008;70:2321–8. http://dx.doi.org/10.1212/01.wnl.0000314667.16386.5e
38. Ajimsha MS, Majeed NA, Chinnavan E, Thulasyammal RP. Effectiveness of autogenic training in
improving motor performances in Parkinson’s disease. Complement Ther Med 2014;22:419–25.
http://dx.doi.org/10.1016/j.ctim.2014.03.013
39. Franklin SA, Walther MR, Woods DW. Behavioral interventions for tic disorders. Psychiatr Clin
North Am 2010;33:641–55. http://dx.doi.org/10.1016/j.psc.2010.04.013
40. Elkins G, Sliwinski J, Bowers J, Encarnacion E. Feasibility of clinical hypnosis for the treatment of
Parkinson’s disease: a case study. Int J Clin Exp Hypn 2013;61:172–82. http://dx.doi.org/10.1080/
00207144.2013.753829
41. McGrath J, Davies G, Soares K. Writing to authors of systematic reviews elicited further data in
17% of cases. BMJ 1998;316:631. https://doi.org/10.1136/bmj.316.7131.631a
42. Soares K, McGrath J, Adams C. Evidence and tardive dyskinesia. Lancet 1996;347:1696–7.
https://doi.org/10.1016/S0140-6736(96)91525-1
43. Alabed S, Latifeh Y, Mohammad HA, Rifai A. Gamma-aminobutyric acid agonists for neuroleptic-
induced tardive dyskinesia. Cochrane Database Syst Rev 2011;4:CD000203. http://dx.doi.org/
10.1002/14651858.CD000203.pub3
44. Bhoopathi PS, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia.
Cochrane Database Syst Rev 2006;3:CD000205. http://dx.doi.org/10.1002/14651858.
CD000205.pub2
45. Essali A, Deirawan H, Soares-Weiser K, Adams CE. Calcium channel blockers for neuroleptic-
induced tardive dyskinesia. Cochrane Database Syst Rev 2011;11:CD000206. http://dx.doi.org/
10.1002/14651858.CD000206.pub3
DOI: 10.3310/hta21430 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 43
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bergman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
59
46. Soares-Weiser K, Irving Claire B, Rathbone J. Miscellaneous treatments for neuroleptic-induced
tardive dyskinesia. Cochrane Database Syst Rev 2003;2:CD000208. https://doi.org/10.1002/
14651858.cd000208
47. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia.
Cochrane Database Syst Rev 2011;2:CD000209. http://dx.doi.org/10.1002/14651858.
CD000209.pub2
48. Soares-Weiser K, Mobsy C, Holliday E. Anticholinergic medication for neuroleptic-induced
tardive dyskinesia. Cochrane Database Syst Rev 1997;2:CD000204. https://doi.org/10.1002/
14651858.cd000204
49. Tammenmaa IA, McGrath JJ, Sailas E, Soares-Weiser K. Cholinergic medication for neuroleptic-
induced tardive dyskinesia. Cochrane Database Syst Rev 2002;3:CD000207. https://doi.org/
10.1002/14651858.cd000207
50. Soares KV, McGrath JJ. The treatment of tardive dyskinesia – a systematic review and
meta-analysis. Schizophr Res 1999;39:1–16. https://doi.org/10.1016/S0920-9964(99)00021-3
51. Rana AQ, Chaudry ZM, Blanchet PJ. New and emerging treatments for symptomatic tardive
dyskinesia. Drug Des Devel Ther 2013;7:1329–40. http://dx.doi.org/10.2147/DDDT.S32328
52. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network
meta-analysis. Ann Intern Med 2013;159:130–7. http://dx.doi.org/10.7326/0003-4819-159-2-
201307160-00008
53. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0.
London: The Cochrane Collaboration; 2011. URL: www.cochrane-handbook.org (accessed 11
April 2017).
54. Adamd CE, Walker D-M, Gray B, Shokraneh F. Appendix: Traceable Extracted Data from Included
Studies of Tardive Dyskinesia Reviews. 2016. URL: www.researchgate.net/publication/
308698005_Appendix_Traceable_Extracted_Data_from_Included_Studies_of_Tardive_Dyskinesia_
Reviews?channel=doi&linkId=57ebe1c508ae92a5dbd051c1&showFulltext=true (accessed
13 June 2017).
55. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799–812.
https://doi.org/10.2466/pr0.1962.10.3.799
56. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The Extrapyramidal Symptom Rating Scale.
Can J Neurol Sci 1980;7:233.
57. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl
1970;212:11–19. https://doi.org/10.1111/j.1600-0447.1970.tb02066.x
58. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new
comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in
neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1–100. https://doi.org/
10.1111/j.1600-0447.1987.tb10566.x
59. Higgins JPT, Ramsay C, Reeves BC, Deeks JJ, Shea B, Valentine JC, et al. Issues relating to study
design and risk of bias when including non-randomized studies in systematic reviews on the
effects of interventions. Res Synth Methods 2013;4:12–25. https://doi.org/10.1002/jrsm.1056
60. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales:
a major source of bias in randomised controlled trials of treatments for schizophrenia.
Br J Psychiatry 2000;176:249–52. https://doi.org/10.1192/bjp.176.3.249
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
60
61. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving
cross-over trials: methodological issues. Int J Epidemiol 2002;31:140–9. https://doi.org/10.1093/
ije/31.1.140
62. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses.
BMJ 2003;327:557–60. http://dx.doi.org/10.1136/bmj.327.7414.557
63. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med
1996;15:2733–49. https://doi.org/10.1002/(SICI)1097-0258(19961230)15:24%3C2733::AID-
SIM562%3E3.0.CO;2-0
64. Raudenbush SW. Analyzing Effect Sizes: Random Effects Models. In Cooper H, Hedges LV,
Valentine C, eds. The Handbook of Research Synthesis and Meta-Analysis. New York, NY: Russel
Sage Foundation; 2009. pp. 295–316.
65. Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis. Stat Med
2007;26:37–52. http://dx.doi.org/10.1002/sim.2514
66. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12.
Preparing summary of findings tables-binary outcomes. J Clin Epidemiol 2013;66:158–72.
http://dx.doi.org/10.1016/j.jclinepi.2012.01.012
67. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9.
Rating up the quality of evidence. J Clin Epidemiol 2011;64:1311–16. http://dx.doi.org/10.1016/
j.jclinepi.2011.06.004
68. Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is
reproducible in assessing the quality of evidence of quantitative evidence syntheses. J Clin
Epidemiol 2013;66:736–42. http://dx.doi.org/10.1016/j.jclinepi.2013.02.004
69. Sutton AJ, Cooper NJ, Jones DR, Lambert PC, Thompson JR, Abrams KR. Evidence-based sample
size calculations based upon updated meta-analysis. Stat Med 2007;26:2479–500. http://dx.doi.
org/10.1002/sim.2704
70. Langan D, Higgins JP, Gregory W, Sutton AJ. Graphical augmentations to the funnel plot
assess the impact of additional evidence on a meta-analysis. J Clin Epidemiol 2012;65:511–19.
http://dx.doi.org/10.1016/j.jclinepi.2011.10.009
71. Cai N. [A controlled study on the treatment of tardive dyskinesia using 1-stepholidine.] Zhonghua
Shen Jing Jing Shen Ke Za Zhi 1988;21:281–3.
72. Chen J, Zhong X, Cao Z. A double-blind auto-control study on the effect of bromocriptine on
tardive dyskinesia. Chin J Pharmacoepidemiol 1995;4:203–5.
73. Mei H, Zhu Q. γ-aminobutyric acid in the treatment of 20 cases of tardive dyskinesia. Herald Med
2008;27:304–5.
74. Shi X, Zhu F, Zhang X, Zhang JX, Zhang XM, Wei LH, et al. Melatonin in treatment of
schizophrenia with tardive dyskinesia: a comparison study of cognitive function. Linchuang
Jingshen Yixue Zazhi 2009;19:391–3.
75. Xiang H, Zhen C. Clonazepam therapy of tardive dyskinesia: a double-blind trial. West China Med J
1997;12:17–18.
76. Yang X, Meng F, Cui Y. Promethazine treatment of tardive dyskinesia: a double blind placebo
controlled study. Chin Ment Health J 1999;13:365–7.
77. Yin XR, Xie BQ, Jiang L. A double-blind comparative study of sodium valproate in treating of TD.
J Clin Psychol Med 2004;14:92–3.
78. Zeng ZX. Treatment of tardive dyskinesia with buspirone. Med J Chinese Civil Admin 1995;7:202–3.
DOI: 10.3310/hta21430 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 43
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bergman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
61
79. Zeng ZX. Pemoline in the treatment of tardive dyskinesia. Chin J New Drugs Clin Remedies
1996;15:240–1.
80. Zeng ZX, Li ZC, Yu XW, Zhang YD, Cao ZC. A double-blind trial of flunarizine therapy for tardive
dyskinesia. Chin J Pharmaco Epidemiol 1994;3:183–4.
81. Hebenstreit GF, Hoffmann H, Hoffmann W, Pittner H. [Beta blockade with celiprolol in tardive
dyskinesia patients treated with neuroleptics.] Wien Klin Wochenschr 1986;98:388–92.
82. Kocher R, Hobi V, Linder M, Studer K. [Treatment with dimethylaminoethanol (deanol) in
neuroleptic induced tardive dyskinesia.] Schweiz Arch Neurol Neurochir Psychiatr 1980;126:103–9.
83. Lucius G. Uber die Therapeutische Wirksamkeit von Dimethylaminoaethanol bei
Neuroleptikainduzierten Späthyperkinesen. Dissertation. Freiburg im Breisgau: Albert Ludwigs
University of Freiburg; 1978.
84. Koshino Y, Hiramatsu H, Isaki K, Yamaguchi N. A double-blind clinical trial of dihydrogenated
ergot alkaloids in antipsychotic-induced tardive dyskinesia. Clin Psychiatry 1983;25:627–35.
85. Koshino Y, Kurata K, Hosokawa K, Yamaguchi N. Double-blind trial of cyproheptadine on
neuroleptic induced tardive dyskinesia. Clin Psychiatry 1979;21:421–6.
86. Yagi G, Kamishima K, Miura S. Meclofenoxate hydrochloride (Lucidril) in tardive dyskinesia –
a double-blind placebo-controlled study. Rinsho Hyoka 1990;18:455–79.
87. Jahanian AA, Rezaei O, Fadai F, Yaraghchi A. The effectiveness of rivastigmine in reducing tardive
dyskinesia symptoms in patients with schizophrenia. Iran J Psychiatry Clin Psychol 2014;20:29–34.
88. Karniol IG, Giampietro AC, Moura DS, Vilela WA, Oliveira MA, Zuardi AW. [A double-blind study
of the effect of L-dopa in psychotic patients with tardive dyskinesia.] Acta Psiquiatr Psicol Am Lat
1983;29:261–6.
89. Weber SS, Dufresne RL, Becker RE, Mastrati P. Diazepam in tardive dyskinesia. Drug Intell Clin
Pharm 1983;17:523–7. https://doi.org/10.1177/106002808301700705
90. Dorevitch A, Kalian M, Shlafman M, Lerner V. Treatment of long-term tardive dyskinesia with
vitamin E. Biol Psychiatry 1997;41:114–16. https://doi.org/10.1016/S0006-3223(96)00367-8
91. Dorevitch A, Lerner V, Shalfman M, Kalian M. Lack of effect of vitamin E on serum creatine
phosphokinase in patients with long-term tardive dyskinesia. Int Clin Psychopharmacol
1997;12:171–3. https://doi.org/10.1097/00004850-199705000-00008
92. Egan MF, Hyde TM, Albers GW, Elkashef A, Alexander RC, Reeve A, et al. Treatment of
tardive dyskinesia with vitamin E. Am J Psychiatry 1992;149:773–7. http://dx.doi.org/10.1176/
ajp.149.6.773
93. Elkashef AM, Ruskin PE, Bacher N, Barrett D. Vitamin E in the treatment of tardive dyskinesia.
Am J Psychiatry 1990;147:505–6. http://dx.doi.org/10.1176/ajp.147.4.505
94. Lam LC, Chiu HF, Hung SF. Vitamin E in the treatment of tardive dyskinesia: a replication study.
J Nerv Ment Dis 1994;182:113–14. https://doi.org/10.1097/00005053-199402000-00009
95. Schmidt M, Meister P, Baumann P. Treatment of tardive dyskinesias with vitamin E. Eur Psychiatry
1991;6:201–7.
96. Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol
and tetrabenazine. Am J Psychiatry 1973;130:479–83. http://dx.doi.org/10.1176/ajp.130.4.479
97. Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramos-Lorenzi J. Low-dose
neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch
Gen Psychiatry 1983;40:893–6. https://doi.org/10.1001/archpsyc.1983.01790070083010
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
98. Cookson IB. The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic
schizophrenic patients maintained on a high dose regime. Int Clin Psychopharmacol 1987;2:141–9.
https://doi.org/10.1097/00004850-198704000-00008
99. Chouinard G, Arnott W. The effect of risperidone on extrapyramidal symptoms in chronic
schizophrenic patients. Biol Psychiatry 1992;31(Suppl. 5):158. https://doi.org/10.1016/0006-3223
(92)90579-O
100. Chouinard G, Arnott W. Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clin
Neuropharmacol 1992;15(Suppl. 1):266. https://doi.org/10.1097/00002826-199202001-00514
101. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter
risperidone study. J Clin Psychopharmacol 1995;15(Suppl. 1):36–44. https://doi.org/10.1097/
00004714-199502001-00007
102. Chouinard G. Arnott W. An Antidyskinetic Effect of Risperidone. Proceedings of the 9th World
Congress of Psychiatry, Rio de Janeiro, 6–12 June, 1993.
103. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian
multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment
of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25–40. https://doi.org/10.1097/
00004714-199302000-00004
104. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. Clozapine in tardive dyskinesia:
observations from human and animal model studies. J Clin Psychiatry 1994;55(Suppl. B):102–6.
105. Bai YM, Lin CC, Yu SC. Risperidone for severe tardive dyskinesia: one year follow up study.
Int J Neuropsychopharmacol 2002;5:S165.
106. Bai YM, Yu SC, Chen JY, Lin CY, Chou P, Lin CC. Risperidone for pre-existing severe tardive
dyskinesia: a 48-week prospective follow-up study. Int Clin Psychopharmacol 2005;20:79–85.
https://doi.org/10.1097/00004850-200503000-00003
107. Pai YM, Yu SC, Lin CC. Risperidone in Reducing Tardive Dyskinesia: A Double-Blind,
Placebo-Controlled Study. Proceedings of the 155th Annual Meeting of the American Psychiatric
Association, Philadelphia, PA, 18–23 May 2002.
108. Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized,
double-blind, placebo-controlled study. J Clin Psychiatry 2003;64:1342–8. https://doi.org/10.4088/
JCP.v64n1110
109. Pai YM, Yu SC, Lin CC. Risperidone in Reducing Tardive Dyskinesia: A Double-Blind,
Placebo-Controlled Study. Proceedings of the 154th Annual Meeting of the American Psychiatric
Association, New Orleans, LA, 5–10 May 2001.
110. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial
comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry
2004;65:696–701. https://doi.org/10.4088/JCP.v65n0516
111. Emsley RA, Turner J, Schronen J, Botha K, Smit R, Oosthuizen PP. Quetiapine: Greater
Improvements in Tardive Dyskinesia versus Haloperidol. 157th Annual Meeting of the American
Psychiatric Association, New York, NY, 1–6 May 2004.
112. Bai YM, Ping LY, Lin CC, Wang YC, Liou YL, Wu BJ, et al. Comparative effects of atypical
antipsychotic on tardive dyskinesia and neurocognition: a 24-week randomized, single-blind,
controlled study. Eur Neuropsychopharmacol 2005;15(Suppl. 3):473. https://doi.org/10.1016/
S0924-977X(05)80979-4
DOI: 10.3310/hta21430 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 43
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bergman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
63
113. Bai YM, Ping LY, Lin CC, Wang YC, Liou YL, Wu BJ, et al. Comparative Effects of Atypical
Antipsychotic on Tardive Dyskinesia and Neurocognition: A 24-week Randomized, Single-Blind,
Controlled Study. Proceedings of the 8th World Congress of Psychiatry, Cairo, Egypt,
10–15 September 2005.
114. Bai YM. Tardive Dyskinesia and Cognitive Function. 2008. URL: https://clinicaltrials.gov/ct2/show/
NCT00926965 (accessed 20 January 2017).
115. Chan HY, Chiang SC, Chang CJ, Gau SS, Chen JJ, Chen CH, et al. A randomized controlled trial
of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive
dyskinesia. J Clin Psychiatry 2010;71:1226–33. https://doi.org/10.4088/JCP.09m05155yel
116. NCT00621998. Risperidone and Olanzapine for the Schizophrenic Patients with Neuroleptic-
Induced Tardive Dyskinesia. 2008. URL: https://clinicaltrials.gov/ct2/show/NCT00621998 (accessed
20 January 2017).
117. Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, et al. Treatment outcomes
of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry 2011;72:295–303.
http://dx.doi.org/10.4088/JCP.09m05793yel
118. Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, et al. Clinical correlates of
tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr
Res 2005;80:33–43. https://doi.org/10.1016/j.schres.2005.07.034
119. Greil W, Haag H, Rossnagl G, Rüther E. Effect of anticholinergics on tardive dyskinesia.
A controlled discontinuation study. Br J Psychiatry 1984;145:304–10. https://doi.org/10.1192/
bjp.145.3.304
120. Bobruff A, Gardos G, Tarsy D, Rapkin RM, Cole JO, Moore P. Clonazepam and phenobarbital in
tardive dyskinesia. Am J Psychiatry 1981;138:189–93. http://dx.doi.org/10.1176/ajp.138.2.189
121. Csernansky JG, Riney SJ, Lombrozo L, Overall JE, Hollister LE. Double-blind comparison of
alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms. Arch
Gen Psychiatry 1988;45:655–9. https://doi.org/10.1001/archpsyc.1988.01800310063008
122. Csernansky JG, Tacke U, Rusen D, Hollister LE. The effect of benzodiazepines on tardive
dyskinesia symptoms. J Clin Psychopharmacol 1988;8:154–5. https://doi.org/10.1097/00004714-
198804000-00028
123. Adler LA, Edson R, Lavori P, Peselow E, Duncan E, Rosenthal M, Rotrosen J. Long-term treatment
effects of vitamin E for tardive dyskinesia. Biol Psychiatry 1998;43:868–72. https://doi.org/
10.1016/S0006-3223(97)00027-9
124. Adler LA, Peselow E, Angrist B, Duncan E, Lee M, Rosenthal M, et al. Vitamin E in Tardive
Dyskinesia: Effects of Longer Term Treatment. Proceedings of the 31st Annual Meeting of the
American College of Neuropsychopharmacology, San Juan, Puerto Rico, 14–18 December 1992.
125. Adler LA, Peselow E, Duncan E, Rosenthal M, Angrist B. Vitamin E in tardive dyskinesia: time
course of effect after placebo substitution. Psychopharmacol Bull 1993;29:371–4.
126. Adler LA, Peselow E, Rotrosen J, Duncan E, Lee M, Rosenthal M, Angrist B. Vitamin E treatment
of tardive dyskinesia. Am J Psychiatry 1993;150:1405–7. http://dx.doi.org/10.1176/ajp.150.9.1405
127. Akhtar S, Jajor TR, Kumar S. Vitamin E in the treatment of tardive dyskinesia. J Postgrad Med
1993;39:124–6.
128. Dabiri LM, Pasta D, Darby JK, Mosbacher D. Effectiveness of vitamin E for treatment of long-term
tardive dyskinesia. Am J Psychiatry 1994;151:925–6. http://dx.doi.org/10.1176/ajp.151.6.925
129. Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive
dyskinesia. J Clin Psychiatry 1996;57:167–73.
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
130. Sajjad SH. Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at
different doses. Int Clin Psychopharmacol 1998;13:147–55. https://doi.org/10.1097/00004850-
199807000-00001
131. Tracy K, Adler LA, Rotrosen J, Edson R, Lavori P. Interrater reliability issues in multicentric trials,
part I: theoretical concepts and operational procedures used in Department of Veterans Affairs
Cooperative Study 394. Psychopharmacol Bull 1997;33:53–7.
132. Lohr JB, Lavori P. Whither vitamin E and tardive dyskinesia? Biol Psychiatry 1998;43:861–2.
133. Edson R, Lavori P, Tracy K, Adler LA, Rotrosen J. Interrater reliability issues in multicentric trials,
part II: statistical procedures used in Department of Veterans Affairs Cooperative Study #394.
Psychopharmacol Bull 1997;33:59–67.
134. Caligiuri MP, Lohr JB, Rotrosen J, Adler L, Lavori P, Edson R, Tracy K. Reliability of an instrumental
assessment of tardive dyskinesia: results from VA Cooperative Study #394. Psychopharmacology
1997;132:61–6. https://doi.org/10.1007/s002130050320
135. Adler LA, Rotrosen J, Lavori P, Edson R. Vitamin E treatment of TD: development of a VA
cooperative study. Biol Psychiatry 1994;35:730–1. https://doi.org/10.1016/0006-3223(94)91073-1
136. Bridler R. [Vitamin E is ineffective in treatment of late dyskinesias.] Praxis 2001;90:809–10.
137. Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R, et al. Vitamin E treatment for tardive
dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry
1999;56:836–41. https://doi.org/10.1001/archpsyc.56.9.836
138. Zhang XY, Zhou DF, Cao LY, Xu CQ, Chen DC, Wu GY. The effect of vitamin E treatment on
tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. J Clin
Psychopharmacol 2004;24:83–6. http://dx.doi.org/10.1097/01.jcp.0000104912.75206.2b
139. Glover O. Alternative Treatment Modalities for Drug Induced Psychomotor Dysfunctions.
PhD thesis. Berkeley, CA: The Wright Institute;1980.
140. Zeng ZX, Fenglian C, Lin L. A clinical research of dexetimide and benzhexol for treatment of
drug-induced tremor. Herald Med 1996;15:130–1.
141. Kar-Ahmadi M. Vitamin E in the management of drug induced tardive dyskinesia: a double-blind
randomized clinical trial. J Res Med Sci 2002;4:311–20.
142. Garcia G, Crismon ML. Double-blind placebo controlled study using buspirone in the treatment of
tardive dyskinesia. ASHP Midyear Clin Meet 1992;27:91.
143. Reynolds C. A Six Month, Rater Blind Comparison of Quetiapine and Risperidone in the Treatment
of Tardive Dyskinesia in Patients with Schizophrenia. Leeds: National Research Register; 2002.
144. Kajero J. Investigation of the Potential Beneficial Effects of Cannabidiol in the Treatment of
Tardive Dyskinesia. 2015. URL: www.isrctn.com/ISRCTN14688109 (accessed 20 January 2017).
145. Casey DE, Toenniessen LM. Neuroleptic treatment in tardive dyskinesia: can it be developed into
a clinical strategy for long-term treatment? Mod Probl Pharmacopsychiatry 1983;21:65–79.
https://doi.org/10.1159/000408484
146. Damier P, Thobois S, Witjas T, Cuny E, Derost P, Raoul S, et al. Bilateral deep brain stimulation of
the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry 2007;64:170–6. https://doi.org/
10.1001/archpsyc.64.2.170
147. Pouclet-Courtemanche H, Rouaud T, Thobois S, Nguyen JM, Brefel-Courbon C, Chereau I, et al.
Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia.
Neurology 2016;86:651–9. http://dx.doi.org/10.1212/WNL.0000000000002370
DOI: 10.3310/hta21430 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 43
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bergman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
65
148. Hardoy MC, Carta MG, Carpiniello B, Cianchetti C, Congia S, D’Errico I, et al. Gabapentin in
antipsychotic-induced tardive dyskinesia: results of 1-year follow-up. J Affect Disord
2003;75:125–30. https://doi.org/10.1016/S0165-0327(02)00043-5
149. Huang CC. Comparison of two groups of tardive dyskinesia patients. Psychiatry Res 1986;19:335–6.
https://doi.org/10.1016/0165-1781(86)90128-9
150. Koshino Y, Wada Y, Isaki K, Kurata K. A long-term outcome study of tardive dyskinesia in
patients on antipsychotic medication. Clin Neuropharmacol 1991;14:537–46. https://doi.org/
10.1097/00002826-199112000-00006
151. Peselow ED, Angrist BM, Rotrosen J. Changes in tardive dyskinesia after fluphenazine decanoate
discontinuation. Ann Clin Psychiatry 1989;1:187–91. https://doi.org/10.3109/10401238909149978
152. Yagi G, Itoh H. A 10-year follow-up study of tardive dyskinesia – with special reference to the
influence of neuroleptic administration on the long-term prognosis. Keio J Med 1985;34:211–19.
https://doi.org/10.2302/kjm.34.211
153. Yassa R, Nair NP. A 10-year follow-up study of tardive dyskinesia. Acta Psychiatr Scand
1992;86:262–6. https://doi.org/10.1111/j.1600-0447.1992.tb03264.x
154. Yassa R, Nair V, Schwartz G. Tardive dyskinesia: a two-year follow-up study. Psychosomatics
1984;25:852–5. https://doi.org/10.1016/S0033-3182(84)72946-X
155. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis:
many names, many benefits, many concerns for the next generation evidence synthesis tool. Res
Synth Methods 2012;3:80–97. https://doi.org/10.1002/jrsm.1037
156. White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis:
model estimation using multivariate meta-regression. Res Synth Methods 2012;3:111–25.
http://dx.doi.org/10.1002/jrsm.1045
157. Lu G, Welton NJ, Higgins JP, White IR, Ades AE. Linear inference for mixed treatment comparison
meta-analysis: A two-stage approach. Res Synth Methods 2011;2:43–60. https://doi.org/10.1002/
jrsm.34
158. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison
of the performance of meta-analytical methods with rare events. Stat Med 2007;26:53–77.
http://dx.doi.org/10.1002/sim.2528
159. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity
corrections in meta-analysis of sparse data. Stat Med 2004;23:1351–75. http://dx.doi.org/
10.1002/sim.1761
160. Soares MO, Dumville JC, Ades AE, Welton NJ. Treatment comparisons for decision making:
facing the problems of sparse and few data. J R Stat Soc Ser A 2014;177:259–79. https://doi.org/
10.1111/rssa.12010
161. Rücker G, Schwarzer G, Carpenter J, Olkin I. Why add anything to nothing? The arcsine
difference as a measure of treatment effect in meta-analysis with zero cells. Stat Med
2009;28:721–38. http://dx.doi.org/10.1002/sim.3511
162. Kuss O. Statistical methods for meta-analyses including information from studies without any
events-add nothing to nothing and succeed nevertheless. Stat Med 2015;34:1097–116.
https://doi.org/10.1002/sim.6383
163. Warren FC, Abrams KR, Golder S, Sutton AJ. Systematic review of methods used in meta-analyses
where a primary outcome is an adverse or unintended event. BMC Med Res Methodol
2012;12:64. http://dx.doi.org/10.1186/1471-2288-12-64
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
66
164. Fleiss JL. The Crossover Study. The Design and Analysis of Clinical Experiments. Chichester:
John Wiley & Sons; 1984.
165. Armitage P. Should we cross off the crossover? Br J Clin Pharmacol 1991;32:1–2. https://doi.org/
10.1111/j.1365-2125.1991.tb05604.x
166. Pocock SJ. Crossover Trials. Clinical Trials A Practical Approach. Chichester: John Wiley & Sons; 1983.
167. Ferreira ML, Herbert RD, Crowther MJ, Verhagen A, Sutton AJ. When is a further clinical trial
justified? BMJ 2012;345:e5913. http://dx.doi.org/10.1136/bmj.e5913
168. Clarke M. Doing new research? Don’t forget the old. PLOS Med 2004;1:e35. http://dx.doi.org/
10.1371/journal.pmed.0010035
169. Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. II. Short-term efficacy of
dopamine-blocking agents haloperidol and thiopropazate. Arch Gen Psychiatry 1972;27:100–3.
https://doi.org/10.1001/archpsyc.1972.01750250086012
170. Borenstein M, Hedges LV, Higgins JPT. Introduction to Meta-Analysis. Chichester: John Wiley &
Sons; 2011.
171. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting
results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol
2011;64:163–71. http://dx.doi.org/10.1016/j.jclinepi.2010.03.016
172. Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without
resampling methods. BMC Med Res Methodol 2015;15:58. http://dx.doi.org/10.1186/s12874-
015-0060-8
173. Higgins JP, Green S, Scholten RJ. Maintaining Reviews: Updates, Amendments and Feedback. In
Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester:
John Wiley & Sons, Ltd; 2008. pp. 31–49. https://doi.org/10.1002/9780470712184.ch3
174. Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all
depends on the distribution of effect modifiers. BMC Med 2013;11:159. http://dx.doi.org/
10.1186/1741-7015-11-159
175. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
https://doi.org/10.1016/0197-2456(86)90046-2
176. White IR. Network meta-analysis. Stata J 2015;15:951–85.
177. Rücker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods
2012;3:312–24. http://dx.doi.org/10.1002/jrsm.1058
178. Rücker G, Schwarzer G. Reduce dimension or reduce weights? Comparing two approaches to
multi-arm studies in network meta-analysis. Stat Med 2014;33:4353–69. http://dx.doi.org/
10.1002/sim.6236
179. R Development Core Team. R: A Language and Environment for Statistical Computing. 2008.
URL: www.r-project.org/ (accessed 11 April 2017).
180. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-
analysis in STATA. PLOS ONE 2013;8:e76654. http://dx.doi.org/10.1371/journal.pone.0076654
181. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity
in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J
Epidemiol 2012;41:818–27. https://doi.org/10.1093/ije/dys041
182. Rhodes KM, Turner RM, Higgins JP. Predictive distributions were developed for the extent of
heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol 2015;68:52–60.
http://dx.doi.org/10.1016/j.jclinepi.2014.08.012
DOI: 10.3310/hta21430 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 43
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bergman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
67
183. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment
comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683–91.
https://doi.org/10.1016/S0895-4356(97)00049-8
184. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in
network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods
2012;3:98–110. http://dx.doi.org/10.1002/jrsm.1044
185. Jackson D, Barrett JK, Rice S, White IR, Higgins JP. A design-by-treatment interaction model
for network meta-analysis with random inconsistency effects. Stat Med 2014;33:3639–54.
http://dx.doi.org/10.1002/sim.6188
186. Hempel S, Miles JN, Booth MJ, Wang Z, Morton SC, Shekelle PG. Risk of bias: a simulation
study of power to detect study-level moderator effects in meta-analysis. Syst Rev 2013;2:107.
http://dx.doi.org/10.1186/2046-4053-2-107
187. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study
effects in a network of interventions. Res Synth Methods 2012;3:161–76. http://dx.doi.org/
10.1002/jrsm.57
188. Lublin H, Gerlach J, Hagert U, Meidahl B, Mølbjerg C, Pedersen V, et al. Zuclopenthixol, a
combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive
dyskinesia. Eur Neuropsychopharmacol 1991;1:541–8. https://doi.org/10.1016/0924-977X(91)
90008-I
189. Glazer WM, Hafez H. A comparison of masking effects of haloperidol versus molindone in tardive
dyskinesia. Schizophr Res 1990;3:315–20. https://doi.org/10.1016/0920-9964(90)90016-Z
190. Glazer WM, Hafez HM, Benarroche CL. Molindone and haloperidol in tardive dyskinesia. J Clin
Psychiatry 1985;46:4–7.
191. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV.
Washington, DC: American Psychiatric Association; 2000.
192. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry
1982;39:486–7. https://doi.org/10.1001/archpsyc.1982.04290040080014
193. American Psychiatric Association. DSM-IIl-R: Diagnostic and Statistical Manual of Mental
Disorders. 3rd edn, revised. Washington, DC: American Psychiatric Association; 1987.
194. National Center for Health Statistics. Classification of Diseases and Injuries. 2002. URL: ftp://ftp.
cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD-9/ucod.txt (accessed on 6 June 2017).
195. Chinese Medical Association and Nanjing Medical University. Chinese Classification of Mental
Disorders, Second Edition, Revised (CCMD-2-R). Nanjing: Dong Nan University Press; 1995.
196. World Health Organization. The Classification of Mental and Behavioural Disorders: Clinical
Descriptions and Diagnostic Guidelines. URL: www.who.int/classifications/icd/en/bluebook.pdf
(accessed 20 July 2017).
197. Bucci L. The dyskenesias: a new therapeutic approach. Dis Nerv Syst 1971;32:324–7.
198. Loonen AJM, Verwey HA, Roels PR, van Bavel LP, Doorschot CH. Is diltiazem effective in treating
the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind,
placebo-controlled trial. J Clin Psychopharmacol 1992;12:39–42. https://doi.org/10.1097/
00004714-199202000-00007
199. Schwartz B, McCarthy MF, Kendrick K, Rosse R, Deutsch S. Effect of nifedipine on motor skill
learning in schizophrenia. Schizophr Res 1997;24:125. https://doi.org/10.1016/S0920-9964(97)
82352-3
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
68
200. Schwartz BL, Fay-McCarthy M, Kendrick K, Rosse RB, Deutsch SI. Effects of nifedipine, a calcium
channel antagonist, on cognitive function in schizophrenic patients with tardive dyskinesia.
Clin Neuropharmacol 1997;20:364–70. https://doi.org/10.1097/00002826-199708000-00009
201. Beckham BJ. Lecithin Therapy for Tardive Dyskinesia. Dissertation. Denton, TX: North Texas State
University; 1981.
202. Caroff SN, Walker P, Campbell C, Lorry A, Petro C, Lynch K, Gallop R. Treatment of tardive
dyskinesia with galantamine: a randomized controlled crossover trial. J Clin Psychiatry
2007;68:410–15.
203. Caroff SN. Treatment of Tardive Dyskinesia with Galantamine. 2005. URL: https://clinicaltrials.gov/
ct2/show/NCT00164242 (accessed 20 January 2017).
204. de Montigny C, Chouinard G, Annable L. Ineffectiveness of deanol in tardive dyskinesia:
a placebo controlled study. Psychopharmacology 1979;65:219–23. https://doi.org/10.1007/
BF00492207
205. Gelenberg AJ, Dorer DJ, Wojcik JD, Falk WE, Brotman AW, Leahy L. A crossover study of lecithin
treatment of tardive dyskinesia. J Clin Psychiatry 1990;51:149–53.
206. George J, Pridmore S, Aldous D. Double blind controlled trial of deanol in tardive dyskinesia. Aust
N Z J Psychiatry 1981;15:68–71. https://doi.org/10.3109/00048678109159413
207. Jackson IV. Cholinergic enhancement in tardive dyskinesia. Curr Ther Res Clin Exp 1978;24:725–33.
208. Jackson IV, Davis LG, Cohen RK, Nuttall EA. Lecithin administration in tardive dyskinesia: clinical
and biomedical correlates. Biol Psychiatry 1981;16:85–90.
209. Jackson IV, Nuttall EA, Ibe IO, Perez-Cruet J. Treatment of tardive dyskinesia with lecithin. Am J
Psychiatry 1979;136:1458–60. http://dx.doi.org/10.1176/ajp.136.11.1458
210. Bockenheimer S, Lucius G. [Deanol in tardive dyskinesia: a double-blind study.] Arch Psychiatr
Nervenkr 1976;222:69–75. https://doi.org/10.1007/BF00369796
211. Ogunmefun A, Hasnain M, Alam A, Osuala T, Regenold WT. Effect of donepezil on tardive dyskinesia.
J Clin Psychopharmacol 2009;29:102–4. http://dx.doi.org/10.1097/JCP.0b013e3181934475
212. Price LA. Lecithin Treatment for Tardive Dyskinesia: A Clinical Evaluation. Dissertation. Denton, TX:
North Texas State University; 1982.
213. Tarsy D, Bralower M. Deanol acetamidobenzoate treatment in choreiform movement disorders.
Arch Neurol 1977;34:756–8. https://doi.org/10.1001/archneur.1977.00500240044007
214. Ojima Y, Tsubaki M, Yagi G, Kamishima K, Miura S. Experimental design and analysis for
determination of improvement rating by video imaging – a double-blind placebo-controlled study
for Meclofenoxate hydrochloride (Lucidril) in tardive dyskinesia. Rinsho Hyoka 1991;19:267–76.
215. Yagi G, Kamizima K, Miura S. Meclofenoxate (Lucidril) in Tardive Dyskinesia – A Double-Blind
Placebo-Controlled Study. Proceedings of the 17th Collegium Internationale Neuro-
Psychopharmacologicum Congress, Kyoto, Japan, September 10–14 1990.
216. Ananth J, Djenderedjian A, Beshay M, Kamal M, Kodjian A, Barriga C. Baclofen in the treatment
of tardive dyskinesia. Curr Ther Res Clin Exp 1987;42:111–14.
217. Burner M, Giroux C, L’Heritier C, Garreau M, Morselli PL. Preliminary observations on the
therapeutic action of progabide in tardive dyskinesia. Brain Dysfunct 1989;2:289–96.
218. Fisk GG, York SM. The effect of sodium valproate on tardive dyskinesia – revisited. Br J Psychiatry
1987;150:542–6. https://doi.org/10.1192/bjp.150.4.542
DOI: 10.3310/hta21430 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 43
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bergman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
69
219. Gerlach J. The relationship between parkinsonism and tardive dyskinesia. Am J Psychiatry
1977;134:781–4. http://dx.doi.org/10.1176/ajp.134.7.781
220. Gerlach J, Rye T, Kristjansen P. Effect of baclofen on tardive dyskinesia. Psychopharmacology
1978;56:145–51. https://doi.org/10.1007/BF00431840
221. Glazer WM, Moore DC, Bowers MB, Bunney BS, Roffman M. The treatment of tardive dyskinesia
with baclofen. Psychopharmacology 1985;87:480–3. https://doi.org/10.1007/BF00432517
222. Linnoila M, Viukari M, Kietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry
1976;129:114–19. https://doi.org/10.1192/bjp.129.2.114
223. Nair NP, Yassa R, Ruiz-Navarro J, Schwartz G. Baclofen in the treatment of tardive dyskinesia.
Am J Psychiatry 1978;135:1562–3. http://dx.doi.org/10.1176/ajp.135.12.1562
224. Nair NP, Lal S, Schwartz G, Thavundayil JX. Effect of sodium valproate and baclofen in tardive
dyskinesia: clinical and neuroendocrine studies. Adv Biochem Psychopharmacol 1980;24:437–41.
225. Stewart RM, Rollins J, Beckham B, Roffman M. Baclofen in tardive dyskinesia patients maintained
on neuroleptics. Clin Neuropharmacol 1982;5:365–73. https://doi.org/10.1097/00002826-
198212000-00004
226. Stewart RM, Rollins J, Beckam B, Roffman M. Baclofen for tardive dyskinesia: a double-blind
placebo-controlled trial. Neurology 1982;32:A114.
227. Thaker GK, Tamminga CA, Alphs LD, Lafferman J, Ferraro TN, Hare TA. Brain gamma-
aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels
and therapeutic response to GABA agonist treatment. Arch Gen Psychiatry 1987;44:522–9.
https://doi.org/10.1001/archpsyc.1987.01800180032006
228. Castro F, Carrizo E, Prieto de Rincón D, Rincón CA, Asián T, Medina-Leendertz S, Bonilla E.
Effectiveness of melatonin in tardive dyskinesia. Invest Clin 2011;52:252–60.
229. Emsley R, Niehaus DJ, Koen L, Oosthuizen PP, Turner HJ, Carey P, et al. The effects of
eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr Res
2006;84:112–20. https://doi.org/10.1016/j.schres.2006.03.023
230. Elmsley R, Oosthuizen PP. Double-Blind, Randomized, Parallel-Group Comparison of Ethyl-
eicosapentaenoic Acid (ethyl-EP A) versus Placebo as add-on Medication in 84 Patients with
Established Tardive Dyskinesia. Muscatine, IA: Stanley Foundation Research Programs; 2002.
231. Emsley R. Ethyl Eicosapentanoic Acid for Tardive Dyskinesia. Muscatine, IA: Stanley Foundation
Research Programs; 2009.
232. NCT00114595. A Double-Blind, Randomised, Parallel-Group Comparison of Ethyl-
eicosapentaenoic Acid (ethyl-epa) versus Placebo as add-on Medication in Patients with
Established Tardive Dyskinesia. 2005. URL: https://clinicaltrials.gov/ct2/show/NCT00114595
(accessed 20 January 2017).
233. Emsley R, Niehaus DJ, Oosthuizen PP, Koen L, Ascott-Evans B, Chiliza B, et al. Safety of the
omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a
randomized, placebo-controlled trial. Psychiatry Res 2008;161:284–91. http://dx.doi.org/10.1016/
j.psychres.2007.06.029
234. Gardos G, Granacher RP, Cole JO, Sniffin C. The effects of papaverine in tardive dyskinesia.
Prog Neuropsychopharmacol 1979;3:543–50. https://doi.org/10.1016/0364-7722(79)90008-0
235. Glazer WM, Naftolin F, Morgenstern H, Barnea ER, MacLusky NJ, Brenner LM. Estrogen
replacement and tardive dyskinesia. Psychoneuroendocrinology 1985;10:345–50. https://doi.org/
10.1016/0306-4530(85)90011-3
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
236. Goff DC, Renshaw PF, Sarid-Segal O, Dreyfuss DA, Amico ET, Ciraulo DA. A placebo-controlled
trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry
1993;33:700–6. https://doi.org/10.1016/0006-3223(93)90119-X
237. Hajioff J, Wallace M. Effect of co-dergocrine mesylate on tardive dyskinesia. A preliminary report.
Psychopharmacology 1983;79:1–3. https://doi.org/10.1007/BF00433006
238. Kojima T, Yamauchi T, Miyasaka M, Isaki K, Nakane Y, Takahashi R, et al. Treatment of tardive
dyskinesia with ceruletide: a double-blind placebo-controlled study. Saishin-Igaku 1989;44:2177–88.
239. Kojima T, Yamauchi T, Miyasaka M, Koshino Y, Nakane Y, Takahashi R, et al. Treatment of
tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study. Psychiatry Res
1992;43:129–36. https://doi.org/10.1016/0165-1781(92)90127-O
240. Lerner V. Piracetam for Tardive Dyskinesia. Muscatine, IA: Stanley Foundation Research
Programs; 2009.
241. Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V. Efficacy of piracetam in the treatment
of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled
crossover study. J Clin Psychiatry 2007;68:1031–7. https://doi.org/10.4088/JCP.v68n0709
242. Anon. Piracetam reduces TD symptoms tardive dyskinesia. Brown Uni Psychopharmacol Update
2007;18:3–4.
243. NCT00190008. Therapeutic use of Piracetam for Treatment of Patients Suffering from Tardive
Dyskinesia – A Double Blind, Placebo-Controlled Crossover Study. 2005. URL: https://clinicaltrials.
gov/ct2/show/NCT00190008 (accessed 20 January 2017).
244. MacKay AV, Sheppard GP, Saha BK, Motley B, Johnson AL, Marsden CD. Failure of lithium
treatment in established tardive dyskinesia. Psychol Med 1980;10:583–7. https://doi.org/
10.1017/S0033291700047498
245. Matsunaga T, Ohyama S, Takehara S, Kabashima K, Moriyama S, Tsuzuki J, et al. The effect of
ceruletide on tardive dyskinesia: a double-blind placebo-controlled study. Prog Neuropsychopharmacol
Biol Psychiatry 1988;12:533–9. https://doi.org/10.1016/0278-5846(88)90112-1
246. Meco G, Bedini L, Bonifati V, Sonsini U. Ritanserin in tardive dyskinesia: a double-blind crossover
study versus placebo. Curr Ther Res Clin Exp 1989;46:884–94.
247. Mosnik DM, Spring B, Rogers K, Baruah S, Waziri R. Phenylalanine loading effects on tardive
dyskinesia severity in schizophrenics. Schizophr Res 1995;15:208. https://doi.org/10.1016/
0920-9964(95)95640-U
248. Mosnik DM. Phenylalanine Loading Effects on Tardive Dyskinesia Severity in Schizophrenics.
Master of Science dissertation. North Chicago, IL: Finch University of Health Sciences; 1994.
249. Mosnik DM, Spring B, Rogers K, Baruah S. Tardive dyskinesia exacerbated after ingestion
of phenylalanine by schizophrenic patients. Neuropsychopharmacology 1997;16:136–46.
https://doi.org/10.1016/S0893-133X(96)00054-1
250. Mouret J, Khomais M, Lemoine P, Sebert P. Low doses of insulin as a treatment of tardive
dyskinesia: conjuncture or conjecture? Eur Neurol 1991;31:199–203. https://doi.org/10.1159/
000116678
251. O’Brien CF, Jimenez R, Hauser RA, Factor SA, Mandri DF, Castro-Gyol JC. Kinect 2: NBI-98854
Treatment of Moderate to Severe Tardive Dyskinesia. 18th International Congress of Parkinson’s
Disease and Movement Disorders, Stockholm, Sweden, 2014.
252. NCT01733121. Nbi-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia. 2012.
URL: http://ClinicalTrials.gov/show/NCT01733121 (accessed 20 January 2017).
DOI: 10.3310/hta21430 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 43
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bergman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
71
253. Rastogi SC, Blowers AJ, Gibson AC. Co-dergocrine (hydergine) in the treatment of tardive
dyskinesia. Psychol Med 1982;12:427–9. https://doi.org/10.1017/S0033291700046778
254. Richardson MA, Bevans ML, Read LL, Chao HM, Clelland JD, Suckow RF, et al. Efficacy of the
branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry
2003;160:1117–24. http://dx.doi.org/10.1176/appi.ajp.160.6.1117
255. Shamir E, Barak Y, Plopsky I, Zisapel N, Elizur A, Weizman A. Is melatonin treatment effective for
tardive dyskinesia? J Clin Psychiatry 2000;61:556–8. https://doi.org/10.4088/JCP.v61n0803
256. Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, et al. Melatonin treatment for
tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry
2001;58:1049–52. https://doi.org/10.1001/archpsyc.58.11.1049
257. Shamir EZ, Barak F, Shalman I, et al. Melatonin Treatment for Tardive Dyskinesia: A Double-Blind,
Placebo-Controlled, Cross-Over Study. Annual Meeting of the American Psychiatric Association,
Los Angeles, CA, USA, 5–10 May 2001.
258. NCT00175955. An 8-week Exploratory, Double-Blind, Placebo Controlled, Randomized Trial –
Evaluation of the Efficacy and Safety of Levetiracetam up to 3000 mg/day (250-500 mg Oral
Tablets in Bid Administration) on Neuroleptic-Induced Tardive Dyskinesia in Subjects with Stable
Axis I Psychiatric Disorder, Aged from at least 18 Years to 80 Years. 2005. URL: https://
clinicaltrials.gov/ct2/show/NCT00175955 (accessed 20 January 2017).
259. Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J. Essential fatty acid supplementation in
tardive dyskinesia. Am J Psychiatry 1986;143:912–14. http://dx.doi.org/10.1176/ajp.143.7.912
260. Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia:
a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2008;69:546–54.
https://doi.org/10.4088/JCP.v69n0405
261. NCT00291213. Levetiracetam Treatment of Tardive Dyskinesia. 2006. URL: https://clinicaltrials.
gov/ct2/show/NCT00291213 (accessed 20 January 2017).
262. Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for
tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin
Psychiatry 2011;72:615–21. http://dx.doi.org/10.4088/JCP.09m05125yel
263. Zhang F, Bigos K, Weinberger D. Genome-Wide Analysis of Antipsychotic Drug Response in
Schizophrenia. Proceedings of the 50th Annual Meeting of the American College of
Neuropsychopharmacology, Waikoloa, HI, USA, 4–8 December 2011.
264. Tan Y. Extract of Ginkgo biloba and Tardive Dyskinesia. 2008. URL: https://clinicaltrials.gov/ct2/
show/NCT00672373 (accessed 20 January 2017).
265. Buruma OJ, Roos RA, Bruyn GW, Kemp B, van der Velde EA. Tiapride in the treatment of tardive
dyskinesia. Acta Neurol Scand 1982;65:38–44. https://doi.org/10.1111/j.1600-0404.1982.tb03059.x
266. Roos RAC, Buruma OJS, Bruyn GW, Kemp B, van der Velde EA, Zelvelder WG. [Tiapride in
Huntington's chorea and tardive dyskinesia. A double-blind, placebo controlled crossover clinical
trial.] J Drug Res 1982;7:1234–9.
267. Huang CC, Wang RI, Hasegawa A, Alverno L. Evaluation of reserpine and alpha-methyldopa in
the treatment of tardive dyskinesia. Psychopharmacol Bull 1980;16:41–3.
268. Huang CC, Wang RI, Hasegawa A, Alverno L. Reserpine and alpha-methyldopa in the treatment
of tardive dyskinesia. Psychopharmacology 1981;73:359–62. https://doi.org/10.1007/BF00426466
269. Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive
dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol
2010;33:271–5. https://doi.org/10.1097/WNF.0b013e3181ffde32
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
72
270. Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Efficacy of amantadine in the treatment of
tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Biol Psychiatry 2009:171.
271. Pappa S, Tzouli S, Mavreas V, Konitsiotis S. Efficacy of an NMDA receptor antagonist in the
treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Schizophr
Res 2012;136:S358. https://doi.org/10.1016/S0920-9964(12)71045-9
272. Rust M. Tiapride treatment of tardive dyskinesia due to long-term neuroleptic treatment. Sem Hop
1984;60:2195–6.
273. Simpson GM, Yadalam KG, Stephanos MJ. Double-blind carbidopa/levodopa and placebo study in
tardive dyskinesia. J Clin Psychopharmacol 1988;8(Suppl. 4):49–51. https://doi.org/10.1097/
00004714-198808001-00009
274. Soni SD, Freeman HL, Bamrah JS, Sampath G. Oxypertine in tardive dyskinesia: a long-term
controlled study. Acta Psychiatr Scand 1986;74:446–50. https://doi.org/10.1111/j.1600-0447.
1986.tb06267.x
DOI: 10.3310/hta21430 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 43
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bergman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
73

Appendix 1 Patient and public involvement
report: tardive dyskinesia – adding perspectives from
personal experience to the research agenda
Introduction
On 15 April 2016, the McPin Foundation hosted a consultation group to gather feedback from people
with a lived experience of TD. This endeavour was undertaken by the Cochrane Schizophrenia Group
at the University of Nottingham in an effort to inform our systematic review. The consultation was
commissioned by a group of researchers who have completed a NIHR-funded systematic review to
ascertain effective interventions to treat TD. An integral part of any health research is to gain the service
user perspective; therefore, the results of the review were discussed. Another aim of the session was to
elicit what people with lived experience thought would be a good research project in this area.
Methods
The consultation was planned to enable the voices of people with personal experience of TD to be heard.
The consultation was advertised by e-mail via the McPin Foundation’s large circulation list of people who
have an expressed interest in being involved, as well as on their website. Interested people were asked to
contact the McPin Foundation to book a place to attend. Prior to the meeting, two documents were
circulated to attendees: a lay report providing an overview of the review and one of the individual systematic
reviews that had been included. These documents gave the foundation for the discussions of the day.
The consultation was held at the McPin Foundation offices in London, UK. Reimbursement for time and
out-of-pocket expenses was offered. The consultation was facilitated by Ruth Sayers (Peer Researcher at the
McPin Foundation), with support from Megan Rees (Public Involvement in Research Co-ordinator at the
McPin Foundation) and Dr Dawn-Marie Walker (Associate Professor at the University of Southampton). All of
these researchers have extensive experience in involving patients and the public in research consultation.
Furthermore, although this collaboration is not empirical qualitative research per se, both Ruth and Dawn-Marie
have expert knowledge in this paradigm, including hosting focus groups (or in this case a collaboration). The
session was planned to provide time to reflect on current research on TD and to consider gaps in knowledge.
Following an introduction to the consultation by Ruth Sayers, Dr Dawn-Marie Walker gave an oral
overview of the review and the findings.
The group was then shown a video clip from YouTube (YouTube, LLC, San Bruno, CA, USA) showing
people with TD. The primary purpose of showing the clip was to give attendees an overview of the effects
of TD and to provide a common starting point for the discussion. The YouTube clip shown towards the
beginning of the consultation was entitled ‘Tardive Dyskinesia’. Uploaded on 12 June 2016, the clip is a
training digital versatile disc (DVD) that presents the AIMS exam by showing a range of abnormal
involuntary movement-associated conditions in patients, including scoring by an expert medical panel.
The clip can be found at www.youtube.com/watch?v=FUr8ltXh1Pc (accessed 13 June 2017).
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Attendees were then asked to consider:
l What is important to people who have experience of managing TD alongside living with severe
mental illness?
l Are the outcomes used in current TD research, as reflected in the Cochrane reviews, appropriate from
a lived experience perspective?
l What other outcomes might be important to service users and carers for research into TD?
l Ideas for future research in the area.
The consultation included open group discussions and prioritisation of ideas. All discussions were
audio-recorded, while the attendees were asked to write down their ideas throughout the day on paper
tablecloths and Post-it notes to help keep an accurate record of discussion and in order to encourage
everyone to participate (see Figures 1, 8 and 9). The researchers listened to the recordings after the session
and noted any points relevant to the above mentioned questions that would have impact on the funded
systematic review. Full transcription and formal analyses were not appropriate in this case, as the
consultation was not a piece of empirical qualitative work.
Group demographics
A total of six people attended the consultation, excluding facilitators. All collaborators were mental health
service users and one was a carer. All service users were taking, or had previously taken, antipsychotics.
The researchers acknowledge that a larger, diverse group may have presented a wider range of
perspectives on the review; however, for the type of involvement we anticipated, a more formal method
for recruitment (e.g. purposive sampling) would not have been appropriate.
Findings
Within the relatively open format of the consultation, the group were asked to bear in mind the four
consultation questions. A number of attendees, including facilitators, were disturbed by the YouTube clip
shown at the session, particularly its sole emphasis on identifying the physical symptoms of TD.
That’s how others see me! Mad old woman from a 1950s asylum.
TABLE 3 Demographic details
Category Participants’ details
Sex Male, n= 0; female, n= 6
Age group (years) 25–34, n = 2; 35–44, n= 1; 45–54, n= 1; 55–64, n = 1; ≥ 65, n= 1
Ethnic group White British, n= 4; other, n= 2
Service user/carer Service user, n= 5; carer, n= 1
Antipsychotic use Taken in past: olanzapine, quetiapine, thioridazine, haloperidol, risperidone olanzapine,
sulpiride, quetiapine, haloperidol
Currently taking antipsychotics: olanzapine, Depakote® (AbbVie Inc., North Chicago, IL, USA),
venlafaxine
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The group went on to discuss the debilitating nature of TD. One attendee noted that, unlike symptoms of
psychosis such as hearing voices and hallucinations, people with TD are unable to conceal the effects of TD
when they are out in public. This, in turn, can have a very negative impact on a person’s self-esteem and
ability to maintain social networks.
TD can be as debilitating as the psychosis itself.
From group discussions, a key theme that emerged was informed consent and the extent to which service
users are made aware of the adverse effects of antipsychotic medication. There was a consensus that, on
the whole, people are not given enough information about the adverse effects of antipsychotic medication.
This lack of information makes it impossible for people to weigh the pros and cons of taking medications
prior to beginning treatment. Informed consent is not only a key principle of treatment, but it also leads to
higher levels of ‘treatment adherence’ and treatment satisfaction. Attendees felt that informed consent was
important in both inpatient and outpatient settings.
I think psychiatrists presume that patients are stupid and can’t make an informed choice.
Although attendees acknowledged that increasing the level of information provided to people would not
directly lead to a lower incidence of TD, it would probably lead to people feeling more empowered and
better able to accept the consequences of any treatment. Although we acknowledge that published
evidence suggests that clinical efficacy is more important to patients than the side-effect profile of
antipsychotics, a clear message that emerged from this consultation was the need for full informed
consent obtained by outlining adverse effects in a patient-centred consultation. Only one of the
collaborators had heard of TD before, although all had taken antipsychotics at some time.
Key recommendation for research outcomes in TD: measure the extent to which people feel informed
about their treatment and the possibility of adverse effects such as TD.
Participants also noted the importance of people having access to quality, evidence-based information
about TD. This would make service users less reliant on clinicians for information, and support full
informed consent.
Key recommendation for research outcomes in TD: measure service users’ access to quality
information about TD.
Discussions about informed consent led into a discussion about accountability. Attendees highlighted
service users’ feelings of anger and impotence that result from experiencing the distressing adverse effects
of medication, particularly in cases in which people have not previously been provided with adequate
information. In many cases, people have no way of holding the medical profession to account because
adverse effects of medication are often similar to defined symptoms of mental illness and, thus, it is
difficult for people to prove a direct link with medication. This is not the case with TD, as there is a general
consensus that TD results solely from medication consumption. Accountability was an important outcome,
particularly for people who have developed lifelong TD as a result of taking medication.
Key recommendation for research outcomes in TD: for people who have developed lifelong TD as a
result of taking medication, to what extent do organisations/individuals take responsibility? Are people
supported or encouraged to seek accountability?
Prevention was another key theme in the discussion. Attendees were concerned that adverse effects of
medication are often treated with more medication and that the research included in the Cochrane review
placed an over-reliance on pharmaceutical interventions to treat TD. They wondered, ‘Why are all of the
approaches pharmacological?’.
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Furthermore, in light of the Cochrane review’s findings, attendees were not confident that reducing or
stopping taking antipsychotic drugs reduces instances of TD.
I’m appalled by the poverty of this evidence base given how debilitating tardive dyskinesia is.
Attendees suggested other avenues that may be worth exploring, including attempting to understand the
causal mechanisms behind TD through brain imaging.
Key recommendation for future research in TD: understanding the causal mechanisms that result in TD as
well as developing methods to assess individuals’ risk of developing TD as a result of medication consumption.
As the group discussed ideas for future research into TD, the issue of prevalence was raised. Is TD a
diminishing problem? Prevalence was not addressed in the research compiled by the Cochrane review and
the group were not aware of any substantive data to suggest that the prevalence of TD is decreasing.
A number of recommendations were made in relation to prevalence.
Key recommendation for future research in TD: understanding the prevalence of medication-related TD.
Key recommendation for research outcomes in TD: measuring clinician awareness of TD as a side
effect of psychiatric medications.
Key recommendation for research outcomes in TD: measuring the level of reporting with regard to
incidences of TD.
Following the discussion about prevention and prevalence, the group considered the best ways of
supporting those already living with TD and the role that research can play. None of the research that has
taken place thus far has explored the effectiveness of psychological therapies, peer support and social
interventions to help people to cope with the symptoms of TD. Coping mechanisms are very important in
the absence of effective treatments, particularly for those who experience these adverse effects long term.
Attendees noted that some of the most debilitating aspects of living with TD stem from social stigma and
the negative impacts of TD on an individual’s confidence:
Look at that lady!
People point at me, particularly children.
Tardive dyskinesia makes you feel vulnerable because it’s so obvious.
The group made a number of suggestions relating to managing the symptoms of TD, as well as measuring
the effectiveness of particular treatments in relation to service users’ confidence, social inclusion and
quality of life.
FIGURE 9 A key concern.
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Key recommendation for future research in TD: what psychological therapies are effective in
managing the symptoms of TD?
Key recommendation for future research in TD: is peer support effective in managing the symptoms
of TD?
Key recommendation for research outcomes in TD: social confidence, social inclusion, social networks,
personalised quality-of-life measures and employment.
The group discussed the parallels between Tourette syndrome and TD. A number of public awareness
campaigns have been successful in informing the public about Tourette syndrome, and this in turn has
reduced social stigma. The group suggested that similar campaigns would probably be effective in
reducing the stigma associated with TD.
Key recommendation for future research in TD: measuring public awareness of TD.
Finally, attendees were asked to review the outcomes that have been used in TD research to date to assess
their relevance. As illustrated in the Cochrane review, the outcomes used in research relating to TD are
as follows:
1. improvement in TD
2. level of functioning
3. improvement/reduction in psychiatric symptoms
4. deterioration
5. relapse
6. mental state changes
7. acceptability of treatment
8. quality of life
9. satisfaction with care
10. adverse effects
11. hospital admission
12. death
13. dropped out of trial/left the study early.
There was consensus within the group that all of the outcomes used to date have their merits and that
their relevance would depend on a large number of factors including the type of treatment being assessed
and trial design. However, the list of outcomes included in the Cochrane review has some notable
omissions. Outcomes and areas of research that have thus far been underexplored are listed below.
List of key recommendations for outcomes and research in to
tardive dyskinesia
Outcomes
l Measure the extent to which service users feel informed about their treatment and the possibility of
adverse effects such as TD.
l Measure patients’ access to quality information about TD.
l For people who have developed lifelong TD as a result of taking medication, to what extent do
organisations/individuals take responsibility? Are service users supported or encouraged to
seek accountability?
l Measuring clinician awareness of TD as a side effect of psychiatric medications.
l Measuring the level of reporting with regard to incidences of TD.
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l Measuring social confidence, social inclusion, social networks, personalised quality-of-life measures
and employment.
l Measuring public awareness of TD (Figure 10).
Future research
l Understanding the causal mechanisms that result in TD as well as developing methods to assess
individuals’ risk of developing TD as a result of medication consumption.
l Understanding the prevalence of medication-related TD.
l What psychological therapies are effective in managing the symptoms of TD?
l Is peer support effective in managing the symptoms of TD?
It is important to note that the above list of recommendations reflects the context within which they were
suggested, either as additional outcomes to be considered within future TD research or as future
research projects.
However, it was clear that almost all of the recommendations relating to ‘outcomes’ could equally be
important areas of interest for future research in and of themselves. Moreover, some studies that are not
solely focused on ascertaining the prevalence of medication-related TD may be improved by including an
outcome measure to understand the prevalence of TD among their participant group.
Reflections of the facilitating team
Megan Rees
I really enjoyed the session and given I had little prior experience of working in the field of TD, I found
the group’s discussions very enlightening.
FIGURE 10 Key outcomes of interest.
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When it came to the most important outcomes for research, attendees unanimously supported the
goals of research included in the Cochrane review. Preventing and treating the symptoms of TD were,
for obvious reasons, a key concern of service users. However, attendees were quick to highlight
important outcomes that appeared to be missing from the research. One such ‘missing’ outcome
referred to as ‘informed prescribing’ particularly struck me. After watching a rather graphic video of
the effects of TD, there was a palpable sense of injustice. A number of attendees wondered how
many people who are prescribed antipsychotics are made aware of such severe side effects and
expressed how important it is that service users are given the opportunity to make an informed choice
before taking medication. If, as the review found, we are unable to effectively prevent or treat this
particular side effect, some emphasis must be placed on giving service users enough information that
they are able to essentially own their decisions when it comes to medication. This would at least
mitigate against the feeling of powerlessness and subjugation that many people feel when they
experience medication side effects that they were not initially made aware of.
The group made a number of highly insightful suggestions throughout the day but it was their focus
on outcomes relating to empowerment and autonomy that were so striking given that these outcomes
were conspicuous by their absence in the research that has taken place so far.
Dawn Marie-Walker
I really enjoyed the session, and was reassured by the passionate responses from the service users that
this research is really worthwhile.
Since being part of this work, one of my PhD [doctor of philosophy] students from Saudi Arabia has
had a nephew with severe mental health difficulties. His nephew has been given vast amounts of
medication, including anti psychotics, and what has resulted, from the description of my student,
as TD.
Although initially my colleagues and I thought TD was a declining problem (due to having far more
knowledge about it and medication regimes), it appears that it is still a grave problem internationally.
Also in dementia, where antipsychotics are prescribed off licence, it may also be more of a problem.
Ruth Sayers
I appreciated the openness and engagement of the people who attended the workshop. Individual
accounts of experiencing TD differed considerably, but all showed clearly the level of distress,
vulnerability and stigmatisation that can be associated with tardive dyskinesia. Lack of awareness of TD
was compared with the growing awareness of Tourette’s, and the efforts being made to de-stigmatise
that condition, especially with young people.
Several felt angry that they had not been given sufficient information at the time of prescribing about
side effects of antipsychotics to make an informed choice – to enable them to balance the risks for
themselves. There were many questions raised about how much was known, and how much doctors
know, or reported, about TD, and therefore whether the actual prevalence is known, in the UK or
elsewhere. Suggestions about what might help people included greater knowledge and an
opportunity to avoid TD, and personal and social support to cope with the stigmatising condition.
I hope that the workshop raised some important issues for further exploration.
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Conclusion and next steps
It is clear that service users and carers from the consultation thought that research into TD to date has
been limited and that further exploration is required. They supported the outcomes used in Cochrane
schizophrenia review work on TD, but would recommend that the field is broadened. In addition, a formal
recommendation was to put information on the prevalence of TD into the public domain. If data on
prevalence do not currently exist, service users and carers recommend that this be sought out urgently.
There was acknowledgement that data might include under-reporting, but this was felt to be an important
benchmark for understanding.
The ultimate goal of research is to improve service user outcomes. The consultation group felt that there
were some key issues that needed to be addressed. First, it was felt that better information about TD was
needed, so that service users and their carers can make informed choices about medication. Second,
strategies for coping with TD were identified as essential. A greater emphasis needs to be placed on
psychological and social interventions for managing the symptoms of TD. For people already living with
persistent symptoms of TD, supporting people in the management of the numerous impacts of TD was
very important. Third, the consultation group felt that social stigma needed to be addressed as public
reactions to people living with TD can be as hard to cope with as the symptoms of underlying mental
health problems themselves, such as schizophrenia.
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Appendix 2 Differences between protocol
and review
Details of difference Comments
We planned to include evidence from crossover
trials. We only included evidence from the first
phase of crossover trials
A major concern of crossover trials is the carry-over effect. This occurs
if an effect (e.g. pharmacological, physiological or psychological) of
the treatment in the first phase is carried over to the second phase.
As a consequence, on entry to the second phase the participants can
differ systematically from their initial state despite a washout phase.
For the same reason, crossover trials are not appropriate if the
condition of interest is unstable.61 As both effects are very likely in
severe mental illness, we used only data of the first phase of crossover
studies
The planned outcomes list was reviewed and
updated
As a consequence of the PPI session, outcome measures for the
review were reviewed to also reflect outcomes important to patients
We planned to rely on evidence from the NMA.
We decided not to rely on evidence from the
NMA
The complete NMA was performed and it is available in Appendix 4.
We have very little confidence in the results of the NMA because of
(1) few data, (2) few studies in each comparison, (3) no differences
between pairwise meta-analyses and NMA, and (4) not sufficiently
connected networks. Therefore, we only used the results of the NMA
to support planning future studies in this area
We carried out a different search from the
protocol-specified search
As the Cochrane Schizophrenia Group maintains a good register that
is regularly updated with a variety of databases and grey literature, we
believed it was more appropriate to run the searches for all potential
RCT TD references in their register. We also searched included and
excluded studies of published Cochrane reviews
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Appendix 3 Observational studies: additional
methods and results
Search strategy and results
See Figure 11 for the PRISMA diagram of observational study screening and study selection process.
The search strategy and results per database are presented below.
EMBASE
Date searched: 9 January 2017.
Date range searched: 1974 to 2017 week 2.
Number of results: 696.
Records identified through
database searching
(n = 3312)
Additional records identified
through other sources
(n = 0)
Records after duplicates removed
(n = 2702)
Records screened
(n = 2702)
Records excluded
(n = 2661)
Full-text articles assessed
for eligibility
(n = 41)
Full-text articles excluded,
with reasons (30 studies)
(n = 31)
Included observational
studies (10 references)
(n = 8)
FIGURE 11 The PRISMA diagram of observational study screening and study selection process.
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Search strategy
1. exp cohort analysis/ or exp longitudinal study/ or exp prospective study/ or exp case control study/ or
exp follow up/ or cohort$.tw. or (case$ and control$).tw.
2. tardive dyskinesia/ or ‘tardive dyskinesia?’.mp.
3. 1 and 2
4. Limit 3 to human
Ovid MEDLINE In-Process & Other Non-Indexed Citations and Ovid MEDLINE
Date searched: 9 January 2017.
Date range searched: 1946 to 9 January 2017.
Number of results: 2072.
Search strategy
1. exp cohort studies/ or epidemiologic methods/ or exp case-control studies/ or (case$ and control$).tw.
or cohort$.tw.
2. tardive dyskinesia/ or ‘tardive dyskinesia?’.mp.
3. 1 and 2
4. Limit 3 to humans
PubMed
Date searched: 9 January 2016.
Date range searched: up to 9 January 2017.
Number of results: 377.
Search strategy
1. Therapy/Broad[filter] AND (‘observational study’[Publication Type] OR ‘observational studies as
topic’[MeSH Terms] OR ‘observational studies’[All Fields]).
2. tardive dyskinesia/ or ‘tardive dyskinesia?’.mp.
3. 1 and 2
4. Limit 3 to humans
PsycINFO
Date searched: 9 January 2017.
Date range searched: 1806 to January week 1 2017.
Number of results: 167.
Search strategy
1. cohort analysis/ or followup studies/ or exp longitudinal studies/ or (case$ and control$).tw. or
cohort$.tw.
2. tardive dyskinesia/ or ‘tardive dyskinesia?’.mp.
3. 1 and 2
4. Limit 3 to human
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Description of excluded studies
Thirty studies (31 references) were excluded at full-text screening. Reasons for exclusion were: not an
observational study (seven studies), observational study with no control group (19 studies), study only
measuring prevalence (three studies) or no treatment was provided (one study). Table 5 shows full
references and reasons for exclusion per study.
TABLE 5 Studies excluded from the observational studies review search, with reasons for exclusion
Study Reason for exclusion
Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive
dyskinesia and the 3-year course of schizophrenia: results from a large,
prospective, naturalistic study. J Clin Psychiatry 2008;69:1580–8
No treatment provided
Bai YM, Yu SC, Chen JY, Lin CY, Chou P, Lin CC. Risperidone for
pre-existing severe tardive dyskinesia: a 48-week prospective follow-up
study. Int Clin Psychopharmacol 2005;20:79–85
48-week open-label follow-up of RCT
(12 weeks: risperidone × placebo) with all
receiving risperidone
Barron ET, McCreadie RG. One year follow-up of tardive dyskinesia.
Br J Psychiatry 1983;143:423–4
TD prevalence only
Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine
for abnormal involuntary movement disorders. Am J Psychiatry
1979;136:317–20
Already excluded RCT: Tourette syndrome,
Huntington disease and drug-induced atypical
dyskinesia, no TD symptoms at baseline
Chaplin RH. Risperidone, tardive dyskinesia, and the elderly. Am J
Psychiatry 2001;158:1336–7
Review/commentary/editorial
Chen PH, Liu HC. Rapid improvement of neuroleptic-induced tardive
dyskinesia with levetiracetam in an interictal psychotic patient. J Clin
Psychopharmacol 2010;30:205–7
Case series/case report
Chouinard G, Annable L, Mercier P, Ross-Chouinard A. A five year
follow-up study of tardive dyskinesia. Psychopharmacol Bull
1986;22:259–63
TD prevalence only
Cortese L, Caligiuri MP, Williams R, Schieldrop P, Manchanda R, Malla A,
Harricharan R. Reduction in neuroleptic-induced movement disorders
after a switch to quetiapine in patients with schizophrenia. J Clin
Psychopharmacol 2008;28:69–73
Already excluded RCT; people with
schizophrenia, no TD symptoms at baseline
Factor SA. Propranolol therapy for tardive dyskinesia revisited. Mov Disord
2012;27:1703
Case series/case report
Glazer WM, Moore DC, Schooler NR, Brenner LM, Morgenstern H.
Tardive dyskinesia. A discontinuation study. Arch Gen Psychiatry
1984;41:623–7
No comparison group. Reported probabilities
based on regression analyses
Glazer WM, Morgenstern H, Schooler N, Berkman CS, Moore DC.
Predictors of improvement in tardive dyskinesia following discontinuation
of neuroleptic medication. Br J Psychiatry 1990;157:585–92
No comparison group. Reported probabilities
based on regression analyses
Hatcher-Martin JM, Armstrong KA, Scorr LM, Factor SA. Propranolol
therapy for tardive dyskinesia: a retrospective examination. Parkinsonism
Relat Disord 2016;32:124–6
Observational study without a control group
(mentioned tetrabenazine as treatment of
choice)
Heimburger RF. Dentatectomy in the treatment of dyskinetic disorders.
Confin Neurol 1967;29:101–6
Case series/case report
Kantrowitz JT, Srihari VH, Tek C. Resolution of tardive dyskinesia after
addition of aripiprazole to haloperidol depot. J Clin Psychopharmacol
2007;27:525–6
Case series/case report
Kucerová H. Olanzapine and improvement of tardive dyskinesia.
Eur Psychiatry 2002;17:421–4
Case series/case report
continued
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TABLE 5 Studies excluded from the observational studies review search, with reasons for exclusion (continued )
Study Reason for exclusion
Lee JG, Shin BS, Lee YC, Park SW, Kim YH. Clinical effectiveness of the
Kampo medicine kamishoyosan for adjunctive treatment of tardive
dyskinesia in patients with schizophrenia: a 16-week open trial. Psych Clin
Neurosci 2007;61:509–14
Observational study without a control group
Louzã MR, Bassitt DP. Maintenance treatment of severe tardive dyskinesia
with clozapine: 5 years’ follow-up. J Clin Psychopharmacol
2005;25:180–2
Case series/case report
Mendhekar D, Aggarwal A. Olanzapine and trihexyphenidyl-induced
tardive dyskinesia. Indian J Pharmacol 2005;37:263
Case series/case report
Michael N, Sourgens H, Arolt V, Erfurth A. Severe tardive dyskinesia in
affective disorders: treatment with vitamin E and C. Neuropsychobiology
2002;46(Suppl. 1):28–30
Case series/case report
Morgenstern H, Glazer WM, Woods SW. Risperidone and tardive
dyskinesia. Int J Geriatr Psychiatry 2001;16:541–2
Review/commentary/editorial
Naber D, Leppig M, Grohmann R, Hippius H. Efficacy and adverse effects
of clozapine in the treatment of schizophrenia and tardive dyskinesia – a
retrospective study of 387 patients. Psychopharmacology 1989;99:S73–6
Retrospective case series
O’Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, et al.
NBI-98854, a selective monoamine transport inhibitor for the treatment
of tardive dyskinesia: a randomised, double-blind, placebo-controlled
study. Mov Disord 2015;30:1681–7
RCT – included in Cochrane review
Pi EH, Simpson GM. Atypical neuroleptics: clozapine and the benzamides
in the prevention and treatment of tardive dyskinesia. Mod Probl
Pharmacopsychiatry 1983;21:80–6
Review/commentary/editorial
Rajarethinam R, Dziuba J, Manji S, Pizzuti A, Lachover L, Keshavan M.
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
World J Biol Psychiatry 2009;10:416–19
Case series/case report
Saltz BL, Kane JM, Woerner MG, Lieberman JA, Alvir JM, Blank K, et al.
Prospective study of tardive dyskinesia in the elderly. Psychopharmacol
Bull 1989;25:52–6
Only TD prevalence
Sharma A, Ramaswamy S, Dewan VK. Resolution of ziprasidone-related
tardive dyskinesia with a switch to aripiprazole. Prim Care Companion J
Clin Psychiatry 2005;7:36
Case series/case report
Singh MM, Becker RE, Pitman RK, Nasrallah HA, Lal H. Sustained
improvement in tardive dyskinesia with diazepam: indirect evidence for
corticolimbic involvement. Brain Res Bull 1983;11:179–85
Before-and-after study, irrelevant study design
Thara R. Use of antipsychotics and tardive dyskinesia. J Postgrad Med
2004;50:172
Review/commentary/editorial
van Harten PN, Hoek HW, Matroos GE, van Os J. Evidence that lithium
protects against tardive dyskinesia: the Curaçao Extrapyramidal
syndromes study VI. Eur Neuropsychopharmacol 2008;18:152–5
Observational study without a control group
Viallet F, Gayraud D, Gombert C, Renie L, Martinez-Almoyna L, Di Legge S,
et al. Utility of tetrabenazine for managing L-Dopa induced dyskinesias
in advanced Parkinson’s disease: a retrospective observational study on
10 patients. Mov Disord 2014;29:S149
Observational study without a control group
Yasui-Furukori N, Kikuchi A, Katagai H, Kaneko S. The effects of
electroconvulsive therapy on tardive dystonia or dyskinesia induced by
psychotropic medication: a retrospective study. Neuropsychiatr Dis Treat
2014;10:1209–12
Case series/case report
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
94
Appendix 4 Network meta-analysis on
comparative safety and clinical effectiveness of
interventions for antipsychotic-induced tardive
dyskinesia: methods and results
Objectives
We aimed to compare the safety and clinical effectiveness of interventions for deterioration of symptoms
of antipsychotic-induced TD. We also aimed to generate a clinically meaningful hierarchy of the eligible
interventions according to their efficacy and safety.
Methods
Criteria for considering studies for this review
Types of interventions
We included interventions used to treat or prevent deterioration of symptoms of antipsychotic-induced TD
of relevance for people in the NHS, indicated as priority interventions: ‘switch to SGA (including switch to
amisulpride, clozapine, olanzapine, quetiapine, risperidone, ziprasidone)’, ‘antipsychotic (AP) reduction’,
‘antipsychotic maintenance/TAU (including AP)’, ‘antipsychotic withdrawal (with placebo)’, ‘FGA (any)’,
‘anticholinergic and AP continuation’, ‘anticholinergic withdrawal and AP continuation’, ‘benzodiazepines
and AP continuation’, ‘buspirone and AP continuation’, ‘hypnosis or relaxation and AP continuation’,
‘vitamin E and AP continuation’ and ‘placebo (with AP continuation)’.
We assumed that any patient who met the inclusion criteria was, in principle, equally likely to be
randomised to any of the interventions and, thus, the transitivity assumption was likely to hold on the onset.
Types of outcome measures
The following outcomes were measured:
l primary outcome – no clinical improvement of TD symptoms (< 50% improvement on scales)
l secondary outcome – total discontinuation rates.
We intended to analyse all planned outcomes described in the main paper but we were unable to do so
because of the limited data available. We estimated the relative ranking of the competing interventions
according to both of the above outcomes.
Data collection and analysis
Measures of treatment effect
Relative treatment effects
Odds ratios were employed for dichotomous outcomes. When continuous outcomes were measured,
we analysed them using the MD if all studies used the same measure to assess the same outcome.
Standardised mean difference, Hedge’s adjusted g, was used when a different measure was used across
studies to assess a common continuous outcome.170
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Relative treatment ranking
We estimated p-scores, which are the most frequent analogues of surface under the cumulative ranking
curves (SUCRAs), to obtain a hierarchy of the competing interventions.171,172
1. Assessment of clinical and methodological heterogeneity within treatment comparisons.
We assessed the presence of clinical and methodological heterogeneity within each pairwise
comparison by comparing trial and study population characteristics across all eligible trials. Considerable
differentiation in synthesised studies in terms of patient, study and intervention characteristics might
lead to a lack of usefulness of obtained results.173
2. Assessment of transitivity across treatment comparisons
The assumption underlying NMA implies that one can learn about the relative effectiveness of ‘A versus
B’ via a common comparator, for instance C.155,174 We were unable to compare the distribution of effect
modifiers across comparisons because of the limited data, but we compared the particular study
characteristics qualitatively. Moreover, we assessed if the indication of the included interventions varied
according to the alternative it is compared against.
Data synthesis
Methods for direct treatment comparisons
Initially, standard pairwise meta-analysis was performed for all pairwise comparisons with at least two
studies using the random-effects inverse variance model in Stata.175
Methods for indirect and mixed comparisons
Network meta-analysis integrates direct and indirect evidence for each pairwise comparison to derive
relative treatment effects between all competing treatments. We intended to perform NMA using the
methodology of multivariate meta-analysis in which different treatment comparisons are handled as
different outcomes using the ‘network’ package (which includes the ‘mvmeta’ command) in Stata.156,176
As a result of the substantial number of treatment nodes and the version of Stata available, however,
analysis using the ‘network’ package was not feasible and we performed NMA using graph theoretical
methods as described in Rücker.177,178 To this aim, we used the ‘netmeta’ package in R.179 We also used
available Stata routines to present the evidence base and to illustrate the results.180 We produced a plot to
present jointly the relative ranking of treatments for ‘no clinical improvement’ and ‘total discontinuation
rates’, and we used a hierarchical cluster analysis to group interventions in meaningful subsets.180
Assessment of statistical heterogeneity
Assumptions when estimating the heterogeneity
In pairwise meta-analysis we assumed different heterogeneity variances for each comparison. In NMA,
we assumed a common heterogeneity variance across all treatment comparisons in the network.
Measures and tests for heterogeneity
Between-study variance τ2 was estimated in both pairwise and NMA using the DerSimonian and Laird
estimator.175 We assessed statistical heterogeneity based on the magnitude of the estimated parameter.
We also compared the magnitude of τ2 with empirical distributions derived in Turner et al.181 and
Rhodes et al.182
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Assessment of statistical inconsistency
Network meta-analysis assumes consistency between various sources of evidence; that means that direct
and indirect evidence is expected to be in agreement. However, it might be that the assumption of
consistency is violated either in certain parts or in the entire network. We intended to evaluate statistical
inconsistency using both local and global methods. In particular, we intended to evaluate the consistency
assumption using the loop-specific approach.183 Employing this method, we would estimate the
disagreement between direct and indirect evidence in each closed loop (inconsistency factors).
Moreover, we intended to evaluate inconsistency in the entire network using the design-by-treatment
interaction model.156,184,185 However, there was only one closed loop in the network for the ‘total
discontinuation rates’ outcome and, thus, we only judged on inconsistency for this loop using the
loop-specific approach.
Investigation of heterogeneity and inconsistency
Several metaregression and subgroup analyses were planned in order to assess the impact of potential
effect modifiers on the treatment effects. Our intention was to explore the impact of study and population
characteristics fitting network metaregression models in a Bayesian environment using the WinBUGS
software version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK) and considering vague prior distributions
for the covariates. As these analyses are known to have low power,186,187 their presentation would be of
questionable usefulness in the case of very few data.
Sensitivity analysis
We planned to perform the following four sensitivity analyses to ensure the robustness of the NMA results:
1. analysis restricted to studies rated as being at low risk of selection bias
2. analysis restricted to studies rated as being at low or unclear risk of selection bias
3. analysis restricted to studies rated as being at low risk of detection bias
4. analysis restricted to studies rated as being at low or unclear risk of detection bias.
Results
Summary
The primary outcome (no clinical improvement of TD symptoms) was reported in 46 studies (one three-arm
study and 45 two-arm studies), including 1560 patients. Total discontinuation rates were reported in
78 studies (one four-arm study, one three-arm study and 76 two-arm studies) with 2965 patients. The
number of studies and the number of participants per comparison with available direct data are given in
Table 6.
Pairwise meta-analysis results
From the available comparisons with direct data described in Table 6, we kept data only for those that
compared interventions described in Chapter 5, Prioritisation of interventions. Table 7 and Figures 12 and
13 show the available direct estimates for outcomes ‘no clinical improvement of TD symptoms’ and ‘total
discontinuation rates’ for comparisons including interventions of priority with at least two studies available.
Direct evidence suggests that ‘switch to olanzapine’ appears to be associated with lower discontinuation
rates than ‘switch to risperidone’, whereas no important differences were detected between ‘vitamin E
and AP continuation’ and ‘placebo with AP continuation’ for the outcome ‘total discontinuation rates’.
In terms of no clinical improvement of TD symptoms, ‘vitamin E and AP continuation’ has an insignificant
advantage over ‘placebo with AP continuation’. The comparison of ‘antipsychotic maintenance/TAU
(including AP)’ versus ‘antipsychotic reduction (reduced dose FGA)’ is not statistically significant, but the
overall treatment effect estimate does not rule out a beneficial effect of the second intervention.
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TABLE 6 Number of studies and number of participants per comparison for the outcomes ‘no clinical improvement
of TD symptoms’ and ‘total discontinuation rates’
Comparisons
No clinical improvement
of TD symptoms
Total discontinuation
rates
Number
of studies
Number of
participants
Number
of studies
Number of
participants
Placebo (with AP continuation) vs.:
Benzodiazepine (clonazepam, diazepam) and AP
continuation
1 17 2 41
Branched-chain amino acids and AP continuation 1 52 1 52
Buspirone and AP continuation 1 42 1 42
Ceruletide and AP continuation – – 1 85
Cholinergic medication (deanol, galantamine, lecithin,
meclofenoxate hydrochloride) and AP continuation
3 17 11 278
Cyproheptadine and AP continuation – – 1 42
Dihydrogenated ergot alkaloids/co-dergocrine mesylate
and AP continuation
1 28 2 48
Dopaminergic (amantadine, bromocriptine, carbidopa/
levodopa, oxypertine, reserpine, tiapride) and AP
continuation
1 20 6 163
GABA agonist (baclofen, GABA, progabide, sodium
valproate, THIP) and AP continuation
6 258 6 218
Ginkgo biloba standardised extract (EGb-761) and AP
continuation
1 157 1 157
Insulin and AP continuation 1 20 1 20
Levetiracetam and AP continuation – – 2 119
Lithium and AP continuation 1 11 1 11
MAO inhibitor (isocarboxazid, selegiline) and AP
continuation
1 33 1 33
Melatonin and AP continuation 2 32 3 54
Noradrenergic (celiprolol, methyldopa) and AP
continuation
1 20 1 35
Oestrogen and AP continuation 1 12 1 12
Oil of evening primrose and AP continuation 1 16 1 16
Omega-3 fatty acid and AP continuation – – 1 84
Pemoline and AP continuation 1 46 1 46
Phenylalanine and AP continuation – – 1 18
Piracetam and AP continuation – – 1 40
Promethazine and AP continuation 1 34 1 34
Ritanserin and AP continuation 1 10 1 10
VMAT2 inhibitor (NBI-98854) and AP continuation 1 88 1 88
Vitamin B6 and AP continuation 1 45 – –
Vitamin E and AP continuation 6 264 13 475
1-Stepholidine and AP continuation 1 57 1 57
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TABLE 6 Number of studies and number of participants per comparison for the outcomes ‘no clinical improvement
of TD symptoms’ and ‘total discontinuation rates’ (continued )
Comparisons
No clinical improvement
of TD symptoms
Total discontinuation
rates
Number
of studies
Number of
participants
Number
of studies
Number of
participants
MAO inhibitor AP vs. anticholinergic (biperiden, procyclidine)
and AP continuation
1 20 1 20
Antipsychotic maintenance/TAU (including AP) vs.:
Benzodiazepine (clonazepam, diazepam) and AP
continuation
1 15 1 15
Hypnosis or relaxation and AP continuation 1 15 – –
Antipsychotic reduction (reduced dose FGA) 2 17 1 8
Active placebo (phenobarbital) and AP continuation vs.
benzodiazepine (clonazepam, diazepam) and AP
continuation
1 21 1 21
Switch to haloperidol/unspecified FGA vs.:
Dopaminergic (tetrabenazine) and AP withdrawal 1 13 – –
Dopaminergic (amantadine, bromocriptine, carbidopa/
levodopa, oxypertine, reserpine, tiapride) and AP
continuation
1 13 1 13
Switch to amisulpride – – 1 55
Switch to clozapine – – 1 39
Switch to molindone (FGA) – – 1 18
Switch to olanzapine – – 1 56
Switch to quetiapine 1 45 1 45
Switch to thiopropazate (FGA) 1 20 1 20
Switch to zuclopentixol 1 15 – –
Dopaminergic (amantadine, bromocriptine, carbidopa/
levodopa, oxypertine, reserpine, tiapride) and AP
continuation vs. noradrenergic (celiprolol, methyldopa) and
AP continuation
1 20 – –
Switch to risperidone vs.:
Switch to olanzapine 1 60 2 170
Switch to ziprasidone – – 1 84
Switch to quetiapine – – 1 118
Switch to ziprasidone vs.:
Switch to olanzapine – – 1 82
Switch to quetiapine – – 1 90
Switch to amisulpride vs. switch to olanzapine – – 1 57
Switch to quetiapine vs. switch to olanzapine – – 1 116
Antipsychotic withdrawal (placebo) vs. switch to risperidone 1 50 1 50
Anticholinergic withdrawal (biperiden stopped after 1 week)
and AP continuation vs. anticholinergic AP
– – 1 10
THIP, 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol; VMAT2, vesicular monoamine transporter 2.
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Network meta-analysis results
No clinical improvement of tardive dyskinesia symptoms
Evidence for the outcome ‘no clinical improvement of TD symptoms’ formed two disconnected networks
that were analysed separately using NMA. The two formed networks for the outcome ‘no clinical
improvement of TD symptoms’ are illustrated in Figure 14 [included treatments: ‘benzodiazepine
(clonazepam, diazepam) and AP continuation’, ‘buspirone and AP continuation’, ‘MAO inhibitor
(isocarboxazid, selengiline) and AP continuation’, ‘vitamin E and AP continuation’, ‘anticholinergic
(biperiden, procyclidine) and AP continuation’, ‘antipsychotic maintenance/TAU (including AP)’, ‘hypnosis
or relaxation and AP continuation’, ‘antipsychotic reduction (reduced dose FGA)’] and Figure 15 (included
treatments: ‘switch to haloperidol’, ‘switch to thiopropazate’, ‘switch to quetiapine’). Nodes represent
available treatments and edges represent available comparisons. Nodes and edges are weighted according
TABLE 7 Summary estimates for the outcomes ‘no clinical improvement of TD symptoms’ and ‘total discontinuation
rates’ for comparisons with at least two studies available derived from standard pairwise meta-analysis (using a
random-effects model and using different heterogeneity parameters across comparisons)
Comparisons
No clinical improvement
of TD symptoms Total discontinuation rates
OR (95% CI) τ OR (95% CI) τ
Placebo (with AP continuation) vs.:
Benzodiazepine (clonazepam, diazepam) and AP
continuation
– – Excluded Excluded
Vitamin E and AP continuation 2.28 (0.76 to 6.88) 0 1.02 (0.64 to 1.62) 0
Antipsychotic maintenance/TAU (including AP) vs.
antipsychotic reduction (reduced dose FGA)
8.41 (0.91 to 77.72) 0 – –
Switch to risperidone vs. switch to olanzapine – – 2.17 (1.10 to 4.26) 0
Notes
Bold results indicate statistical significance.
Heterogeneity was estimated using the method of moments estimator.
ORs > 1 favour the second treatment.
0.1 0.5 1.0 3.0 8.0 15.0
Favours secondFavours first
21.00 (0.64 to 689.99)
4.50 (0.25 to 80.57)
8.41 (0.91 to 77.72)
40.56
59.44
100.00
2.01 (0.46 to 8.72)
1.40 (0.12 to 16.98)
2.52 (0.09 to 68.60)
7.82 (0.35 to 174.42)
2.28 (0.76 to 6.88)
Kane 198397
Cookson 198798
Adler 1999137
Adler 1993125,126
Schmidt 199195
Lam 199494
56.63
19.57
11.16
12.65
100.00
Antipsychotic maintenance/TAU (including AP) 
vs. antipsychotic reduction (reduced dose FGA)
Study OR (95% CI) Weight (%)
Placebo (with AP continuation) vs. 
vitamin E and AP continuation
FIGURE 12 Pairwise meta-analysis results for active treatments vs. placebo (with AP continuation) for outcome ‘no
clinical improvement of TD symptoms’ (comparisons with more than two studies, random-effects model, different
heterogeneity parameters across comparisons). Heterogeneity was estimated using the method-of-moments estimator.
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48.43
1.89
2.27
1.98
4.68
10.33
3.30
18.09
5.63
3.39
100.00
1.20 (0.61 to 2.35)
0.39 (0.01 to 11.76)
4.51 (0.20 to 100.23)
7.86 (0.28 to 217.11)
1.38 (0.16 to 11.94)
0.78 (0.18 to 3.34)
2.00 (0.15 to 26.19)
0.94 (0.31 to 2.83)
0.24 (0.03 to 1.71)
0.24 (0.02 to 3.01)
1.02 (0.64 to 1.62)
34.51
65.49
100.00
1.41 (0.45 to 4.45)
2.72 (1.18 to 6.27)
2.17 (1.10 to 4.26)
Chan 2010115
Caroff 2011117
Adler 1999137
Dabiri 1994128
Dorevitch 199791
Elkashef 199093
Schmidt 199195
Adler 1993125,126
Egan 199292
Lohr 1996129
Sajjad 1998130
Lam 199494 
Study OR (95% CI) Weight (%)
Switch to risperidone vs. 
switch to olanzapine
Placebo (with AP continuation) vs. 
vitamin E and AP continuation
FIGURE 13 Pairwise meta-analysis results for active treatments vs. placebo (with AP continuation) for outcome
‘total discontinuation rates’ (comparisons with more than two studies, random-effects model, different
heterogeneity parameters across comparisons). Heterogeneity was estimated using the method-of-moments estimator.
Placebo (with AP continuation)
Vitamin E and AP continuation
MAO inhibitor (isocarboxazid and selengiline) 
and AP continuation 
Anticholinergic (biperiden and procyclidine) 
and AP continuation
Benzodiazepine (clonazepam and diazepam) 
and AP continuation
Antipsychotic reduction (reduced dose FGA)
Hypnosis or relaxation and AP continuation
Antipsychotic maintenance/TAU 
(including AP)
Buspirone and AP continuation
FIGURE 14 Network plot for the first subnetwork for the outcome ‘no clinical improvement of TD symptoms’.
Switch to haloperidol
Switch to thiopropazate
Switch to quetiapine
FIGURE 15 Network plot for the second subnetwork for the outcome ‘no clinical improvement of TD symptoms’.
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to the number of studies involved in each treatment. Two studies105–109,115,116 compared treatments that
were connected to neither of the two networks and, thus, were excluded from the NMA. ‘MAO inhibitor
(isocarboxazid, selengiline) and AP continuation’ is included in the first subnetwork of Figure 14 despite
the fact that it is not in the list of priority interventions as it connects ‘placebo (with AP continuation)’ to
‘anticholinergic (biperiden, procyclidine) and AP continuation’, the relative effectiveness of which is
of interest.
Table 8 shows the NMA results for the network illustrated in Figure 14 for the outcome ‘no clinical
improvement of TD symptoms’. Studies in which all participants were classified as events or non-events in
both groups were excluded. The forest plot in Figure 16 shows the ORs of all treatments versus ‘placebo
(with AP continuation)’ derived from the NMA. According to Table 8 and Figure 16, the NMA suggests
that ‘hypnosis or relaxation and AP continuation’ has the greatest benefit over ‘placebo (with AP
continuation)’, whereas ‘buspirone and AP continuation’ and ‘antipsychotic reduction (reduced dose FGA)’
are also more effective than ‘placebo (with AP continuation)’. ‘Anticholinergic (biperiden and procyclidine)
and AP continuation’ appears to be less effective than ‘placebo (with AP continuation)’. The results are
consistent with the corresponding effect estimates derived from pairwise meta-analysis. It should be noted,
however, that any judgements on the relative effectiveness of the treatments are mitigated by the high
imprecision associated with most network estimates.
The subnetwork corresponding to Figure 15 is formed by two studies only; a third study that was
connected to the network188 was excluded as all participants were classified as events. Thus, we do not
present indirect estimates for the particular network as the value of drawing inferences would be doubtful
because of the substantially limited data availability. The only study that compared ‘switch to FGA’ with
‘switch to SGA’ for the outcome ‘no clinical improvement’ was Emsley et al.,110,111 in which an OR of 1.96
(95% CI 0.56 to 6.92) in favour of ‘switch to SGA’ was calculated. This comparison does not benefit from
the NMA as it is not connected with the largest subnetwork of Figure 14 and there is no indirect evidence
that can be used to strengthen evidence on the relative effectiveness of the two interventions.
Total discontinuation rates
Evidence for the outcome ‘total discontinuation rates’ formed two disconnected networks that were
analysed separately using NMA, and are illustrated in Figures 17 and 18. Nodes represent available
treatments and edges represent available comparisons. Nodes and edges are weighted according to the
number of studies involved in each treatment. ‘MAO inhibitor (isocarboxazid, selengiline) and AP
continuation’ is included in the subnetwork of Figure 17 despite the fact that it is not in the list of priority
interventions as it connects ‘placebo (with AP continuation)’ to ‘anticholinergic (biperiden, procyclidine)
and AP continuation’.
Studies in which all participants were classified as events or non-events in both groups were excluded.
The forest plot in Figure 19 shows the ORs of all treatments versus ‘placebo (with AP continuation)’ derived
from the NMA corresponding to the network plot of Figure 17. Tables 9 and 10 summarise the network
estimates corresponding to the networks of Figures 17 and 18, respectively. As is shown in Tables 9 and 10
and Figure 19, most network estimates are highly imprecise (with rather wide CIs), rendering any conclusions
on relative treatment effectiveness impractical. No statistically significant differences occur for any treatment
versus ‘placebo (with AP continuation)’ in terms of discontinuation rates.
Sensitivity analysis merging switch to antipsychotics
As a sensitivity analysis, we further conducted a NMA for the subnetwork of Figure 18 in which all
switches to SGAs were merged into a ‘switch to SGA (any)’ treatment node, and all switches to FGAs
were merged into a ‘switch to FGA (any)’ treatment node. The Caroff et al.,117,118 Chan et al.,115,116 Glazer
et al.189,190 and Kazamatzuri et al.169 studies were excluded from this analysis as they examined either
second- or first-generation antipsychotics only, and thus were representing a single treatment node. The
network plot for this analysis is represented in Figure 20. Nodes and edges are weighted according to the
number of studies involved in each treatment.
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As the network presented in Figure 20 comprised only four trials, we did not perform NMA as the validity
of the results of such an analysis would be questionable. The comparison ‘switch to FGA (any) versus
switch to SGA (any)’ was informed by three studies, resulting in a pairwise meta-analysis OR of 0.54
(95% CI 0.21 to 1.42) in favour of ‘switch to FGA’. There is no indirect evidence to enrich the available
information for this comparison and, thus, the use of NMA does not contribute to the knowledge
regarding the relative effectiveness of the two interventions.
Comparison of heterogeneity parameters with empirical distributions
For a binary mental health outcome and a ‘non-pharmacological versus any’ comparison type, a median
value of 0.13 is suggested for τ.181 The specific value is greater than our estimation of heterogeneity (0) for
both outcomes ‘no clinical improvement of TD symptoms’ and ‘total discontinuation rates’.
Evaluation of inconsistency
We intended to evaluate the consistency assumption using the loop-specific approach in Stata using
a common heterogeneity within each loop (but different across loops).180 We also intended to further
assess the assumption of consistency in the entire network simultaneously using the design-by-treatment
interaction model in Stata.156,176 However, for the outcome ‘no clinical improvement of TD symptoms’ all
loops were formed by multiarm studies only (consistent by definition) and, thus, consistency could not be
evaluated. For the outcome ‘total discontinuation rates’ only one loop was formed for the subnetwork
illustrated in Figure 18, ‘switch to olanzapine – switch to quetiapine – switch to haloperidol’; the
inconsistency factor using the loop-specific approach was estimated at 1.45, with a (truncated) CI
(0 to 4.51) indicating a lack of evidence of inconsistency.
Relative ranking of treatments
Table 11 shows the p-scores of the treatments involved in the outcomes ‘no clinical improvement of TD
symptoms’ and ‘total discontinuation rates’ (networks of Figures 14 and 17), which are frequent analogues
of SUCRAs.171,172
Neuroleptic withdrawal (placebo)
Switch to FGA (any)
Switch to SGA (any)
FIGURE 20 Network plot for the second subnetwork of Figure 18 for the outcome ‘total discontinuation rates’, in
which switch to first- and second-generation antipsychotics have been merged to ‘switch to FGA (any)’ and ‘switch
to SGA (any)’ treatment nodes, respectively.
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No clinical improvement of tardive dyskinesia symptoms
The p-score value of ‘hypnosis or relaxation and AP continuation’ is 89%, indicating that it is 89% as
effective as a treatment that would be ranked always first without uncertainty. ‘Anticholinergic (biperiden,
procyclidine) and AP continuation’ appears to be the worst treatment in terms of ‘no clinical improvement
of TD symptoms’ as it has a p-score close to 0. These findings are in agreement with the network effect
estimates presented in Table 8 and Figure 16.
Total discontinuation rates
‘Antipsychotic reduction (reduced dose FGA)’ has the greatest p-score (90%) in terms of total
discontinuation rates. Uncertainty in treatment effects escalates in uncertainty in treatment ranking
resulting in many p-scores around 50%.
Clustered ranking plot for the outcomes ‘no clinical improvement of tardive
dyskinesia symptoms’ and ‘total discontinuation rates’
In Figure 21 we have ranked treatments according to the outcomes ‘no clinical improvement of TD
symptoms’ and ‘total discontinuation rates’. Hierarchical cluster analysis is performed to group the competing
treatments. Different colours represent different groups of treatments considering jointly their relative
ranking for two outcomes. Treatments that belong to the same group may be considered as being of
comparable performance with respect to both outcomes. According to Figure 21, ‘antipsychotic reduction
(reduced dose FGA)’ has the highest performance on both outcomes in terms of ranking for the two
considered outcomes. ‘Anticholinergic (biperiden, procyclidine) and AP continuation’ and ‘MAO inhibitor
(isocarboxazid, selengiline) and AP continuation’ can be considered as the treatments having the worst joint
performance for the outcomes ‘no clinical improvement of TD symptoms’ and ‘total discontinuation rates’.
TABLE 11 p-scores for the outcomes ‘no clinical improvement of TD symptoms’ and ‘total discontinuation rates’
Treatment
No clinical improvement
of TD symptoms
Total discontinuation
rates
Hypnosis or relaxation and AP continuation 0.89 –
Antipsychotic reduction (reduced dose FGA) 0.85 0.90
Buspirone and AP continuation 0.66 0.56
Antipsychotic maintenance/TAU (including AP) 0.62 0.74
Vitamin E and AP continuation 0.36 0.59
Benzodiazepine (clonazepam, diazepam) and AP
continuation
0.35 0.61
Placebo (with AP continuation) 0.24 0.58
MAO inhibitor (isocarboxazid, selengiline) and AP
continuation
0.10 0.19
Anticholinergic (biperiden, procyclidine) and AP
continuation
0.01 0.38
Anticholinergic withdrawal (biperiden stopped after 1 week)
and AP continuation
– 0.29
Note
Treatments are ordered according to the p-scores for the outcome ‘no clinical improvement of TD symptoms’.
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FIGURE 21 Clustered ranking based on p-scores for the outcomes ‘no clinical improvement of TD symptoms’ and
‘total discontinuation rates’. Hierarchical cluster analysis is performed to group the competing treatments.
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Appendix 5 Studies excluded from the search:
reasons for exclusion
Summary
Table 12 summarises the number of studies and references excluded from the review with reasons
for exclusion.
References for Appendix 5 and reasons for exclusion
Not randomised controlled trial or randomised comparison
Adler L, Duncan E, Reiter S, Angrist B, Peselow E, Rotrosen J. Effects of calcium-channel antagonists on
tardive dyskinesia and psychosis. Psychopharmacol Bull 1988;24:421–5.
Albus M, Naber D, Muller-Spahn F, Douillet P, Reinertshofer T, Ackenheil M. Tardive dyskinesia: relation to
computer-tomographic, endocrine, and psychopathological variables. Biol Psychiatry 1985;20:1082–9.
Alexander PE, Van Kammen DP, Bunney WE. Serum calcium and magnesium in schizophrenia: relationship
to clinical phenomena and neuroleptic treatment. Br J Psychiatry 1978;133:143–9.
Alexander PE, Van Kammen DP, Bunney WE Jr. Serum calcium and magnesium levels in schizophrenia. II.
Possible relationship to extrapyramidal symptoms. Arch Gen Psychiatry 1979;36:1372–7.
Ananth JV, Ban TA, Lehmann HE. An uncontrolled study with thiopropazate in the treatment of persistent
dyskinesia. Psychopharmacol Bull 1977;13:9.
TABLE 12 Summary of excluded studies with reasons for exclusion
Reason for exclusion
Number of studies (number
of references from which
studies found)
Not RCT or randomised comparison 170 (201)
Randomised but not TD 88 (103)
Randomised, TD, but not stabilised on antipsychotics 5 (6)
Randomised, TD, no usable data reported – authors contacted to confirm lack of data 15 (19)
Randomised, TD, but no usable data reported – no author contact details, study
> 20 years old
8 (12)
Randomised, TD, but no separate data reported on minority with TD – authors contacted
to confirm lack of data
3 (3)
Randomised, TD, but crossover trial with no separate data reported for phase before
crossing over to second treatment – authors contacted to confirm lack of data
26 (36)
Randomised, TD, but crossover trial with no separate data reported for phase before
crossing over to second treatment – no author contact details, study > 20 years old
14 (18)
Total 329 (398)
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Appendix 6 Cochrane reviews on
antipsychotic-induced tardive dyskinesia
Published Cochrane reviews on TD are listed below. They can be accessed through The CochraneLibrary. All these reviews have been updated and are in the pre-publication process at the time
of writing.
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Appendix 7 Detailed study characteristics and
risk-of-bias assessments
Adler 1993125,126
Adler 1999137
Akhtar 1993127
Bai 2003108
Bai 2005112,113
Bobruff 1981120
Caroff 2011117
Chan 2010115
Chouinard 1993102,103
Cookson 198798
Csernansky 1988121,122
Dabiri 1994128
Dorevitch 199791
Dorevitch 199790
Egan 199292
?
+
?
?
?
?
?
+
?
+
?
?
?
?
?
?
+
?
?
?
?
?
?
?
?
?
+
?
?
?
?
?
+
+
–
?
+
–
+
?
+
?
?
?
?
?
?
+
+
?
?
?
+
?
?
+
?
?
+
+
+
+
+
+
+
+
–
+
+
+
?
+
+
?
–
?
?
?
?
+
?
–
+
–
?
?
?
–
–
–
?
?
?
+
+
?
–
+
–
–
–
?
?
?
?
R
an
d
o
m
 s
eq
u
en
ce
 g
en
er
at
io
n
 (
se
le
ct
io
n
 b
ia
s)
A
llo
ca
ti
o
n
 c
o
n
ce
al
m
en
t 
(s
el
ec
ti
o
n
 b
ia
s)
B
lin
d
in
g
 o
f 
p
ar
ti
ci
p
an
ts
 a
n
d
 p
er
so
n
n
el
 (
p
er
fo
rm
an
ce
 b
ia
s)
B
lin
d
in
g
 o
f 
o
u
tc
o
m
e 
as
se
ss
m
en
t 
(d
et
ec
ti
o
n
 b
ia
s)
In
co
m
p
le
te
 o
u
tc
o
m
e 
d
at
a 
(a
tt
ri
ti
o
n
 b
ia
s)
Se
le
ct
iv
e 
re
p
o
rt
in
g
 (
re
p
o
rt
in
g
 b
ia
s)
O
th
er
 b
ia
s
Elkashef 199093
Emsley 2004110
Glover 1980139
Greil 1984119
Kane 198397
Kazamatsuri 197396
Lam 199494
Lohr 1996129
Sajjad 1998130
Schmidt 199195
Tamminga 1994104
Weber 198389
Xiang 199775
Zeng 199578
Zhang 2004138
?
?
–
?
+
?
?
?
+
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
–
–
+
?
–
?
+
–
?
?
–
+
+
+
?
?
?
?
?
+
+
?
–
?
+
+
?
?
+
–
–
+
+
–
–
–
–
–
+
–
+
+
+
+
–
–
+
–
–
–
–
–
?
?
?
?
+
+
–
?
+
?
?
–
?
?
?
?
?
?
?
+
+
+
R
an
d
o
m
 s
eq
u
en
ce
 g
en
er
at
io
n
 (
se
le
ct
io
n
 b
ia
s)
A
llo
ca
ti
o
n
 c
o
n
ce
al
m
en
t 
(s
el
ec
ti
o
n
 b
ia
s)
B
lin
d
in
g
 o
f 
p
ar
ti
ci
p
an
ts
 a
n
d
 p
er
so
n
n
el
 (
p
er
fo
rm
an
ce
 b
ia
s)
B
lin
d
in
g
 o
f 
o
u
tc
o
m
e 
as
se
ss
m
en
t 
(d
et
ec
ti
o
n
 b
ia
s)
In
co
m
p
le
te
 o
u
tc
o
m
e 
d
at
a 
(a
tt
ri
ti
o
n
 b
ia
s)
Se
le
ct
iv
e 
re
p
o
rt
in
g
 (
re
p
o
rt
in
g
 b
ia
s)
O
th
er
 b
ia
s
FIGURE 22 Summary of risk-of-bias assessments for included studies. –, high risk of bias; +, low risk of bias;
?, unclear risk of bias.
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Antipsychotic drugs
TABLE 13 Characteristics and risk of bias of included studies evaluating antipsychotic drugs as treatment for TD
Included study Description
Bai et al., 2003108
Study characteristics
Characteristic Description
Methods l Allocation: ‘randomly assigned’, not described
l Blindness: ‘double blind’, partially described
l Design: parallel groups
l Setting: inpatients, Taiwan
l Duration: 12 weeks
Participants l Diagnosis: schizophrenia with persistent severe tardive dyskinesia (DSM-IV,191
Kane criteria). n = 49 randomised, 42 completed
l Age: 50.2 (SD 9.7) years
l Sex: 28 male and 14 female
l History: maintenance on conventional antipsychotics for > 1 year with an equivalent
dosage of < 200mg/day of chlorpromazine; duration of TD not reported
Interventions After a 4-week washout period with all original conventional antipsychotics
discontinued:
1. risperidone – started at 2 mg/day and increased, with a 2-mg increase every 2 weeks,
to 6 mg/day over 6 weeks, then maintenance dose of 6 mg/day for 12 weeks, n = 22
2. placebo – placebo for 12 weeks, n= 20
Concomitant medication included benzodiazepines (86–90%) and antiparkinsonism
drugs (50–86%)
Outcomes l TD symptoms: AIMS
l Adverse effects: extrapyramidal symptoms (parkinsonism) (ESRS)
l Adverse effects: dystonia (ESRS)
l TD symptoms: clinical efficacy (decrease in AIMS of 3 or 4 = responder), BPRS
Notes Sponsorship source: supported by Janssen-Cilag Taiwan, Johnson & Johnson Taiwan Ltd
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk ‘. . . subjects were randomly assigned to the risperidone or placebo
groups’, further details not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Low risk . . . double-blind . . . A placebo with an identical appearance to
the risperidone dose was prescribed for the placebo group using
the same dose schedule
Blinding of outcome
assessment (detection bias)
Low risk The TD condition was evaluated blindly by a psychiatrist with the
Abnormal Involuntary Movement Scale (AIMS) every 2 weeks
Incomplete outcome data
(attrition bias)
Low risk Seven of 49 participants withdrew:
Four subjects dropped out due to psychotic symptom
exacerbation (2 subjects during the washout period: 1 subject in
the placebo group and 1 subject in the risperidone group).
Another 3 subjects withdrew due to a medical condition
(infectious disease, heart condition, and lung carcinoma)
Selective reporting (reporting
bias)
Unclear risk Unclear if all predefined outcomes have been reported. A protocol is
not available for verification
Other bias Low risk The study seems to be free of other sources of bias
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TABLE 13 Characteristics and risk of bias of included studies evaluating antipsychotic drugs as treatment for TD
(continued )
Included study Description
Bai et al., 2005112,113
Study characteristics
Characteristic Description
Methods l Allocation: ‘randomised’, not described
l Blindness: ‘single blind’, partially described
l Design: parallel groups
l Setting: inpatients, Taiwan
l Duration: 24 weeks
Participants l Diagnosis: schizophrenia (DSM-IV191), Schooler and Kane’s criteria192 for persistent
TD, n= 80
l Age: 50.2 (SD 7.1) years
l Sex: 39 male and 41 female
l History: duration of TD not reported; treatment with conventional antipsychotics for
> 1 year
Interventions No washout period on the discontinuation of all conventional antipsychotics was
reported:
1. olanzapine: dose not reported, 24 weeks, n= 27
2. amisulpride: dose not reported, 24 weeks, n= 27
3. FGA: dose not reported, 24 weeks, n= 26
Outcomes l TD symptoms: AIMS
l Adverse effects: extrapyramidal side effects (SAS); akathisia (BAS); general (UKU)
l General mental state (BPRS)
l Leaving the study early
Notes Sponsorship source: the study was supported by grants from National Science Council,
Taiwan
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk ‘The subjects were randomized to three groups’, further details not
reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
High risk . . . single-blind and controlled study
Blinding of outcome
assessment (detection bias)
Unclear risk ‘. . . single-blind and controlled study’. Blinding details of outcome
assessors not reported
Incomplete outcome data
(attrition bias)
Low risk Finally 76 cases (95%) completed the 24-week study, 2 cases in
the olanzapine groups withdrew due to impaired liver function,
1 case in the amisulpride group due to infectious disease, and
1 case in the FGA controlled groups withdrew due to unstable
psychiatric condition
Intention-to-treat analyses with last-observation-carried-forward
method applied
Selective reporting (reporting
bias)
Low risk All outcomes appear to have been reported
Other bias Low risk The study seems to have been free of other sources of bias
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TABLE 13 Characteristics and risk of bias of included studies evaluating antipsychotic drugs as treatment for TD
(continued )
Included study Description
Caroff et al., 2011117
Study characteristics
Characteristic Description
Methods l Allocation: ‘randomly assigned’, not described
l Blindness: ‘double blind’, partially described
l Design: post hoc analysis of parallel group RCT
l Setting: inpatients, USA
l Duration: 18 months
Participants l Diagnosis: schizophrenia and TD (DSM-IV,191 Schooler-Kane criteria192), n= 200
l Age: 47.2 (SD 9.4) years (range 18–65 years)
l Sex: 158 male and 42 female
l History: duration of TD not reported
Interventions Overlap in administration of the antipsychotic drugs that patients received before study
entry was permitted for the first 4 weeks after randomisation to allow a gradual
transition to study medication:
1. olanzapine – flexible dose of 7.5 mg q.d./b.i.d./t.i.d./q.i.d. for 18 months, n = 54
2. quetiapine – flexible dose of 200 mg q.d./b.i.d./t.i.d./q.i.d. for 18 months, n = 62
3. risperidone – flexible dose of 1.5 mg q.d./b.i.d./t.i.d./q.i.d. for 18 months, n = 56
4. ziprasidone – flexible dose of 40 mg q.d./b.i.d./t.i.d./q.i.d. for 18 months, n= 28
Medications were flexibly dosed with 1–4 capsules daily, as judged by the study doctor.
Concomitant medications were permitted, except for additional antipsychotic agents
Outcomes l Leaving the study early
l Unable to use AIMS, PANSS, SAS, BAS Cognitive composite score (not reported in
means and SDs for the separate intervention groups)a
Notes Sponsorship source: supported by the Clinical Antipsychotic Trials of Intervention
Effectiveness project, National Institute of Mental Health. This article was based on
results from the Clinical Antipsychotic Trials of Intervention Effectiveness project,
supported by the National Institute of Mental Health. Astra Zeneca Pharmaceuticals LP,
Bristol-Myers Squibb Company, Forest Pharmaceuticals Inc., Janssen Pharmaceutical
Products LP, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd, Pfizer Inc. and Zenith
Goldline Pharmaceuticals Inc. provided medications for the studies. This material is based
on work also supported in part by the Department of Veterans Affairs, Veterans Health
Administration, Office of Research Development, with resources and the use of facilities
at the Philadelphia Veterans Affairs Medical Center
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk ‘Patients were initially randomly assigned’, further details not
reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Low risk . . ., double-blind conditions, . . . Identical-appearing capsules
contained olanzapine (7.5 mg), quetiapine (200 mg), risperidone
(1.5 mg), perphenazine (8 mg), or ziprasidone (40mg)
Blinding of outcome
assessment (detection bias)
Unclear risk Blinding of outcome assessors not reported
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TABLE 13 Characteristics and risk of bias of included studies evaluating antipsychotic drugs as treatment for TD
(continued )
Included study Description
Incomplete outcome data
(attrition bias)
High risk The primary clinical outcome measure was time to all-cause
treatment discontinuation. Total population (n = 200): 74%
discontinuation. Olanzapine: 31/54 (57%); quetiapine: 51/62 (82%);
risperidone: 44/56 (79%); ziprasidone: 21/28 (75%). Reasons for
withdrawal reported
Selective reporting (reporting
bias)
High risk Original CATIE study:
The primary clinical outcome measure was time to all-cause
treatment discontinuation. Secondary outcomes included
discontinuations for intolerability, inefficacy, and patient decision;
rates of discontinuations; mean modal dose; and change from
baseline in the PANSS and neurocognitive composite scores
All outcomes not fully reported for the TD population
Other bias High risk Post hoc analysis; modified diagnostic criteria for TD were applied at
baseline and a 3-month history of antipsychotic exposure was not
required
Chan et al., 2010115
Study characteristics
Characteristic Description
Methods l Allocation: ‘randomly assigned by coin method’
l Blindness: single-blind (outcome assessor)
l Design: parallel groups
l Setting: inpatients, Taiwan
l Duration: 24 weeks
Participants l Diagnosis: schizophrenia (n= 58) and schizoaffective disorder (n = 2) (DSM-IV
criteria191); antipsychotic-induced TD, n= 60
l Age: 45.3 (SD 11.6) years (range 18–70 years)
l Sex: 21 male and 39 female
l History: duration of TD not reported. Antipsychotic exposure ≈10 years. All of the
subjects received FGAs prior to participation in this study
Interventions Following a washout period of 3–7 days:
1. risperidone – flexible dose of 1.9 ± 0.7 mg/day (baseline) to 4.1± 1.4 mg/day
(end point) for 24 weeks, n= 30
2. olanzapine – flexible dose of 8.1 ± 2.0 mg/day (baseline) to 12.6± 5.4 mg/day
(end point) for 24 weeks, n= 30
Outcomes l TD symptoms: no clinical improvement > 50% (AIMS)
l TD symptoms: AIMS
l Adverse effect: dyskinesia; parkinsonism; dystonia; akathisia; general adverse events
l General mental state: BPRS
l Leaving the study early
Notes Sponsorship source: supported by research grant from the Taoyuan Mental Hospital and
from the Department of Health, Executive Yuan, Taiwan
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk . . . randomly assigned to receive either olanzapine or risperidone
with a 1-to-1 ratio by coin method with a 6-block design
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
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TABLE 13 Characteristics and risk of bias of included studies evaluating antipsychotic drugs as treatment for TD
(continued )
Included study Description
Blinding of participants and
personnel (performance bias)
High risk . . . primary care physicians and patients were not blinded
Blinding of outcome
assessment (detection bias)
Low risk Two investigators (C.-H.C. and J.-J.C.) served as blinded raters . . .
The BPRS, CGI-S, AIMS and global impression of ESRS were
performed at baseline and at weeks 1, 2, 3, 4, 8, 12, 16, 20, and
24 or at end point visit by blinded-rater
Incomplete outcome data
(attrition bias)
Low risk Nine out of 30 in the risperidone and 7 out of 30 in the olanzapine
groups dropped out from the study; reasons reported
All patients who were randomly assigned and had at least 1
post-baseline assessment were included in the intent-to-treat (ITT)
analysis. If the ITT subjects withdrew from the study earlier than
scheduled, then the last observation carried forward method was
employed to extend the end point scores
Selective reporting (reporting
bias)
Low risk Data for all outcomes in the trial registry, NCT00621998, have been
reported
Other bias Low risk The study seems to be free of other sources of bias
Chouinard et al., 1993102,103
Study characteristics
Characteristic Description
Methods l Allocation: ‘randomly assigned’, not described
l Blindness: ‘double blind’, partially described
l Design: post-hoc analysis of parallel 6-group RCTs
l Setting: inpatients, Canada
l Duration: 8 weeks
Participants Diagnosis: chronic schizophrenia (DSM-III-R criteria193), n= 135
Age: mean 39 years, range 19–60 years
Sex: 34 male and 14 female
History: duration TD not reported; the most common pre-study medications were
haloperidol, procyclidine, lorazepam, benztropine and chlorpromazine; the most
commonly used depot antipsychotic agents were haloperidol decanoate, fluphenazine
decanoate, flupentixol decanoate and pipothiazine palmitate
Interventions Mean duration of washout phase 6 days:
1. risperidone – dose 2 mg/day for 8 weeks, n= 8
2. risperidone – dose 6 mg/day for 8 weeks, n= 6
3. risperidone – dose 10mg/day for 8 weeks, n = 6
4. risperidone – dose 16mg/day for 8 weeks, n = 11
5. haloperidol – dose 20mg/day for 8 weeks, n= 6
6. placebo – n= 11
Psychotropic and antiparkinsonian medications were discontinued. Chloral hydrate
or benzodiazepine was allowed if a sedative/hypnotic was required, biperiden or
procyclidine was given if clinically significant drug-induced parkinsonism or dystonia
emerged
Outcomes l Adverse events: use of antiparkinsonism medication
l Unable to use (data does not have variability measures and only reports differences
from baseline to worst scores)
l ESRS: dyskinesia symptoms total score, CGI severity dyskinesia,
buccolinguomasticatory factor, choreoathetoid factor
Notes Sponsorship source: not reporteda
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TABLE 13 Characteristics and risk of bias of included studies evaluating antipsychotic drugs as treatment for TD
(continued )
Included study Description
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk ‘. . . randomly assigned’, details not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Low risk . . . identical tablets
Blinding of outcome
assessment (detection bias)
Unclear risk Blinding of raters not reported
Incomplete outcome data
(attrition bias)
Low risk 33% of participants terminated the study early because of an
insufficient therapeutic response. All early terminations were
included in the intention-to-treat analysis
Selective reporting (reporting
bias)
High risk Outcomes not fully reported
Other bias High risk Subgroup with TD
Cookson, 198798
Study characteristics
Characteristic Description
Methods l Allocation: ‘allocated randomly’, not described
l Blindness: ‘double blind’, not described
l Design: parallel groups
l Setting: inpatients, UK
l Duration: 44 weeks
Participants l Diagnosis: hebephrenic or paranoid schizophrenia (ICD-9194 and Feighner criteria),
n = 18 (only three people had TD at baseline)
l Age: mean 44.5 years
l Sex: 12 male and six female
l History: duration of TD not reported; patients resistant to low doses of
antipsychotics but improved with higher dosages and maintained this improvement
for at least 3 months
Interventions No washout period before study entry:
1. antipsychotic reduction – dose 50% previous dose of cis(z)-flupentixol decanoate,
bi-weekly, n= 9
2. antipsychotic maintenance – dose standard dosage of cis(z)-flupentixol decanoate,
n = 9
Procyclidine allowed during study. Supplementary antipsychotics allowed were
haloperidol (oral) or zuclopentixol decanoate (depot). Amitriptyline used for depression
Outcomes l Adverse effects: TD (AIMS derived)
l Unable to use: adverse effects – GSES (no usable data)
l General mental state: BPRS (no usable data)
Notes Dr Cookson kindly provided additional information
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TABLE 13 Characteristics and risk of bias of included studies evaluating antipsychotic drugs as treatment for TD
(continued )
Included study Description
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk ‘. . . randomised in blocks of 4 and stratified by neuroleptic dose and
gender’, implies adequate random sequence generation
Allocation concealment
(selection bias)
Unclear risk No allocation concealment details
Blinding of participants and
personnel (performance bias)
Unclear risk ‘. . . double blind’, no further details
Blinding of outcome
assessment (detection bias)
Unclear risk ‘. . . double blind’, no further details
Incomplete outcome data
(attrition bias)
Low risk All patients seem to have completed the study
Selective reporting (reporting
bias)
Unclear risk All outcomes proposed in the methods were reported, but some were
not presented adequately. No protocol available to check as well
Other bias High risk The randomised allocation of the small number of patients in the
pilot study results in inequalities between the 2 groups at entry and
confounded comparisons of group mean values during the study
Emsley et al., 2004110
Study characteristics
Characteristic Description
Methods l Allocation: ‘randomly assigned’, not described
l Blindness: investigators blinded
l Design: parallel group
l Setting: inpatients and outpatients, South Africa
l Duration: 50 weeks
Participants Diagnosis: schizophrenia (DSM-IV191), TD (Schooler and Kane criteria192), n= 45
Age: 49.2 (SD 14.5) years, range 18–65 years
Sex: 16 male and 29 female
History: duration of TD not reported; at least 3 months antipsychotic exposure; patients
with established psychiatric disorder who do not receive clozapine
Interventions After an initial screening visit, subjects were tapered from all psychotropic medication
over a 2-week period:
1. quetiapine – dose 100 mg/day increased to 400 mg/day, n = 22
2. haloperidol – dose 5 mg/day increased to 10mg/day, n= 23
Concomitant medication allowed were benzodiazepines for agitation or insomnia
and anticholinergic agents in the event of treatment emergent or worsening EPS.
Medications not allowed were other antipsychotics or other medication known to
improve or exacerbate movement disorders
Outcomes l TD symptoms: no clinical improvement
l Leaving the study early
l General mental health (PANSS)
l Unable to use: adverse effects – ESRS, EPS (no usable data)
l Global assessment: CGI (data in graphs, no variability)
Notes Sponsorship source: supported in part by the Medical Research Council of South Africa,
Cape Town and the University of Stellenbosch. Trial medication and monitoring of the
study were provided by AstraZeneca, Wilmington, DE, USA
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TABLE 13 Characteristics and risk of bias of included studies evaluating antipsychotic drugs as treatment for TD
(continued )
Included study Description
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk ‘Subjects were then randomly assigned’, further details not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
High risk ‘. . . investigator-blinded’, further blinding details not reported
Blinding of outcome
assessment (detection bias)
Unclear risk ‘. . . investigator-blinded’, further blinding details not reported
Incomplete outcome data
(attrition bias)
High risk 43% dropouts (including the two subjects excluded in the early
stages). 10/22 (45%) patients in the quetiapine group and 8/23
(35%) haloperidol patients dropped out
Selective reporting (reporting
bias)
High risk Adverse effects: extrapyramidal symptoms (other than dyskinesia)
not fully reported
Other bias Low risk The study seems to be free of other sources of bias. Baseline
characteristics are balanced in the compared groups
Kane et al., 198397
Study characteristics
Characteristic Description
Methods l Allocation: randomised using random numbers table
l Blindness: double
l Design: parallel groups
l Setting: outpatients, USA
l Duration: 48 weeks
Participants l Diagnosis: schizophrenia or schizoaffective disorder (RDC), n= 8
l Age: range 17–60 years
l Sex: not reported
l History: in a state of remission or at a stable clinical plateau
Interventions 1. Fluphenazine decanoate: low dose 1.25–5mg/2 weeks, n= 4
2. Fluphenazine decanoate: antipsychotic maintenance – standard dose 12.5–50mg/
2 weeks, n= 4
Procyclidine, 5–20mg/day, was allowed if needed to treat extrapyramidal side effects.
No other psychotropic medication except flurazepam or diazepam was allowed (these
benzodiazepines were used sparingly for insomnia)
Outcomes TD (‘no clinical improvement’; ‘not any improvement’; ‘deterioration’), reported as
adverse effects:
l incidence of TD (modified versions of SDS)
l leaving the study early
l general mental state – relapse
l unable to use – GAS, BPRS, CGI, SAS
Notes Sponsorship source: this investigation was supported in part by grants from the National
Institute of Mental Health. Dr Woerner kindly provided unpublished data for one site of
the main study and only these are used in this review; the sex ratios are not available. If
people in this study developed TD, participation was stopped and they were classified as
leaving the study early
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TABLE 13 Characteristics and risk of bias of included studies evaluating antipsychotic drugs as treatment for TD
(continued )
Included study Description
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Randomised using random numbers table
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Unclear risk ‘. . . double-blind’. Details not reported
Blinding of outcome
assessment (detection bias)
Unclear risk ‘. . . double-blind’. Details not reported
Incomplete outcome data
(attrition bias)
High risk 4/8 participants left the study early
Selective reporting (reporting
bias)
High risk Not all data were reported
Other bias High risk Only subsample with TD from one site included in this review
Kazamatsuri et al., 197396
Study characteristics
Characteristic Description
Methods l Allocation: ‘randomly’
l Blindness: rater blind
l Duration: 24 weeks (4-week antipsychotic and antiparkinsonian drug cessation and
placebo administration, 18-week intervention and then 2-week placebo)
l Design: parallel
l Setting: inpatients, USA
Participants l Diagnosis: chronic psychotic patients – chronic schizophrenia (n= 10), mentally
deficient (n= 2), chronic brain syndrome (n = 1); all manifesting typical bucco-linguo-
masticatory oral dyskinesia associated with long-term antipsychotic medication, N= 13
l Sex: five female and eight male
l Age: mean 55.8 years, range 41–63 years
l History: duration of TD not reported
Interventions 4-week washout from antiparkinsonian and antipsychotic medication (all replaced by
placebo), then:
1. haloperidol – dose 4 mg b.i.d., from week 15 the dose was doubled to 16mg/day,
n= 7
2. tetrabenazine – dose 50mg b.i.d., from week 15 the dose was doubled to
200mg/day, n= 6
Concomitant medications:
Other medications, such as antidiabetic or anticonvulsant drugs, were continued
unchanged
Outcomes l TD symptoms: not clinically improved
l TD symptoms: not any improvement
l TD symptoms: deterioration
l Leaving the study early
l Unable to use: TD scale scores and adverse effects – EPS; ward behaviour (NOSIE)
(means, SDs not reported)
Notes Sponsorship source: Supported in part by Public Health Service grant from the National
institute of Mental Health. Tetrabenazine and placebo tablets were provided by
Hoffman-La Roche
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TABLE 13 Characteristics and risk of bias of included studies evaluating antipsychotic drugs as treatment for TD
(continued )
Included study Description
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk The 13 patients were divided randomly into two groups
Further details not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
High risk Blinding of participants and personnel not reported
Blinding of outcome
assessment (detection bias)
Low risk A frequency count of mouth movements (18), done by a
psychiatrist blind to the study design was used to assess
oral dyskinesia
Incomplete outcome data
(attrition bias)
High risk Two out of seven (29%) subjects dropped out from the haloperidol
group. There were no dropouts from the tetrabenazine group. The
dropouts were not entered in the analysis (data reported for all
subject up until week 16, inclusive)
Selective reporting (reporting
bias)
High risk TD scale scores and extrapyramidal symptoms scale scores not fully
reported
Other bias Unclear risk Insufficient information to make a judgement
Tamminga et al., 1994104
Study characteristics
Characteristic Description
Methods l Allocation: randomised
l Blindness: double
l Design: parallel groups
l Setting: not reported, USA
l Duration: 12 months
Participants l Diagnosis: schizophrenia; diagnosis of TD of a moderate or severe degree, n= 32b
l Age: mean 35.57 (SD 7.60) years
l Sex: 20 male and 12 female
l History: duration of TD not reported
Before beginning the protocol, each participant was treated with a clinically optimal
dose of haloperidol for an initial 1- to 6-month stabilization period
Interventions After the stabilisation period, each patient was withdrawn from antipsychotic treatment
for 4 weeks to allow a antipsychotic-free assessment of their dyskinetic symptoms. Then:
1. clozapine plus placebo – mean dose at 293.8 ± 171.9 mg/day for 12 months, n= 25
2. haloperidol plus benztropine – mean dose at 28.5± 23.8 mg/day for 12 months,
n = 14
Outcomes l Leaving the study early
l Unable to use: TD symptoms (reported means only in graph)
Notes Sponsorship source: sponsorship source not reported. Authors were contacted for
updated data but at the time of preparing this review no more information had been
received
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TABLE 13 Characteristics and risk of bias of included studies evaluating antipsychotic drugs as treatment for TD
(continued )
Included study Description
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Subjects were then blindly randomised to two different
drug groups
Further details not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Unclear risk Staff, patients, and all raters were blind to the drug group; one
non rating physician and one nurse were non blind to dispense
medication and monitor safety
No further details are provided
Blinding of outcome
assessment (detection bias)
Low risk Staff, patients, and all raters were blind to the drug group; one
non rating physician and one nurse were non blind to dispense
medication and monitor safety’
No further details are provided
Incomplete outcome data
(attrition bias)
High risk Of 43 enrolled participants, four did not complete the study and
seven were withdrawn
One subject from each treatment group was dropped for
leukopenia. The other 5 clozapine subjects were dropped for
noncompliance (1 patient), decompensation (1 patient), seizure
(1 patient), hypotension (1 patient), and ECG [electrocardiogram]
changes (1 patient)
Data has been reported for completers only
Selective reporting (reporting
bias)
Unclear risk Unclear if all predefined outcomes have been reported. Efficacy data
reported in graphs as means only. A study protocol is needed for
firm conclusions
Other bias Unclear risk Preliminary results as four subjects had not completed the study
BAS, Barnes Akathisia Scale; b.i.d., twice per day; CATIE, Clinical Antipsychotic Trials for Intervention Effectiveness;
CGI, Clinical Global Impression; CGI-S, Clinical Global Impression – Severity scale; DSM-III, Diagnostic and Statistical
Manual of Mental Disorders-Third Edition; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition;
EPS, extrapyramidal symptoms; GAS, Global Assessment Scale; GSES, General Side Effects Scale; ICD-9, International
Classification of Diseases, Ninth Edition; NOSIE, Nurses’ Observation Scale for Inpatient Evaluation; q.d., one per day;
q.i.d., four times per day; PANSS, Positive and Negative Syndrome Scale; RDC, Research Diagnostic Criteria; SD, standard
deviation; SDS, Simpson Dyskinesia Scale; t.i.d., three times per day.
a Author kindly replied to our request for data. At the time of preparing this review no more outcome data were available.
b Forty-nine have been recruited for this study but only 32 completed the blind protocol. The authors report only on these
32 patients.
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Anticholinergic drugs
TABLE 14 Characteristics and risk of bias of included studies evaluating anticholinergic drugs as treatment for TD
Included study Description
Greil et al., 1984119
Study characteristics
Characteristic Description
Methods l Allocation: ‘randomly assigned’; no further details provided
l Blind: ‘double-blind’; no further details provided
l Design: parallel group
l Setting: not reported if inpatients or outpatients or both, Germany
l Duration: 7 weeks
Participants l Diagnosis: chronic schizophrenics (ICD-9194) with TD based on the presence of a
‘typical’ bucco-linguo-masticatory syndrome and the absence of other adequate
explanations for the movement disorder, n= 10
l Duration of TD: ≥ 1 year, severity of the symptoms stable for at least 1 month
before admission to the study
l Sex: seven female and three male
l Age: mean 56.6 (SD 9.2) years; range 35–65 years
Interventions 1. Biperiden (same dose as before the trial) stopped after 4 weeks followed by placebo
for 3 weeks, n= 4
2. Biperiden (same dose as before the trial) stopped after 1 week followed by placebo
for 6 weeks, n= 6
All stable on antipsychotics and anticholinergics for at least 5 months before entry and
during the trial. Other concomitant medication: not reported
Outcomes l Leaving the study early
l Unable to use (results not reported per randomised group): TD symptoms – AIMS;
EP symptoms – SAS
Study author was contacted for additional data but no reply was received
Notes l Sponsorship source: not reported. Knoll AG supplied placebo
l Declarations of interest: not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk ‘. . . randomly assigned’; further details not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Low risk Double-blind . . . investigators were not informed about the
study design
Blinding of outcome
assessment (detection bias)
Unclear risk Blinding of raters was not mentioned
Incomplete outcome data
(attrition bias)
Low risk Nine patients completed the trial. One patient dropped out one
week after biperiden withdrawal because of severe parkinsonism;
in this patient, only one rating could be carried out while on
the placebo
Selective reporting (reporting
bias)
High risk TD symptoms data were not reported per randomised group, but
before biperiden removal vs. after biperiden removal
Other bias Unclear risk Insufficient information to make a judgement
EP, extrapyramidal; ICD-9, International Classification of Diseases, Ninth Edition.
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Benzodiazepines
TABLE 15 Characteristics and risk of bias of included studies evaluating benzodiazepines as treatment for TD
Included study Description
Bobruff et al., 1981120
Study characteristics
Characteristic Description
Methods l Allocation: ‘randomly assigned’
l Blindness: ‘double blind’
l Design: parallel group
l Duration: not reported (optimal dose + 2 weeks + taper off)
l Setting: not reported, USA
Participants Diagnosis: psychiatric patients (details not reported). Obvious TD (at least three scores of
mild or one score of moderate on AIMS), n= 21
Duration of TD: not reported
Age: mean 51.6 years; range 36–63 years
Sex: 16 male and five female
Interventions 1. Clonazepam: dose 3.9 ± 2.6 mg daily; optimal dose + 2 weeks + taper, n= 10
2. Phenobarbital (as active placebo): 88.6 ± 45.7 mg daily; optimal dose+ 2 weeks
+ taper, n= 11
There were five patients who were taking no antipsychotics and one patient who was
taking homeopathic doses; doses were stable throughout the study period. Concomitant
medication: not reported
Outcomes l TD symptoms: no improvement (AIMS)
l TD symptoms: not improved more than 50% (AIMS)
l Adverse effects
l Leaving the study early
l Unable to use: Mental State – Profile of Mood States
Notes Sponsorship source: supported in part by NIMH grant. Declarations of interest: not
reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk ‘Patients were randomly assigned’; further details not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Unclear risk ‘. . . double-blind’. Details not reported
Blinding of outcome
assessment (detection bias)
Unclear risk ‘. . . double-blind’. Details not reported
Incomplete outcome data
(attrition bias)
Low risk Although not clearly reported, it seems that all subjects completed
the double-blind phase (data reported for all 21 subjects)
Selective reporting (reporting
bias)
Unclear risk All outcomes seem to have been reported but not as mean (SD).
Also, as protocol is not available, it is not possible to verify that all
predefined outcomes were reported
Other bias Unclear risk Insufficient information to make a judgement
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TABLE 15 Characteristics and risk of bias of included studies evaluating benzodiazepines as treatment for TD
(continued )
Included study Description
Csernansky et al., 1988121,122
Study characteristics
Characteristic Description
Methods l Allocation: ‘randomly assigned’; no details reported
l Blindness: ‘double blind’, described
l Design: parallel group
l Duration: 5–6 weeks
l Setting: outpatients (most) and inpatients from Veterans Administration Medical
Center, USA
Participants l Diagnosis: schizophrenia (RDC criteria), n= 17
l Duration of TD: not reported
l Age: not reported
l Sex: not reported
Interventions 1. Alprozalam: dose 7.2± 1.8 mg daily for 5–6 weeks, n= 5
2. Diazepam: dose 48.3± 17.4 mg daily for 5–6 weeks, n= 5
3. Placebo for 5–6 weeks, n= 6
Participants were stable for at least 2 weeks prior to study and doses were unchanged
during the study. Concomitant medication: 55 patients in the study were also taking
anticholinergic medications
Outcomes l TD symptoms: not improved by 50%; not any improvement; deterioration
l Leaving the study early
l Unusable data: mental state – BPRS, SANS (data not reported for TD subgroup);
adverse effects (data not reported for TD subgroup)
Notes Sponsorship source: supported by a Public Health Service grant and a grant from the
National Institute of Mental Health, a VA Career Development Award to the first author,
a grant from the Upjohn Company and the Research Service of the VA. Participants
were extracted post hoc from a larger study examining benzodiazepines for the
treatment of the negative symptoms of schizophrenia. Data on age, sex, baseline
medication doses, side effects and dropout rate for the initial cohort are provided in the
parent study
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Patients were randomly assigned to the treatment with either
Alprozalam, Diadepam, or placebo . . .
Further details not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Low risk Patients were randomly assigned to the treatment with either
alprozalam, diadepam, or placebo under double-blind conditions.
Identical capsules contained either 1 mg of alprozalam, 10 mg of
diazepam, or the drug carrier as placebo
Blinding of outcome
assessment (detection bias)
Low risk Two independent raters
Incomplete outcome data
(attrition bias)
Unclear risk Fifty-five RDC schizophrenic outpatients were rated using the
Gerlach Dyskinesia Scale (GDS) before, and at weekly intervals
during, treatment . . . 17 patients were identified with rateable
TD symptoms at baseline . . .
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TABLE 15 Characteristics and risk of bias of included studies evaluating benzodiazepines as treatment for TD
(continued )
Included study Description
All 17 subjects were entered to analysis. However, as 72 subjects
were enrolled in the original study, it is unclear if relevant data for
any of the 17 out of 72 subjects that dropped out are missing
Selective reporting (reporting
bias)
Unclear risk All outcomes for the main study seem to have been reported. A
protocol is not available for verification. Although mental state and
adverse effects have not reported separately for subjects with TD
symptoms, TD was not an inclusion criterion and thus does not seem
to affect bias
Since TD was not a criterion for inclusion into or exclusion from
the trial, it was only by chance that we identified 17 patients
with TD symptoms
Other bias High risk Participants with TD at baseline were extracted post hoc from a
larger study examining benzodiazepines for the treatment of the
negative symptoms of schizophrenia
Weber et al., 198389
Study characteristics
Characteristic Description
Methods l Allocation: randomised
l Blindness: single
l Design: crossover
l Duration: 24 weeks (10 weeks followed by 4 weeks washout, then crossed over to
another 10 weeks)
l Setting: inpatients in a long-term state psychiatric hospital, USA
Participants l Diagnosis: schizophrenia (n= 12), organic brain syndrome (n= 1), unknown (n= 2).
Baseline AIMS rating or two or more on one item, and drug-induced parkinsonian
movements of six or less, N= 15
l Duration of TD: TD history of 2–6 years
l Age: mean 57.4 years, 50–65 years (among completers)
l Sex: 10 male and three female (among completers)
Interventions 1. Standard care plus diazepam: dose 6–25 mg/day, mean 12mg/day,
n= 8 (completers)
2. Standard care, n= 5 (completers)
Participants were on stable doses of both antipsychotic and anticholinergic medication
for 2 weeks prior to study, and on stable doses throughout the study except two
participants: medication was altered for two participants in the second period of
crossover. During the study, 10 patients received antipsychotic drugs, whereas eight
received anticholinergic agents, and one received amantadine
Outcomes l TD: AIMS
l Leaving the study early
l Mental state: BPRS
Notes Sponsorship source: not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk ‘Each patient was assigned randomly . . .’; further details not
reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
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TABLE 15 Characteristics and risk of bias of included studies evaluating benzodiazepines as treatment for TD
(continued )
Included study Description
Blinding of participants and
personnel (performance bias)
High risk As one of the groups received an intervention and the second standard
care, blinding of participants and personnel could not have been possible
Blinding of outcome
assessment (detection bias)
Low risk . . . rater-blind . . . The rating scales were administered by trained
observers who did not know which patients received diazepam
Incomplete outcome data
(attrition bias)
Low risk 13% dropout rate
Fifteen patients began the study. Two failed to complete the
entire protocol (one because she continued to receive diazepam
throughout the study and the other because she was discharged
from the hospital)
Selective reporting (reporting
bias)
Unclear risk The outcomes seem to have been reported. However, a protocol is
not available for verification
Other bias Unclear risk Change in medication for two participants may have had a
confounding effect; however, both substitutions occurred 4 weeks
into the second phase of the study
Xiang and Zhen, 199775
Study characteristics
Characteristic Description
Methods l Allocation: ‘randomized controlled trial’
l Blinding: ‘double blind’; ‘The two drugs were contained in capsules with
same appearance’
l Duration: 8 weeks
l Location: ‘inpatients’, China
l Length of follow-up: 8 weeks
Participants l Diagnosis: schizophrenia (CCMD-2-R195) and antipsychotic-induced TD, n= 24
l Duration of TD: mean 2.7 (SD 1.21) years
l Age: mean 39.44 (SD 8.43) years
l Sex: 15 male and nine female
Interventions 1. Standard care plus clonazepam: dose 4–6mg/day, mean 5mg/day, n= 12
2. Standard care plus placebo, n= 12
All cases continued the use of antipsychotics and anticholinergic drugs
Outcomes l TD: AIMS
l Leaving the study early
Notes Sponsorship source: sponsorship source not reported. Participants with stable or
aggravating symptoms of TD after suspending antipsychotics for 2 weeks were excluded
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk ‘. . . randomised controlled trial’. The author did not state the
method of randomisation
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Low risk . . . double blind . . . The two drugs were contained in capsules
with same appearance
Blinding of participants and key study personnel ensured
Blinding of outcome
assessment (detection bias)
Unclear risk Blinding of outcome assessment not reported
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Vitamin E
TABLE 15 Characteristics and risk of bias of included studies evaluating benzodiazepines as treatment for TD
(continued )
Included study Description
Incomplete outcome data
(attrition bias)
Low risk All participants competed the study
Selective reporting (reporting
bias)
Low risk The author reported all measured outcomes
Other bias Low risk Free from other bias
CCMD-2-R, Chinese Classification of Mental Disorders, Second Edition, Revised; NIMH, National Institute of Mental Health;
RDC, Research Diagnostic Criteria; SANS, Scale for Assessment of Negative Symptoms; SD, standard deviation;
VA, Veteran’s Administration.
TABLE 16 Characteristics and risk of bias of included studies evaluating vitamin E as treatment for TD
Included study Description
Adler et al., 1993125,126
Study characteristics
Characteristic Description
Methods l Allocation: ‘random allocation’, ratio of three vitamin E to two placebo
l Blinding: double blind – no further details
l Duration: 36 weeks (preceded by 2-week washout)
l Setting: inpatients and outpatients of the Department of Veterans Affairs Medical
Center, USA
l Design: parallel group
Participants l Diagnosis: schizophrenia, depression (no criteria) and antipsychotic-induced TD
(RDC, Schooler and Kane192). n= 40a
l Sex: two female and 27 malea
l Age: average vitamin E, 58.0 (SD 9.5) years; placebo, 61.0 (SD 9.2) yearsa
Interventions 1. Vitamin E: dose increasing over 3 weeks to 1600 IU/day, n= 24b
2. Placebo, n = 16b
Stable antipsychotic medication: dose average (CPZE) vitamin E 536 mg/day
(SD 642mg/day); placebo 921mg/day (SD 1026mg/day). Compliance assessed by
pill counts
Outcomes l TD symptoms: AIMS
l Leaving the study early
Notes l Source of funding: supported in part by the Department of Veterans Affairs
l Declarations of interest: not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Patients were randomly assigned to treatment with Vitamin E,
400 IU, or one matching placebo capsule, by mouth, b.i.d.
No further details provided
Allocation concealment (selection
bias)
Unclear risk We used a randomisation of 3 : 2 (vitamin E to placebo) to
maximise the number of patients receiving active treatment
while maintaining the blind
No further details provided
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TABLE 16 Characteristics and risk of bias of included studies evaluating vitamin E as treatment for TD (continued )
Included study Description
Blinding of participants and
personnel (performance bias)
Unclear risk Both rater and patient were blind to the patient’s
drug assignment
No further details provided
Blinding of outcome assessment
(detection bias)
Unclear risk Both rater and patient were blind to the patient’s
drug assignment’
No further details provided
Incomplete outcome data
(attrition bias)
Low risk One patient dropped out after 2 weeks due to non-compliance
. . . Two patients developed significant medical illnesses . . .
unrelated to study treatment . . . By prior design, treatment for
the first 8 patients was terminated after 8 weeks
Selective reporting (reporting bias) Unclear risk All expected outcomes have been reported but there is no study
protocol to confirm that all planned outcomes were reported
Other bias Unclear risk Baseline AIMS scores were somewhat higher in the vitamin E
group than in the placebo group; however, this difference was
not statistically significant. Small sample size
Adler et al., 1999137
Study characteristics
Characteristic Description
Methods l Allocation: randomisation co-ordinated centrally, allocation with ‘biased coin’
method, stratified by site, age and baseline TD
l Double blind: no further details
l Duration: 1 year
l Setting: outpatients and inpatients, Department of Veterans Affairs Medical
Center, USA
l Design: parallel
Participants l Diagnosis: schizophrenia, schizoaffective (DSM-IV191), and antipsychotic-induced
TD (RDC), n= 158
l Sex: five female and 153 male
l Age: average 50 years (SD 10 years)
Interventions 1. Vitamin E: 1600 IU/day, n= 73
2. Placebo, n = 85
Antipsychotic medication: not stable dose, average (CPZE) vitamin E 380 mg/day
(SD 110mg/day); placebo 458mg/day (SD 433mg/day)
Compliance assessed by pill counts
Outcomes l TD symptoms: AIMS
l Mental state: BPRS
l Leaving the study early
l Adverse effects: extrapyramidal symptoms (Modified SAS); Akathisia (Barnes
Akathisia Scale)
Notes Source of funding: Cooperative Studies Program of the Department of Veterans
Affairs, Veterans Affairs Headquarters, Washington, DC, USA. Declarations of interest:
not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Randomisation co-ordinated centrally
Allocation concealment (selection
bias)
Low risk Allocation with ‘biased coin’ method, stratified by site, age and
baseline TD
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TABLE 16 Characteristics and risk of bias of included studies evaluating vitamin E as treatment for TD (continued )
Included study Description
Blinding of participants and
personnel (performance bias)
Unclear risk Double blind: no further details
Blinding of outcome assessment
(detection bias)
Unclear risk Double blind: no further details
Incomplete outcome data
(attrition bias)
Low risk Of the 51 subjects who did not complete 1 year, most
changed their minds about participating (n= 18), moved too
far away from a site to continue in the study (n = 11), or were
classified as ‘whereabouts unknown’ (n = 8) . . . Per protocol,
we analysed the data according to the intention-to-treat
principle
Selective reporting (reporting bias) Unclear risk All expected outcomes have been reported but there is no study
protocol to confirm that all planned outcomes were reported
Other bias Unclear risk No significant differences between groups’ baseline
characteristics. Small sample size
Akhtar et al., 1993127
Study characteristics
Characteristic Description
Methods l Allocation: ‘random allocation’, no further details
l Double blind: no further details
l Duration: 4 weeks (preceded by 2 weeks washout)
l Setting: inpatients in a psychiatric hospital, India
l Design: parallel group
Participants Diagnosis: psychiatric disorder (Spitzer criteria) and antipsychotic-induced TD (Schooler
and Kane criteria192), n= 32
Sex: 14 female and 18 male
Age: vitamin E, mean 53.06 years (SD 13.39 years); placebo, mean 56.87 years
(SD 11.13 years)
Interventions l Vitamin E: initial dose 600 mg once daily, doubled in the second week to 600 mg
b.i.d. (1200mg/d), n= 17
l Placebo, n = 15
Stable antipsychotic medication: dose average (CPZE) 323 mg/day (SD 249mg/day);
placebo 187mg/day (SD 189mg/day)
Outcomes l TD symptoms: TDRS
l Mental state: BPRS
l Adverse effects
l Leaving the study early
Notes Authors contacted but did not reply. Source of funding: not reported. Declarations of
interest: not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk The patients were then randomly assigned
Details not reported
Allocation concealment (selection
bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Low risk . . . double blind manner to receive either one capsule of
600 mg vitamin E or an identical placebo
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TABLE 16 Characteristics and risk of bias of included studies evaluating vitamin E as treatment for TD (continued )
Included study Description
Blinding of outcome assessment
(detection bias)
Low risk Both, the investigators and raters were blind to the nature of
therapy . . . active drug or placebo till the completion
of analysis
Incomplete outcome data
(attrition bias)
Low risk The study results seem to include all participants and there seem
to be no dropouts from the study
Selective reporting (reporting bias) Unclear risk All expected outcomes have been reported but there is no study
protocol to confirm that all planned outcomes were reported
Other bias Unclear risk There was no significant difference in the demographic profile of
the two groups. Small sample size
Dabiri et al., 1994128
Study characteristics
Characteristic Description
Methods l Allocation: ‘random allocation’, no further details
l Double blind: yes
l Duration: 12 weeks
l Setting: outpatients, from San Mateo Country Mental Health Services, USA
l Design: parallel group
Participants l Diagnosis: psychiatric disorder (no criteria) and antipsychotic-induced TD
(Research diagnosis, Schooler and Kane criteria192), n= 12
l Sex: five female, six male and one not specified
l Age: average 51 years; range 35–68 years
Interventions 1. Vitamin E: 400 IU/day for the first week, 800 IU/day for the second week and
1200 IU/day during the remaining 10 weeks, n= 7
2. Placebo, n = 5
Stable antipsychotic medication: dose average (CPZE) 444 mg/day; range
200–1000mg/day
Outcomes l TD symptoms: AIMS
l Leaving study early
l Adverse effects: any
Notes Authors contacted but did not reply. Source of funding: not reported. Declarations of
interest: not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk ‘. . . random allocation’, no further details
Allocation concealment (selection
bias)
Low risk . . . patients were randomly divided into treatment and placebo
groups by a non-clinical staff member
Blinding of participants and
personnel (performance bias)
Unclear risk ‘. . . double-blind study’, details not reported
Blinding of outcome assessment
(detection bias)
Unclear risk Each patient was rated blindly by one of us (L.M.D.) before
and after treatment using the Abnormal Involuntary
Movement Scale (AIMS)
Blinding details not reported
Incomplete outcome data
(attrition bias)
Low risk One patient who was taking vitamin E stopped treatment after
2 weeks because of diarrhoea, leaving five patients taking
placebo and six vitamin E
Selective reporting (reporting bias) Unclear risk All expected outcomes have been reported, but there is no study
protocol to confirm that all planned outcomes were reported
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TABLE 16 Characteristics and risk of bias of included studies evaluating vitamin E as treatment for TD (continued )
Included study Description
Other bias Unclear risk No statistically significant differences in AIMS baseline scores
between groups. Very small sample size
Dorevitch et al., 199791
Study characteristics
Characteristic Description
Methods l Allocation: ‘randomised’, no further details
l Double blind: yes
l Duration: 20 weeks (4-week washout)
l Setting: specific setting not reported, Israel
l Design: crossover
Participants l Diagnosis: DSM-III-R193 diagnosis of schizophrenia. All 10 candidates had TD
for a minimum of 5 years and had been exposed to antipsychotic drugs for
> 10 years, n= 10
l Sex: two female and eight male
l Age: average 63.1 years, range 56–70 years
Interventions 1. Vitamin E: dose increasing over 4 weeks to 1600 IU/day, n= 5
2. Placebo, n = 5
At the start of the study, the patients were receiving an average dose of 652mg/day
chlorpromazine equivalents, with a range of 75 to 4000mg/day
Outcomes l Leaving study early
l Adverse effects: parkinsonism, akathisia
l Unable to use: adverse effects – AIMS (data not reported)
Notes Source of funding: not reported. Teva Pharmaceuticals supplied the vitamin E and
placebo for this study. Declarations of interest: not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk ‘. . . randomised’. Details not reported
Allocation concealment (selection
bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Unclear risk ‘. . . double-blind’. Blinding details not reported
Blinding of outcome assessment
(detection bias)
Unclear risk ‘. . . double-blind’. Blinding details not reported
Incomplete outcome data
(attrition bias)
Low risk The study results seem to include all participants and there seem
to be no dropouts from the study
Selective reporting (reporting bias) High risk TD symptoms (AIMS) were assessed but not reported
Other bias Unclear risk Baseline characteristics not reported. Very small sample size
Dorevitch et al., 199790
Study characteristics
Characteristic Description
Methods l Allocation: ‘randomised’, no further details
l Double blind: yes
l Duration: 20 weeks
l Setting: inpatients, Israel
l Design: crossover
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TABLE 16 Characteristics and risk of bias of included studies evaluating vitamin E as treatment for TD (continued )
Included study Description
Participants l Diagnosis: DSM-III-R193 diagnosis of schizophrenia or schizoaffective disorder,
research diagnostic criteria for TD (Schooler and Kane criteria192), n= 40
l Sex: 17 female and 23 male
l Age: average 64.4 years (SD 8.5 years); range 32–80 years
Interventions 1. Vitamin E: 400 IU/day during the first week, titrated to 800 IU/day for the second
week, 1200 IU/day for the third week and 1600 IU/day from week 4 until the end
of week 8, n= 18
2. Placebo, n = 22
Stable antipsychotic medication: dose average (CPZE) 594 mg/day, range
75–5000mg/day
Outcomes l TD symptoms: AIMS
l Leaving study early
l Adverse effects
l Unable to use: mental state – BPRS (data not reported)
Notes Source of funding: not reported. Teva Pharmaceuticals supplied the vitamin E and
placebo for this study. Declarations of interest: not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk ‘Randomised’ – no further details
Allocation concealment (selection
bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Unclear risk ‘. . . double-blind’; blinding details were not reported
Blinding of outcome assessment
(detection bias)
Low risk Two senior psychiatrists served as blinded raters
Incomplete outcome data
(attrition bias)
Unclear risk Two patients did not complete the study. Both patients were
from the placebo phase of the placebo-vitamin E sequence
group. One died while choking on food and the second as the
result of a traffic accident
Selective reporting (reporting bias) High risk Addition of vitamin E or placebo did not adversely affect
patient mental status as measured by brief psychiatric rating
scale (BPRS)
BPRS data not fully reported
Other bias Unclear risk Baseline characteristics not reported. Small sample size
Egan et al., 199292
Study characteristics
Characteristic Description
Methods l Allocation: ‘random allocation’, no further details
l Double blind: no further details
l Duration: 12 weeks (6 weeks then crossed over to another 6 weeks, no washout)
l Setting: inpatients and outpatients, USA
l Design: crossover
Participants l Diagnosis: schizophrenia, schizoaffective, bipolar disorder, depression (DSM-III-R193)
and antipsychotic-induced TD (Schooler and Kane criteria192), n= 21
l Sex: eight female and 13 male
l Age: average 43.9 years (SD 2.8 years)
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TABLE 16 Characteristics and risk of bias of included studies evaluating vitamin E as treatment for TD (continued )
Included study Description
Interventions 1. Vitamin E: 400 IU/day for week 1, 800 lU/day for week 2, 1200 lU/day for week 3
and 1600 IU/day for weeks 4–6, n= 10
2. Placebo, n = 11
Stable antipsychotic medication: dose average (CPZE) 1946 mg/day (no SD, n = 15)
Outcomes l TD symptoms: AIMS
l Side effects
l Leaving study early
l Unable to use: mental symptoms – PSAS, NSRS (means and SDs not reported)
Notes Three patients were not included in the data analysis: one dropped out and two had
inconsistent vitamin E blood levels. Source of funding: not reported. Declarations of
interest: not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Patients were assigned randomly
Details not reported
Allocation concealment (selection
bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Unclear risk ‘. . . double-blind.’ Details not reported
Blinding of outcome assessment
(detection bias)
Low risk All raters were blind to treatment with either placebo or
vitamin E
Incomplete outcome data
(attrition bias)
High risk Not ITT analysis:
Eighteen patients who demonstrated high blood levels of
vitamin E were included in the data analysis
Three patients were excluded from the analysis
Selective reporting (reporting bias) High risk Data for mental state (PSAS and NSAS) not reported
Other bias Unclear risk Baseline characteristics not reported. Very small sample size
Elkashef et al., 199093
Study characteristics
Characteristic Description
Methods l Allocation: ‘random allocation’, no further details
l Double blind: no further details
l Duration: 10 weeks (4 weeks then crossed over to another 4 weeks;
randomisation was preceded by 2 weeks’ washout)
l Setting: outpatients, USA
l Design: crossover
Participants l Diagnosis: schizophrenia or schizoaffective disorder (DSM-III-R193) and
antipsychotic-induced TD (Schooler and Kane criteria192), n = 10
l Sex: one female and seven males (among completers)
l Age: average 56.6 years (SD 12 years) (among completers)
l History: no description of chronicity of TD
Interventions 1. Vitamin E: 400 IU/day for the first week, 400 IU b.i.d. (800 IU/day) for the second
week and 400 IU t.i.d. (1200 IU/day) for the final 2 weeks, n= 5
2. Placebo, n = 5
Stable antipsychotic medication: dose not specified
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TABLE 16 Characteristics and risk of bias of included studies evaluating vitamin E as treatment for TD (continued )
Included study Description
Outcomes l TD symptoms: AIMS
l Adverse effects
l Leaving study early
l Unable to use: mental state – BPRS
Notes Source of funding: not reported. Hollman-La Roche Inc., supplied the drug and
placebo for this study. Declarations of interest: not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk The subjects were then assigned in a random, double-blind
manner . . .
No further details
Allocation concealment (selection
bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Unclear risk Double blind: no further details
Blinding of outcome assessment
(detection bias)
Unclear risk The subjects were evaluated biweekly by a blind trained rater
using the AIMS and the Brief Psychiatric Rating Scale (BPRS)
Details of blinding not reported
Incomplete outcome data
(attrition bias)
High risk 2/5 participants in the placebo group dropped out, whereas none
in the vitamin E group dropped out:
Two patients did not complete the study, one because of
noncompliance and the other experienced substantial side
effects (nausea) while taking placebo
Selective reporting (reporting bias) High risk AIMS data partially reported and BPRS evaluated but not reported
Other bias Unclear risk The baseline severity of TD was closely matched in the two
groups. Very small sample size
Lam et al., 199494
Study characteristics
Characteristic Description
Methods l Allocation: ‘random allocation’, no further details
l Double blind: no further details
l Duration: 16 weeks – 2-week placebo lead-in phase, 6 weeks’ treatment, 2-week
placebo washout phase, crossed over to 6 weeks of another treatment.
Intervention followed by 2 weeks’ washout, then crossed over to another
6 weeks
l Setting: inpatients, Hong Kong
l Design: crossover
Participants Diagnosis: schizophrenia (DSM-III-R193) and antipsychotic-induced TD (Schooler and
Kane criteria192), n= 16
Sex: seven female and five malec
Age: average 61.8 years (SD 12.8 years)c
History: no history of chronicity of TD
continued
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TABLE 16 Characteristics and risk of bias of included studies evaluating vitamin E as treatment for TD (continued )
Included study Description
Interventions 1. Vitamin E: 400 IU/day for the first week, 400 IU b.i.d in the second week, 400 IU
t.i.d. for weeks 3–6, n= 5c
2. Placebo, n = 7c
Stable antipsychotic medication. For those taking antipsychotic medication, the
average daily dose was 365mg CPZE
Outcomes TD symptoms: AIMS
Leaving study early (assuming equal randomisation into the two groups)
Unable to use: mental state – BPRS (no mean or SD reported), adverse effects
Notes Four people left study early (no information about allocation), the reasons being
death, deterioration of symptoms of schizophrenia, bacillary dysentery (all stated not
to be related to treatment) and poor compliance. Authors contacted and replied, no
more information available. Source of funding: not reported. Declarations of interest:
not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Subjects were then selected randomly
No further details
Allocation concealment (selection
bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Unclear risk ‘. . . double-blind’. Details not reported
Blinding of outcome assessment
(detection bias)
Low risk Subjects were evaluated weekly with the AIMS . . . and Brief
Psychiatric Rating Scale . . ., respectively, by two independent
blind raters at the initial stabilisation period, and the last
2 weeks of each test period
Incomplete outcome data
(attrition bias)
High risk Twelve subjects completed the trial. One patient died of unrelated
medical illness, one contracted bacillary dysentery and was
dropped from the trial, and one had poor compliance and refused
to continue medication. It was not reported which groups these
participants were allocated to
Selective reporting (reporting bias) High risk TD symptoms data not reported as mean (SD); BPRS data not
reported per period. Adverse effects not reported per group
Other bias Unclear risk Baseline characteristics not reported. Very small sample size
Lohr et al., 1996129
Study characteristics
Characteristic Description
Methods l Allocation: ‘random assigned’, no further details provided
l Double blind: participants and personnel blinded
l Duration: 8 weeks
l Setting: outpatients, USA
l Design: parallel
Participants l Diagnosis: schizophrenia, bipolar disorder, unipolar depression (no specified
criteria) and antipsychotic-induced TD (Schooler and Kane criteria192); n= 55
l Sex: two female, 33 male and 20 not informed
l Age: average 48.9 years (SD 13.6 years)
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
166
TABLE 16 Characteristics and risk of bias of included studies evaluating vitamin E as treatment for TD (continued )
Included study Description
Interventions 1. Vitamin E: 1600 IU/day, n= 17 (completers)d
2. Placebo, n = 18 (completers)d
Stable psychotropic medication for at least 1 month prior to entry into study.
Antipsychotic dose average (CPZE) vitamin E 706 mg/day (SD 680mg/day); placebo
376mg/day (SD 242mg/day)
Outcomes l TD symptoms: mAIMS
l Mental state: BPRS (reported for subgroup with schizophrenia, n = 29)
l Leaving the study early
Notes Source of funding: Partial funding by a VA Merit Review grant and United States
Public Health Service grants. Vitamin E and placebo supplied by Hoffmann-La Roche
Inc. Declarations of interest: not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Patients were randomly assigned to receive either active
vitamin E or sesame oil placebo gel caps
Allocation concealment (selection
bias)
Unclear risk Allocation concealment details not reported
Blinding of participants and
personnel (performance bias)
Low risk Patients were randomly assigned to receive either active
vitamin E or sesame oil placebo gel caps, which were
indistinguishable from the active gel caps
Blinding of outcome assessment
(detection bias)
Unclear risk Insufficient information to make a judgement
Incomplete outcome data
(attrition bias)
High risk Dropout rate of 36% (20/55 patients) but not reported per study
group:
2 developed manic symptoms necessitating medical changes,
and 18 were non-compliant with either the vitamin E or the
psychotropic medication. These 20 patients, who did not differ
significantly from the remaining 35 patients in terms of age,
gender, or diagnosis, were dropped from the study
Selective reporting (reporting bias) High risk Adverse effects: extrapyramidal side effects (parkinsonism) – data
not reported
Other bias Unclear risk There were no significant differences in baseline characteristics
between the two study groups. Small sample size
Sajjad, 1998130
Study characteristics
Characteristic Description
Methods l Allocation: ‘random allocation’
l Double blind: probably not, there was no placebo administered to the
control group
l Duration: 7 months
l Setting: inpatients, UK
l Design: parallel
Participants l Diagnosis: antipsychotic-induced TD (Schooler and Kane criteria192), n = 20
l Sex: seven female and 13 male
l Age: average 68 years (SD 8.7 years)
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TABLE 16 Characteristics and risk of bias of included studies evaluating vitamin E as treatment for TD (continued )
Included study Description
Interventions 1. Vitamin E: first week 400mg/day, increased to 600 mg/day in the second week,
800mg/day in the fourth month, 1200mg/day in the fifth month and 1600mg/day
in the sixth month, n= 11
2. Placebo, n = 9
Stable antipsychotic medication throughout the trial
Outcomes l TD symptoms: AIMS
l Adverse effects
l Leaving the study early
Notes Source of funding: not reported. Declarations of interest: not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk . . . the patients were randomly divided into two groups using
. . . a computer statistic programme
Allocation concealment (selection
bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
High risk As an active group was compared with TAU, the study could not
be double blinded. The only person blinded seems to have been
the doctor
. . . the dose increased by another doctor not involved in the
ratings and who, therefore, was blind as to whether or not the
patient was receiving a-tocopherol for the first month of
the trial
Blinding of outcome assessment
(detection bias)
High risk Rater initially blind. However, after 1 month, the rater performed
statistical tests and, hence, blindness was not maintained
Incomplete outcome data
(attrition bias)
High risk 40% dropout rate (12/20 participants completed the study): 6 out
of 11 subjects in the intervention and 2 out of 9 subjects in the
control group did not complete the trial. By the fourth month
there were 12 patients left in the trial: five in the treatment group
and seven in the control group. Patients excluded at this stage
included those whose dose of antipsychotic medication was
changed
Selective reporting (reporting bias) Unclear risk All expected outcomes have been reported but there is no study
protocol to confirm that all planned outcomes were reported
Other bias Unclear risk Mean AIMS scores and age were similar between groups at
baseline. Very small sample size
Schmidt et al., 199195
Study characteristics
Characteristic Description
Methods l Allocation: ‘randomised pattern’, no further details
l Double blind: no further details
l Duration: 4 weeks (2 weeks then crossed over to another 2 weeks, no
washout period)
l Setting: inpatients, Switzerland
l Design: crossover
Participants Diagnosis: schizophrenia, depression, schizoaffective psychoses (no criteria) and
antipsychotic-induced TD (no criteria), n= 23
Sex: 12 female and 11 male
Age: average 45 years, range 21–88 years
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TABLE 16 Characteristics and risk of bias of included studies evaluating vitamin E as treatment for TD (continued )
Included study Description
Interventions 1. Vitamin E: dose 1200 IU/day, n = 13
2. Placebo, n = 10
Stable antipsychotic medication: dose unspecified
Outcomes l TD symptoms: AIMS
l Adverse effects
l Leaving study early
Notes It was observed that two of the patients who benefited from the vitamin E therapy
continued taking it: after stopping vitamin E medication, one of them experienced an
increase in TD, whereas in the other the beneficial effect was still observed even
3 months later. Source of funding: not reported. Declarations of interest: not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk ‘. . . randomised pattern’, no further details
Allocation concealment (selection
bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
Unclear risk ‘. . . double-blind’. Details not reported
Blinding of outcome assessment
(detection bias)
Unclear risk Details not reported
Incomplete outcome data
(attrition bias)
Low risk Of the 13 patients initially randomised to vitamin E, two left
before the end of the study (one died and the other withdrew).
Of the 10 patients initially randomised to placebo, two left before
the end of the study (one died and the other had his treatment
modified)
Selective reporting (reporting bias) Unclear risk All expected outcomes have been reported but there is no study
protocol to confirm that all planned outcomes were reported
Other bias Unclear risk Baseline characteristics similar between study groups. Very small
sample size, crossover design
Zhang et al., 2004138
Study characteristics
Characteristic Description
Methods l Allocation: randomly assigned
l Double blind: yes
l Duration: 12 weeks
l Setting: inpatients, China
l Design: parallel
Participants l Diagnosis: DSM-III-R193 criteria for schizophrenia, using the Structured Clinical
Interview for DSM-III-R; TD diagnosed by Schooler and Kane criteria,192 n= 41
l Sex: 18 female and 23 male
l Age: average vitamin E, 54.5 years (SD 10.1 years); placebo 53.3 years
(SD 9.7 years)
Interventions 1. Vitamin E: 800 IU/day during the first week and increased up to 1200 IU/day for
another 11 weeks, n = 22
2. Placebo, n = 17
Clinically stable with duration of TD for at least 1 year; stable dose of oral
antipsychotics
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Buspirone
TABLE 16 Characteristics and risk of bias of included studies evaluating vitamin E as treatment for TD (continued )
Included study Description
Outcomes l TD symptoms: AIMS
l Leaving study early
l Unable to use: mental state: PANSS
Notes Source of funding: Not reported. Declarations of interest: not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk ‘Eligible patients were randomly assigned’; no further details
Allocation concealment (selection
bias)
Unclear risk Allocation concealment method not reported
Blinding of participants and
personnel (performance bias)
Low risk . . . either capsulized vitamin E (n = 22) or identically capsulized
placebo (n = 19) using a double-blind fashion
Blinding of outcome assessment
(detection bias)
Low risk TD and psychotherapy were assess by blinded investigators
Incomplete outcome data
(attrition bias)
Low risk All randomised subjects seem to have completed the study
Selective reporting (reporting bias) High risk Outcome data were not reported for mental symptoms (PANSS)
Other bias Low risk No significant differences in demographic data were observed
between vitamin E and placebo groups
b.i.d., twice per day; CPZE, chlorpromazine equivalents; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders-
Third Edition, Revised; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition; ITT, intention to treat;
mAIMS, modified Abnormal Involuntary Movement Scale; NSRS, Negative Symptom Rating Scale; PANSS, Positive and
Negative Syndrome Scale; PSAS, Psychiatric Symptoms Assessment Scale; RDC, Research Diagnostic Criteria; SD, standard
deviation; TDRS, Tardive Dyskinesia Rating Scale; t.i.d., three times per day; VA, Veteran’s administration.
a Initial report at 8 weeks, n= 29.
b Three people left the study in the first 2 weeks and could not be considered in the analysis – original group assumed
from 3 : 2 randomisation.
c Completers.
d Total numbers randomised per group were imputed from numbers analysed per group. Authors contacted but did not reply.
TABLE 17 Characteristics and risk of bias of included studies evaluating buspirone as treatment for TD
Included study Description
Zeng, 199578
Study characteristics
Characteristic Description
Methods l Allocation: ‘randomly assigned . . .’
l Blinding: double-blind study, details are provided
l Duration: 6 weeks
l Design: parallel
l Setting: inpatients
Participants l Diagnosis: antipsychotic-induced TD, n = 42
l Sex: 14 female and 28 male
l Age: mean ≈32.5 years, SD ≈10.3 years
l Length of illness (schizophrenia): mean ≈7.5 years, SD ≈3.4 years
l History: duration of TD, on average, 5.4 ± 4.2 years in active group, whereas
5.7 ± 4.5 years in control group
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TABLE 17 Characteristics and risk of bias of included studies evaluating buspirone as treatment for TD (continued )
Included study Description
Interventions 1. Buspirone group: management – the initial dosage, one capsule each day, was
titrated to 6–12 capsules each day within 10 days, n= 21
2. Placebo group: management – the initial dosage, one capsule each day, was
titrated to 6–12 capsules each day within 10 days, n= 21
All participants received stable antipsychotic and concomitant anticholinergic drug
Outcomes Clinical response
TD: AIMS
Adverse events: dizziness, headache, nausea, vomiting
Unable to use: blood routine examination, urine routine test and liver function test,
electrocardiography, electroencephalography (the author only stated results of these
tests were normal, but did not report the data)
Notes Funding source: not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk ‘. . . randomly assigned . . .’, the author did not state the method of
randomisation
Allocation concealment (selection
bias)
Unclear risk The author did not state the method of allocation concealment
Blinding of participants and
personnel (performance bias)
Low risk . . . double blind study, the interventions were coded as
intervention A or B by the researcher in pharmacy . . . Participants
and personnel did not know the allocation result. The two drugs
were contained in capsules with same appearance
Blinding of participants and key study personnel ensured
Blinding of outcome assessment
(detection bias)
Unclear risk Not stated
Incomplete outcome data
(attrition bias)
Low risk All participants completed the study
Selective reporting (reporting bias) Low risk The author reported all measured outcomes
Other bias Low risk None obvious
SD, standard deviation.
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Hypnosis and relaxation
TABLE 18 Characteristics and risk of bias of included studies evaluating hypnosis and relaxation as treatment
for TD
Included study Description
Glover, 1980139
Study characteristics
Characteristic Description
Methods l Allocation: randomised
l Blindness: not mentioned
l Duration: eight sessions
l Design: parallel
l Setting: outpatients, USA
Participants l Diagnosis: diagnosis of chronic schizophrenia, diagnoses of either acute extra
pyramidal symptoms, TD and/or pseudo-parkinsonism, n = 15
l Sex: 12 females and three males
l Age: mean 34.9 years
l History: duration of TD not reported. Not reported whether patients were
stabilised prior to study
Interventions 1. Hypnosis: eight sessions, n= 5
2. Relaxation: eight sessions, n= 5
3. TAU (control group): eight sessions, n= 5
Psychotropic medication continued
Outcomes l Leaving the study early: number of dropouts
Notes Sponsorship source: sponsorship source not reported
Risk of bias
Bias
Authors’
judgement Support for judgement
Random sequence generation
(selection bias)
High risk Quasi-randomised. Assigned to the three groups in order of
approaching the clinic
Allocation concealment (selection
bias)
Unclear risk Allocation concealment not reported
Blinding of participants and
personnel (performance bias)
High risk As subjects in group 1 received hypnosis, those in group 2 received
relaxation training and those in group 3 received TAU without any
other treatment, blinding could not be achieved
Blinding of outcome assessment
(detection bias)
Unclear risk Blinding of outcome assessors not reported
Incomplete outcome data
(attrition bias)
Low risk There were no refusals, or drop-outs among the referrals
Selective reporting (reporting bias) Low risk It seems that all outcomes have been reported. However, data is not
usable
Other bias Unclear risk Baseline characteristics were similar but sample sizes very small
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Appendix 8 Characteristics of studies awaiting
classification and ongoing
TABLE 19 Studies awaiting classification
Kar-Ahmadi, 2002141
Methods l Allocation: ‘randomised’ no further details
l Blindness: double – no further details
l Duration: 6 weeks
l Setting: inpatients
l Design: parallel
Participants l Diagnosis: antipsychotic-induced TD, n = 30
l Sex: unknown
l Age: unknown
Interventions 1. Vitamin E: dose 600mg/day, n= 15
2. Placebo, n = 15
Stable antipsychotic medication: dose unspecified
Outcomes l TD symptoms: AIMS
Notes A copy of this study was not available in The British Library
Zeng et al., 1996140
Methods RCT
Participants Schizophrenia with drug-induced tremor, n= 68
Interventions 1. Dexetimide, n = 36
2. Benzhexol, n= 32
Outcomes l Clinical response
l Adverse events
l Treatment Emergent Symptom Scale
Notes In Chinese, assessed by Sai Zhao. Study authors have been contacted to find out if participants were
diagnosed with TD
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TABLE 20 Ongoing studies
Garcia and Crismon, 1992142
Study name Double-blind placebo controlled study using buspirone in the treatment of tardive dyskinesia
Methods l Allocation: randomised
l Blindness: double blind
l Duration: 12 weeks
l Design: crossover
l Setting: USA
Participants l Diagnosis: TD patients criteria not reported, n= 20
l Sex: not reported
l Age: not reported
Interventions 1. Buspirone: not reported, increasing dose, n= 20
2. Placebo, n= 20
Outcomes AIMS score
Notes Abstract of a study protocol, there are no data to be extracted
Kajero, 2015144
Study name Investigation of the potential beneficial effects of cannabidiol in the treatment of tardive dyskinesia
Methods Randomised, double-blind, placebo-controlled study
Participants Target number of participants: 28 per group
Adults aged > 18 years who currently meet the ICD-10196 diagnosis of a psychotic disorder, verified with
the Mini International Neuropsychiatric Interview questionnaire and who currently meet the clinical
diagnosis of TD confirmed with the AIMS. Patients should currently be receiving treatment for a psychotic
disorder and should be on either atypical or conventional antipsychotics
Interventions 1. Group 1 has high cannabidiol extract Nabidiolex® (GW Pharma Limited Corporation, Salisbury, UK)
(CBD) (300mg) administered twice a day for 6 weeks as an adjunctive treatment alongside their usual
antipsychotic medication. CBD will be administered orally in capsules
2. Group 2 has vitamin E (400 IU) administered daily for 6 weeks as an adjunctive treatment alongside
their usual antipsychotic medication
Outcomes l Improvement in symptoms of TD measured using AIMS. Assessments will be conducted at baseline,
2-, 4-, 6- (post treatment) and 12-week follow-up
l Side effects of CBD will be periodically assessed with the Glasgow Checklist and reported at
each assessment
l Improvement in psychotic symptoms
Starting
date
1 December 2015
Notes Source of funding: Federal Neuropsychiatric Hospital, Nigeria. Trial is part of a Stellenbosch University PhD.
Intention to publish date: 1 January 2018
Reynolds, 2002143
Methods l Allocation: randomised
l Blindness: rater blind
l Design: not reported
l Setting: not reported
l Duration: 6 months
Participants Schizophrenic patients with TD
Interventions 1. Quetiapine
2. Risperidone
Outcomes Prevalence and severity of abnormal involuntary movements
Notes Very limited information from two trial registries. We were unable to locate author contact details
ICD-10, International Classification of Diseases, Tenth Edition.
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Appendix 9 Non-prioritised comparisons:
results overview
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